

## **Exhibit 6**

# **CVS Health's Quarterly Report on Form 10-Q For the Quarter Ended September 30, 2017**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Quarterly Period Ended September 30, 2017

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission File Number 001-01011



**CVS HEALTH CORPORATION**

*(Exact name of registrant as specified in its charter)*

Delaware  
*(State of Incorporation)*

05-0494040  
*(I.R.S. Employer Identification Number)*

One CVS Drive, Woonsocket, Rhode Island 02895  
*(Address of principal executive offices)*

Registrant's telephone number, including area code: (401) 765-1500

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Common Stock, \$0.01 par value, issued and outstanding at October 31, 2017:  
1,012,992,425 shares

---

Table of Contents

INDEX

	<b>Page</b>
<b><u>Part I</u></b>	
<b><u>Item 1. Financial Statements</u></b>	3
<u>Condensed Consolidated Statements of Income (Unaudited) – Three and Nine Months Ended September 30, 2017 and 2016</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income (Unaudited) – Three and Nine Months Ended September 30, 2017 and 2016</u>	4
<u>Condensed Consolidated Balance Sheets (Unaudited) – As of September 30, 2017 and December 31, 2016</u>	5
<u>Condensed Consolidated Statements of Cash Flows (Unaudited) – Nine Months Ended September 30, 2017 and 2016</u>	6
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	7
<u>Report of Independent Registered Public Accounting Firm</u>	24
<b><u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u></b>	25
<b><u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u></b>	42
<b><u>Item 4. Controls and Procedures</u></b>	42
<b><u>Part II</u></b>	43
<b><u>Item 1. Legal Proceedings</u></b>	43
<b><u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	43
<b><u>Item 6. Exhibits</u></b>	44
<b><u>Signatures</u></b>	45

---

**CVS Health Corporation**  
**Condensed Consolidated Statements of Income**  
(Unaudited)

<i>In millions, except per share amounts</i>	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2017	2016	2017	2016
Net revenues	\$46,181	\$44,615	\$136,380	\$131,555
Cost of revenues	39,055	37,123	115,739	110,304
Gross profit	7,126	7,492	20,641	21,251
Operating expenses	4,627	4,668	14,232	13,885
Operating profit	2,499	2,824	6,409	7,366
Interest expense, net	245	253	744	816
Loss on early extinguishment of debt	—	101	—	643
Other expense	192	7	206	23
Income before income tax provision	2,062	2,463	5,459	5,884
Income tax provision	777	921	2,115	2,271
Income from continuing operations	1,285	1,542	3,344	3,613
Loss from discontinued operations, net of tax	—	(1)	(8)	(1)
Net income	1,285	1,541	3,336	3,612
Net income attributable to noncontrolling interest	—	(1)	(1)	(2)
Net income attributable to CVS Health	<u>\$ 1,285</u>	<u>\$ 1,540</u>	<u>\$ 3,335</u>	<u>\$ 3,610</u>
<b>Basic earnings per share:</b>				
Income from continuing operations attributable to CVS Health	\$ 1.26	\$ 1.44	\$ 3.26	\$ 3.34
Loss from discontinued operations attributable to CVS Health	\$ —	\$ —	\$ (0.01)	\$ —
Net income attributable to CVS Health	\$ 1.26	\$ 1.44	\$ 3.25	\$ 3.34
Weighted average shares outstanding	1,016	1,068	1,022	1,076
<b>Diluted earnings per share:</b>				
Income from continuing operations attributable to CVS Health	\$ 1.26	\$ 1.43	\$ 3.25	\$ 3.32
Loss from discontinued operations attributable to CVS Health	\$ —	\$ —	\$ (0.01)	\$ —
Net income attributable to CVS Health	\$ 1.26	\$ 1.43	\$ 3.24	\$ 3.32
Weighted average shares outstanding	1,020	1,073	1,026	1,082
Dividends declared per share	\$ 0.50	\$ 0.425	\$ 1.50	\$ 1.275

See accompanying notes to condensed consolidated financial statements.

Table of Contents

**CVS Health Corporation**  
**Condensed Consolidated Statements of Comprehensive Income**  
**(Unaudited)**

<i>In millions</i>	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2016</b>
Net income	\$ 1,285	\$ 1,541	\$ 3,336	\$ 3,612
Other comprehensive income:				
Foreign currency translation adjustments, net of tax	8	(3)	6	37
Net cash flow hedges, net of tax	—	1	1	2
Pension and other postretirement benefits, net of tax	151	—	151	—
Total other comprehensive income (loss)	<u>159</u>	<u>(2)</u>	<u>158</u>	<u>39</u>
Comprehensive income	<u>1,444</u>	<u>1,539</u>	<u>3,494</u>	<u>3,651</u>
Comprehensive income attributable to noncontrolling interest	—	(1)	(1)	(2)
Comprehensive income attributable to CVS Health	<u>\$ 1,444</u>	<u>\$ 1,538</u>	<u>\$ 3,493</u>	<u>\$ 3,649</u>

See accompanying notes to condensed consolidated financial statements.

Table of Contents

**CVS Health Corporation**  
**Condensed Consolidated Balance Sheets**  
**(Unaudited)**

<u><i>In millions, except per share amounts</i></u>	<u>September 30,</u> <u>2017</u>	<u>December 31,</u> <u>2016</u>
<b>Assets:</b>		
Cash and cash equivalents	\$ 2,485	\$ 3,371
Short-term investments	75	87
Accounts receivable, net	12,440	12,164
Inventories	14,147	14,760
Other current assets	776	660
Total current assets	<u>29,923</u>	<u>31,042</u>
Property and equipment, net	9,914	10,175
Goodwill	38,169	38,249
Intangible assets, net	13,303	13,511
Other assets	1,544	1,485
Total assets	<u>\$ 92,853</u>	<u>\$ 94,462</u>
<b>Liabilities:</b>		
Accounts payable	\$ 7,899	\$ 7,946
Claims and discounts payable	9,807	9,451
Accrued expenses	8,404	6,937
Short-term debt	110	1,874
Current portion of long-term debt	2,293	42
Total current liabilities	<u>28,513</u>	<u>26,250</u>
Long-term debt	23,386	25,615
Deferred income taxes	4,442	4,214
Other long-term liabilities	1,644	1,549
<b>Shareholders' equity:</b>		
CVS Health shareholders' equity:		
Preferred stock, par value \$0.01: 0.1 shares authorized; none issued or outstanding	—	—
Common stock, par value \$0.01: 3,200 shares authorized; 1,712 shares issued and 1,013 shares outstanding at September 30, 2017 and 1,705 shares issued and 1,061 shares outstanding at December 31, 2016	17	17
Treasury stock, at cost: 698 shares at September 30, 2017 and 643 shares at December 31, 2016	(37,764)	(33,452)
Shares held in trust: 1 share at September 30, 2017 and December 31, 2016	(31)	(31)
Capital surplus	32,009	31,618
Retained earnings	40,779	38,983
Accumulated other comprehensive income (loss)	(147)	(305)
Total CVS Health shareholders' equity	<u>34,863</u>	<u>36,830</u>
Noncontrolling interest	5	4
Total shareholders' equity	<u>34,868</u>	<u>36,834</u>
Total liabilities and shareholders' equity	<u>\$ 92,853</u>	<u>\$ 94,462</u>

See accompanying notes to condensed consolidated financial statements.

Table of Contents

**CVS Health Corporation**  
**Condensed Consolidated Statements of Cash Flows**  
**(Unaudited)**

<u>In millions</u>	Nine Months Ended September 30,	
	2017	2016
Cash flows from operating activities:		
Cash receipts from customers	\$ 133,055	\$ 128,545
Cash paid for inventory and prescriptions dispensed by retail network pharmacies	(110,788)	(106,371)
Cash paid to other suppliers and employees	(11,230)	(11,020)
Interest received	15	14
Interest paid	(869)	(954)
Income taxes paid	(2,040)	(2,194)
Net cash provided by operating activities	8,143	8,020
Cash flows from investing activities:		
Purchases of property and equipment	(1,412)	(1,607)
Proceeds from sale-leaseback transactions	265	230
Proceeds from sale of property and equipment and other assets	20	22
Acquisitions (net of cash acquired) and other investments	(502)	(333)
Purchase of available-for-sale investments	—	(40)
Maturities of available-for-sale investments	21	76
Net cash used in investing activities	(1,608)	(1,652)
Cash flows from financing activities:		
Increase (decrease) in short-term debt	(1,764)	340
Proceeds from issuance of long-term debt	—	3,455
Repayments of long-term debt	—	(5,185)
Purchase of noncontrolling interest in subsidiary	—	(39)
Payment of contingent consideration	—	(26)
Dividends paid	(1,539)	(1,384)
Proceeds from exercise of stock options	314	277
Payments for taxes related to net share settlement of equity awards	(70)	(72)
Repurchase of common stock	(4,361)	(4,000)
Other	(1)	(6)
Net cash used in financing activities	(7,421)	(6,640)
Effect of exchange rate changes on cash and cash equivalents	—	2
Net decrease in cash and cash equivalents	(886)	(270)
Cash and cash equivalents at the beginning of the period	3,371	2,459
Cash and cash equivalents at the end of the period	\$ 2,485	\$ 2,189
Reconciliation of net income to net cash provided by operating activities:		
Net income	\$ 3,336	\$ 3,612
Adjustments required to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	1,857	1,847
Goodwill impairment	135	—
Losses on settlements of defined benefit pension plans	187	—
Stock-based compensation	173	166
Loss on early extinguishment of debt	—	643
Deferred income taxes and other noncash items	271	119
Change in operating assets and liabilities, net of effects from acquisitions:		
Accounts receivable, net	(280)	(1,714)
Inventories	620	(337)
Other current assets	(212)	2
Other assets	(15)	(86)
Accounts payable and claims and discounts payable	330	1,570
Accrued expenses	1,670	2,149
Other long-term liabilities	71	49
Net cash provided by operating activities	\$ 8,143	\$ 8,020

See accompanying notes to condensed consolidated financial statements.

**CVS Health Corporation**  
**Notes to Condensed Consolidated Financial Statements**  
**(Unaudited)**

**Note 1 – Accounting Policies**

***Basis of Presentation***

The accompanying unaudited condensed consolidated financial statements of CVS Health Corporation and its subsidiaries (collectively, “CVS Health” or the “Company”) have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in Exhibit 13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“2016 Form 10-K”).

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.

***Principles of Consolidation***

The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.

Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.

***Fair Value of Financial Instruments***

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

- Level 1 – Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
- Level 2 – Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.
- Level 3 – Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.



## Table of Contents

As of September 30, 2017, the carrying value of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and the contingent consideration liability included in accrued expenses approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company's short-term investments of \$75 million at September 30, 2017 consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at September 30, 2017. The carrying amount and estimated fair value of the Company's total long-term debt was \$25.7 billion and \$27.0 billion, respectively, as of September 30, 2017. The fair value of the Company's long-term debt was estimated based on quoted prices currently offered in active markets for the Company's debt, which is considered Level 1 of the fair value hierarchy.

### ***Related Party Transactions***

The Company has an equity method investment in SureScripts, LLC ("SureScripts"), which operates a clinical health information network. The Pharmacy Services and Retail/LTC segments utilize this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of approximately \$5 million and \$7 million in the three months ended September 30, 2017 and 2016, respectively, and expensed fees for the use of this network of approximately \$29 million in the nine months ended September 30, 2017 and 2016. The Company's investment in and equity in earnings of SureScripts for all periods presented is immaterial.

The Company has an equity method investment in Heartland Healthcare Services ("Heartland"). Heartland operates several long-term care pharmacies in four states. Heartland paid the Company approximately \$36 million and \$46 million for pharmaceutical inventory purchases during the three months ended September 30, 2017 and 2016, respectively, and approximately \$106 million and \$116 million for pharmaceutical inventory purchases during the nine months ended September 30, 2017 and 2016. Additionally, the Company performs certain collection functions for Heartland and then passes those customer cash collections back to Heartland. The Company's investment and equity in earnings of Heartland for all periods presented is immaterial.

### ***Discontinued Operations***

In connection with certain business dispositions completed between 1991 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Bob's Stores and Linens 'n Things, both of which subsequently filed for bankruptcy. See "Note 12 – Commitments and Contingencies" to the condensed consolidated financial statements. The Company's discontinued operations include lease-related costs which the Company believes it will likely be required to satisfy pursuant to its lease guarantees.

### ***New Accounting Pronouncements Recently Adopted***

In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-11, *Inventory*, which amends Accounting Standard Codification ("ASC") Topic 330. This ASU simplifies current accounting treatments by requiring entities to measure most inventories at "the lower of cost and net realizable value" rather than using lower of cost or market. This guidance does not apply to inventories measured using the last-in, first-out method or the retail inventory method. The Company adopted this standard effective January 1, 2017. The adoption of this new guidance did not have any impact on the Company's condensed consolidated results of operations, financial position or cash flows.

In March 2016, the FASB issued ASU No. 2016-09, *Improvements to Employee Share-Based Payment Accounting*, which amends the accounting for certain aspects of share-based payments to employees in ASC Topic 718, *Compensation - Stock Compensation*. The new guidance eliminates the accounting for any excess tax benefits and deficiencies through equity, and requires all excess tax benefits and deficiencies related to employee share-based compensation arrangements to be recorded in the income statement. This aspect of the guidance is required to be applied prospectively. The guidance also requires the presentation of excess tax benefits on the statement of cash flows as an operating activity rather than a financing activity, a change which may be applied prospectively or retrospectively. The

Table of Contents

guidance further provides an accounting policy election to account for forfeitures as they occur rather than utilizing the estimated amount of forfeitures at the time of issuance. The Company adopted this guidance effective January 1, 2017. The primary impact of adopting this guidance was the recognition of excess tax benefits in the income statement instead of recognizing them in equity. This income statement guidance was adopted on a prospective basis. As a result, a discrete tax benefit of \$18 million and \$51 million was recognized in the income tax provision in the three and nine months ended September 30, 2017, respectively.

The Company elected to retrospectively adopt the guidance on the presentation of excess tax benefits in the statement of cash flows. The following is a reconciliation of the effect of the resulting reclassification of the excess tax benefits on the Company's condensed consolidated statement of cash flows for the nine months ended September 30, 2016:

<u>In millions</u>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
Cash paid to other suppliers and employees	\$ (11,092)	\$ 72	\$ (11,020)
Net cash provided by operating activities	7,948	72	8,020
Excess tax benefits from stock-based compensation	72	(72)	—
Net cash used in financing activities	(6,568)	(72)	(6,640)
Reconciliation of net income to net cash provided by operating activities:			
Accrued expenses	2,077	72	2,149

The Company elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. None of the other provisions in this guidance had a material impact on the Company's condensed consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which amends ASC Topic 715, *Compensation – Retirement Benefits*. ASU 2017-17 requires entities to disaggregate the current service cost component from the other components of net benefit cost and present it with other current compensation costs for related employees in the income statement and present the other components of net benefit cost elsewhere in the income statement and outside of operating income. Only the service cost component of net benefit cost is eligible for capitalization. The guidance is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of any annual periods for which an entity's financial statements have not been issued. Entities are required to retrospectively apply the requirement for a separate presentation in the income statement of service costs and other components of net benefit cost and prospectively adopt the requirement to limit the capitalization of benefit costs to the service component. The Company adopted the income statement presentation aspects of this new guidance on a retrospective basis effective January 1, 2017. Nearly all of the Company's net benefit costs for the Company's defined benefit pension and postretirement plans do not contain a service cost component as most of these defined benefit plans have been frozen for an extended period of time. The following is a reconciliation of the effect of the reclassification of the net benefit cost from operating expenses to other expense in the Company's condensed consolidated statements of income for the three and nine months ended September 30, 2016:

<u>In millions</u>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
<b>Three Months Ended September 30, 2016</b>			
Operating expenses	\$ 4,675	\$ (7)	\$ 4,668
Operating profit	2,817	7	2,824
Other expense	—	7	7
<b>Nine Months Ended September 30, 2016</b>			
Operating expenses	13,908	(23)	13,885
Operating profit	7,343	23	7,366
Other expense	—	23	23

In January 2017, the FASB issued ASU 2017-04, *Simplifying the Test for Goodwill Impairment*, which amends ASC Topic 350, *Intangibles – Goodwill and Other*. This ASU requires the Company to perform its annual, or applicable interim, goodwill impairment test by comparing the fair value of each reporting unit with its carrying amount. An impairment charge must be recognized at the amount by which the carrying amount exceeds the fair value of the reporting unit; however, the charge recognized should not exceed the total amount of goodwill allocated to that reporting unit. Income tax effects resulting from any tax deductible goodwill should be considered when measuring a goodwill impairment charge, if applicable. The guidance in ASU 2017-04 is effective for annual or interim goodwill impairment

## Table of Contents

tests in fiscal years beginning after December 15, 2019. The Company elected to early adopt this standard as of January 1, 2017. At the date of adoption of this new guidance, the guidance did not have any impact on the Company's condensed consolidated results of operations, financial position or cash flows.

### ***New Accounting Pronouncements Not Yet Adopted***

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers* (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, "*Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)*," which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "*Identifying Performance Obligations and Licensing*," which amends the guidance in those areas in the new revenue recognition standard. Both ASUs were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. The new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018. The Company chose not to early adopt the new standard. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the standard. The Company intends to adopt the new standard on a modified retrospective basis. The Company formed a project team to assess and implement the new revenue standard and is substantially complete in documenting its accounting policies applying the new revenue guidance. The Company does not expect that the implementation of the new standard will have a material effect on the Company's consolidated results of operations, cash flows or financial position. The new standard will however require more extensive revenue-related disclosures. The Company has identified one difference in its Retail/LTC Segment related to the accounting for its ExtraBucks Rewards customer loyalty program, which is currently accounted for under a cost deferral method. Under the new standard, this program will be accounted for under a revenue deferral method; however, the difference is not expected to be material.

In February 2016, the FASB issued ASU 2016-02, *Leases* (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet. The Company is currently evaluating the effect that implementation of this standard will have on the Company's consolidated results of operations, cash flows, financial position and related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, *Classification of Certain Cash Receipts and Cash Payments*. ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this accounting guidance.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows*, which amends ASC Topic 230. This ASU requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer be required to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. Entities will also have to disclose the nature of their restricted cash and restricted cash equivalent balances. The guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted. Entities are required to apply the guidance retrospectively. The Company is currently evaluating the effect of adopting this accounting guidance.

Table of Contents

**Note 2 – Goodwill and Intangible Assets**

Goodwill is not amortized, but is subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate there may be impairment.

Below is a summary of the changes in the carrying value of goodwill by segment for the nine months ended September 30, 2017:

<u><i>In millions</i></u>	<u>Pharmacy Services</u>	<u>Retail/LTC</u>	<u>Total</u>
Balance, December 31, 2016	\$ 21,637	\$ 16,612	\$38,249
Acquisitions	—	52	52
Foreign currency translation adjustments	—	3	3
Impairment	—	(135)	(135)
Balance, September 30, 2017	<u>\$ 21,637</u>	<u>\$ 16,532</u>	<u>\$38,169</u>

During 2017, the Company began pursuing various strategic alternatives for its RxCrossroads (“RxC”) reporting unit. In connection with this ongoing effort, the Company performed an interim goodwill impairment test in the second quarter of 2017. In conjunction with the impairment test, the fair value of the RxC reporting unit was estimated to be lower than the carrying value, resulting in a \$135 million goodwill impairment charge within operating expenses during the second quarter of 2017. The fair value of the RxC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. During the second quarter of 2017, the Company also performed an impairment test of the intangible assets of the RxC reporting unit and none were impaired. During the third quarter of 2017, the Company performed its required annual impairment tests and concluded there was no impairment of goodwill or trade names.

On November 6, 2017, the Company entered into a definitive agreement to sell RxC to McKesson Corporation for \$735 million. The transaction is subject to a working capital adjustment and is expected to close in the first quarter of 2018, subject to customary regulatory approvals.

The following is a summary of the Company’s intangible assets as of September 30, 2017 and December 31, 2016:

<u><i>In millions</i></u>	<u>September 30, 2017</u>			<u>December 31, 2016</u>		
	<u>Gross Carrying Amount</u>	<u>Accumulated Amortization</u>	<u>Net Carrying Amount</u>	<u>Gross Carrying Amount</u>	<u>Accumulated Amortization</u>	<u>Net Carrying Amount</u>
Trademark (indefinitely-lived)	\$ 6,398	\$ —	\$ 6,398	\$ 6,398	\$ —	\$ 6,398
Customer contracts and relationships and covenants not to compete	11,848	(5,345)	6,503	11,485	(4,802)	6,683
Favorable leases and other	1,151	(749)	402	1,123	(693)	430
	<u>\$ 19,397</u>	<u>\$ (6,094)</u>	<u>\$ 13,303</u>	<u>\$ 19,006</u>	<u>\$ (5,495)</u>	<u>\$ 13,511</u>

**Note 3 – Share Repurchase Programs**

During the nine months ended September 30, 2017, the Company had the following outstanding share repurchase programs, both of which had previously been authorized by the Company’s Board of Directors:

*In billions*

<u>Authorization Date</u>	<u>Authorized</u>	<u>Remaining</u>
November 2, 2016 (“2016 Repurchase Program”)	\$ 15.0	\$ 13.9
December 15, 2014 (“2014 Repurchase Program”)	10.0	—

Each of the 2014 and 2016 Repurchase Programs, which were effective immediately, permitted the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. Each of the repurchase programs could be modified or terminated by the Board of Directors at any time. The 2014 Repurchase Program was completed during the second quarter of 2017.

## Table of Contents

During the three months ended September 30, 2017, the Company repurchased an aggregate of approximately 5.0 million shares of common stock for approximately \$0.4 billion pursuant to the 2016 Repurchase Program. During the nine months ended September 30, 2017, the Company repurchased an aggregate of approximately 55.4 million shares of common stock for approximately \$4.4 billion pursuant to the 2014 and 2016 Repurchase Programs. This activity includes the accelerated share repurchase agreements (“ASRs”) described below.

Pursuant to the authorization under the 2014 Repurchase Program, effective August 29, 2016, the Company entered into two fixed dollar ASRs with Barclays Bank PLC (“Barclays”) for a total of \$3.6 billion. Upon payment of the \$3.6 billion purchase price on January 6, 2017, the Company received a number of shares of its common stock equal to 80% of the \$3.6 billion notional amount of the ASRs or approximately 36.1 million shares, which were placed into treasury stock in January 2017. The ASRs were accounted for as an initial treasury stock transaction for \$2.9 billion and a forward contract for \$0.7 billion. In April 2017, the Company received 9.9 million shares of common stock, representing the remaining 20% of the \$3.6 billion notional amount of the ASRs, thereby concluding the ASRs. The remaining 9.9 million shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in April 2017.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.

### **Note 4 – Pension Settlements**

As of December 31, 2016, the Company sponsored seven defined benefit pension plans. Two of the plans are tax-qualified plans that are funded based on actuarial calculations and applicable federal laws and regulations. The other five plans are unfunded nonqualified supplemental retirement plans. All seven of these plans are closed to new participants. During the three months ended September 30, 2017, the Company settled the pension obligations of its two tax-qualified plans by irrevocably transferring pension liabilities to an insurance company through the purchase of group annuity contracts and through lump sum distributions. These purchases, funded with pension plan assets, resulted in pre-tax settlement losses of \$187 million in the three months ended September 30, 2017, related to the recognition of accumulated deferred actuarial losses. The settlement losses are included in other expense in the condensed consolidated statement of income.

### **Note 5 – Accumulated Other Comprehensive Income**

Accumulated other comprehensive income consists of foreign currency translation adjustments, unrealized losses on cash flow hedges executed in previous years associated with the issuance of long-term debt, and changes in the net actuarial gains and losses associated with pension and other postretirement benefit plans. The following table summarizes the activity within the components of accumulated other comprehensive income.

Table of Contents

Changes in accumulated other comprehensive income (loss) by component is shown on the following tables:

<i>In millions</i>	<b>Three Months Ended September 30, 2017 <sup>(1)</sup></b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, June 30, 2017	\$ (129)	\$ (4)	\$ (173)	\$ (306)
Other comprehensive income before reclassifications	8	—	—	8
Amounts reclassified from accumulated other comprehensive income	—	—	151	151
Net other comprehensive income	8	—	151	159
Balance, September 30, 2017	\$ (121)	\$ (4)	\$ (22)	\$ (147)

  

<i>In millions</i>	<b>Three Months Ended September 30, 2016 <sup>(1)</sup></b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, June 30, 2016	\$ (125)	\$ (6)	\$ (186)	\$ (317)
Other comprehensive income (loss) before reclassifications	(3)	—	—	(3)
Amounts reclassified from accumulated other comprehensive income	—	1	—	1
Net other comprehensive income (loss)	(3)	1	—	(2)
Balance, September 30, 2016	\$ (128)	\$ (5)	\$ (186)	\$ (319)

  

<i>In millions</i>	<b>Nine Months Ended September 30, 2017 <sup>(1)</sup></b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, December 31, 2016	\$ (127)	\$ (5)	\$ (173)	\$ (305)
Other comprehensive income before reclassifications	6	—	—	6
Amounts reclassified from accumulated other comprehensive income	—	1	151	152
Net other comprehensive income	6	1	151	158
Balance, September 30, 2017	\$ (121)	\$ (4)	\$ (22)	\$ (147)

  

<i>In millions</i>	<b>Nine Months Ended September 30, 2016 <sup>(1)</sup></b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, December 31, 2015	\$ (165)	\$ (7)	\$ (186)	\$ (358)
Other comprehensive income before reclassifications	37	—	—	37
Amounts reclassified from accumulated other comprehensive income	—	2	—	2
Net other comprehensive income	37	2	—	39
Balance, September 30, 2016	\$ (128)	\$ (5)	\$ (186)	\$ (319)

(1) All amounts are net of tax.

(2) The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statements of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in other expense on the condensed consolidated statements of income.

**Note 6 – Stock-Based Compensation**

A summary of stock-based compensation for each of the respective periods is as follows:

<i>In millions</i>	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2016</b>
Stock-based compensation:				
Stock options	\$ 15	\$ 20	\$ 49	\$ 60
Restricted stock units	50	38	124	106
Total stock-based compensation	\$ 65	\$ 58	\$ 173	\$ 166

## Table of Contents

During the nine months ended September 30, 2017, the Company granted approximately 4 million stock options with a weighted average fair value of \$9.43 and a weighted average fair value exercise price of \$78.05. The Company had approximately 21 million stock options outstanding as of September 30, 2017 with a weighted average exercise price of \$75.09 and a weighted average contractual term of 3.87 years. During the nine months ended September 30, 2017, the Company granted approximately 3 million restricted stock units with a weighted average fair value of \$78.35. The Company had approximately 6 million restricted stock units unvested as of September 30, 2017 with a weighted average fair value of \$87.20.

### **Note 7 – Sale-Leaseback Transactions**

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which approximates fair value, and the resulting leases typically qualify and are accounted for as operating leases. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Proceeds from sale-leaseback transactions totaled \$265 million and \$230 million for the nine months ended September 30, 2017 and 2016, respectively.

### **Note 8 – Store Closures**

In December 2016, the Company announced an enterprise streamlining initiative designed to reduce costs and enhance operating efficiencies to allow the Company to be more competitive in the current health care environment. In connection with the enterprise streamlining initiative, the Company announced its intention to rationalize the number of retail stores by closing approximately 70 underperforming stores during the year ending December 31, 2017. During the three and nine months ended September 30, 2017, the Company closed five and 68 retail stores, respectively, and recorded charges of \$6 million and \$211 million, respectively, within operating expenses in the Retail/LTC Segment. The charges are primarily comprised of provisions for the present value of noncancelable lease obligations.

The noncancelable lease obligations associated with stores closed during the nine months ended September 30, 2017 extend through the year 2039. In connection with the enterprise streamlining initiative, the Company expects to record additional charges of approximately \$9 million during the fourth quarter of 2017 as it continues to rationalize the number of retail stores.

### **Note 9 – Interest Expense, Net**

The following are the components of interest expense, net:

<i>In millions</i>	Three Months Ended		Nine Months Ended	
	September 30, 2017	September 30, 2016	September 30, 2017	September 30, 2016
Interest expense	\$ 250	\$ 258	\$ 759	\$ 830
Interest income	(5)	(5)	(15)	(14)
Interest expense, net	<u>\$ 245</u>	<u>\$ 253</u>	<u>\$ 744</u>	<u>\$ 816</u>

### **Note 10 – Earnings Per Share**

Earnings per share is computed using the two-class method. Options to purchase 10.9 million and 9.9 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share, for the three and nine months ended September 30, 2017, respectively, because the exercise prices of the options were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, options to purchase approximately 7.7 million and 6.4 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share for the three and nine months ended September 30, 2016, respectively.

Table of Contents

The following is a reconciliation of basic and diluted earnings per share from continuing operations for the respective periods:

	Three Months Ended		Nine Months Ended	
	September 30, 2017	2016	September 30, 2017	2016
<i>In millions, except per share amounts</i>				
Numerator for earnings per share calculation:				
Income from continuing operations	\$ 1,285	\$ 1,542	\$ 3,344	\$ 3,613
Income allocated to participating securities	(3)	(7)	(12)	(18)
Net income attributable to noncontrolling interest	—	(1)	(1)	(2)
Income from continuing operations attributable to CVS Health	<u>\$ 1,282</u>	<u>\$ 1,534</u>	<u>\$ 3,331</u>	<u>\$ 3,593</u>
Denominator for earnings per share calculation:				
Weighted average shares, basic	1,016	1,068	1,022	1,076
Effect of dilutive securities	4	5	4	6
Weighted average shares, diluted	<u>1,020</u>	<u>1,073</u>	<u>1,026</u>	<u>1,082</u>
Earnings per share from continuing operations:				
Basic	\$ 1.26	\$ 1.44	\$ 3.26	\$ 3.34
Diluted	\$ 1.26	\$ 1.43	\$ 3.25	\$ 3.32

**Note 11 – Segment Reporting**

The Company has three reportable segments: Pharmacy Services, Retail/LTC and Corporate. The Retail/LTC Segment includes the operating results of the Company's Retail Pharmacy and LTC/RxCrossroads operating segments as the operations and economic characteristics are similar. The Company's three reportable segments maintain separate financial information by which operating results are evaluated on a regular basis by the Company's chief operating decision maker in deciding how to allocate resources and in assessing performance.

The Company evaluates its Pharmacy Services and Retail/LTC segments' performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.

The Pharmacy Services Segment provides a full range of pharmacy benefit management ("PBM") solutions including plan design offerings and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management. The Company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D, Managed Medicaid plans, plans offered on the public and private exchanges, and other sponsors of health benefit plans and individuals throughout the United States. Through the Company's SilverScript Insurance Company subsidiary, the Pharmacy Services Segment is a national provider of drug benefits to eligible beneficiaries under the federal government's Medicare Part D program. The Pharmacy Services Segment operates under the CVS Caremark<sup>®</sup> Pharmacy Services, Caremark<sup>®</sup>, CVS Caremark<sup>™</sup>, CarePlus CVS Pharmacy<sup>™</sup>, Accordant<sup>®</sup>, SilverScript<sup>®</sup>, Coram<sup>®</sup>, CVS Specialty<sup>™</sup>, NovoLogix<sup>®</sup>, Navarro<sup>®</sup> Health Services, Advanced Care Scripts and ACS Pharmacy names. As of September 30, 2017, the Pharmacy Services Segment operated 23 retail specialty pharmacy stores, 15 specialty mail order pharmacies, four mail service dispensing pharmacies, and 82 branches for infusion and enteral services, including approximately 73 ambulatory infusion suites and three centers of excellence, located in 41 states, Puerto Rico and the District of Columbia.

The Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing services, seasonal merchandise and greeting cards. The Retail/LTC Segment also includes providing the distribution of prescription drugs, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services that are provided under the name RxCrossroads<sup>®</sup>. The Retail/LTC



## Table of Contents

Segment also provides health care services through its MinuteClinic<sup>®</sup> health care clinics. MinuteClinics are staffed by nurse practitioners and physician assistants who utilize nationally recognized protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. As of September 30, 2017, our Retail/LTC Segment included 9,751 retail locations (of which 8,016 were the Company's stores that operated a pharmacy and 1,687 were the Company's pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy<sup>®</sup>, CVS<sup>®</sup>, CVS Pharmacy y más<sup>®</sup>, Longs Drugs<sup>®</sup>, Navarro Discount Pharmacy<sup>®</sup> and Drogeria Onofre<sup>™</sup> names, 38 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy<sup>™</sup>, CarePlus<sup>®</sup> and CVS Pharmacy<sup>®</sup> names, 1,129 retail health care clinics operating under the MinuteClinic<sup>®</sup> name (of which 1,122 were located in CVS Pharmacy and Target stores), and our online retail websites, CVS.com<sup>®</sup>, Navarro.com<sup>™</sup> and Onofre.com.br<sup>™</sup>. LTC operations are comprised of 143 spoke pharmacies that primarily handle new prescription orders, of which 31 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare<sup>®</sup> and NeighborCare<sup>®</sup> names.

The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

Table of Contents

<i>In millions</i>	Pharmacy Services Segment <sup>(1)</sup>	Retail/LTC Segment	Corporate Segment	Intersegment Eliminations	Consolidated Totals
<b>Three Months Ended</b>					
<b>September 30, 2017:</b>					
Net revenues	\$ 32,896	\$ 19,593	\$ —	\$ (6,308)	\$ 46,181
Gross profit <sup>(3)</sup>	1,645	5,685	—	(204)	7,126
Operating profit (loss) <sup>(4)(5)(6)</sup>	1,353	1,553	(220)	(187)	2,499
<b>September 30, 2016:</b>					
Net revenues	30,429	20,143	—	(5,957)	44,615
Gross profit <sup>(3)</sup>	1,797	5,893	—	(198)	7,492
Operating profit (loss) <sup>(5)(6)(7)</sup>	1,459	1,778	(228)	(185)	2,824
<b>Nine Months Ended</b>					
<b>September 30, 2017:</b>					
Net revenues	96,444	58,488	—	(18,552)	136,380
Gross profit <sup>(3)</sup>	4,210	17,036	—	(605)	20,641
Operating profit (loss) <sup>(4)(5)(6)</sup>	3,272	4,375	(686)	(552)	6,409
<b>September 30, 2016:</b>					
Net revenues	88,704	60,253	—	(17,402)	131,555
Gross profit <sup>(3)</sup>	4,266	17,560	—	(575)	21,251
Operating profit (loss) <sup>(5)(6)(7)</sup>	3,282	5,273	(660)	(529)	7,366

- (1) Net revenues of the Pharmacy Services Segment include approximately \$2.6 billion and \$2.5 billion of retail co-payments for the three months ended September 30, 2017 and 2016, respectively, as well as \$8.4 billion and \$8.1 billion of retail co-payments for the nine months ended September 30, 2017 and 2016, respectively.
- (2) Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients ("members") fill prescriptions at the Company's retail pharmacies to purchase covered products, when members enrolled in programs such as Maintenance Choice<sup>®</sup> elect to pick up maintenance prescriptions at one of the Company's retail pharmacies instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
- (3) The Retail/LTC Segment gross profit for the three months ended September 30, 2017 and 2016 includes \$2 million and \$5 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment gross profit for the nine months ended September 30, 2017 and 2016 includes \$7 million and \$15 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (4) The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2017 includes \$6 million and \$211 million, respectively, of charges associated with store closures (see "Note 8 – Store Closures" to the condensed consolidated financial statements). The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 also includes a \$135 million goodwill impairment charge related to the segment's RxCrossroads reporting unit (see "Note 2 – Goodwill and Intangible Assets" to the condensed consolidated financial statements).
- (5) The Retail/LTC Segment operating profit for the three months ended September 30, 2017 and 2016 includes \$9 million and \$52 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 and 2016 includes \$34 million and \$194 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (6) The Corporate Segment operating loss for the three and nine months ended September 30, 2017 include a \$3 million reduction in integration costs for a change in estimate related to the acquisition of Omnicare. The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes \$13 million of integration costs related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (7) Amounts revised to reflect the adoption of ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which increased consolidated operating profit by \$7 and \$23 million for the three and nine months ended September 30, 2016, respectively (see "Note 1 – Accounting Policies" to the condensed consolidated financial statements).

**Note 12 – Commitments and Contingencies**

***Lease Guarantees***

Between 1991 and 1997, the Company sold or spun off a number of subsidiaries, including Bob's Stores, Linens 'n Things, Marshalls, Kay-Bee Toys, Wilsons, This End Up and Footstar. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store's lease obligations. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company's guarantees remained in place, although each initial purchaser has agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of September 30, 2017, the Company guaranteed approximately 86 such store leases (excluding the lease guarantees related to Linens 'n Things, which have been recorded as a liability on the condensed consolidated balance sheet), with the maximum remaining lease term extending through 2047.

In April 2016 and again in February 2017, Bob's Stores and its related and successor entities filed for Chapter 11 bankruptcy protection. As described above, the Company, through one or more of its affiliates, is alleged to have guaranteed certain of the Bob's Stores' leases (the "Bob's Leases"). Following these bankruptcy filings, in May 2017 the Company and SDI Stores, LLC ("SDI Stores"), entered into an agreement regarding the Bob's Leases, which was amended in August 2017 (the "CVS/SDI Stores Agreement"). Pursuant to the CVS/SDI Stores Agreement, SDI Stores has accepted the assignment of the Bob's Leases and has agreed to be bound by certain restrictions regarding renewals, extensions and modifications to the Bob's Leases, in exchange for a series of payments that are immaterial to the Company.

***Legal Matters***

The Company is a party to legal proceedings, investigations and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company's accruals for outstanding legal matters are material individually or in the aggregate to the Company's financial position.

Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters.

- *Indiana State District Council of Laborers and HOD Carriers Pension and Welfare Fund v. Omnicare, Inc., et al.* (U.S. District Court for the Eastern District of Kentucky). In February 2006, two substantially similar putative class action lawsuits were filed and subsequently consolidated. The consolidated complaint was filed against Omnicare, three of its officers and two of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought shares of Omnicare common stock in Omnicare's public offering in December 2005. The complaint alleged violations of the Securities Exchange Act of 1934 and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. After dismissals and appeals to the United States Court of Appeals for the Sixth Circuit, the United States Supreme Court remanded the case to the district court. In October 2016, Omnicare filed an answer to plaintiffs' third amended complaint, and discovery commenced.
- *FTC and Multi-State Investigation.* In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies were conducting a multi-state investigation of certain of the Company's business practices similar to those being investigated at that time by the U.S. Federal Trade Commission ("FTC"). Twenty-eight states, the District of Columbia and the County of Los Angeles are known to be participating in this investigation. The prior FTC investigation, which commenced in August 2009, was officially concluded in May 2012 when the consent order entered into between the FTC and the Company became final. The Company has cooperated with the multi-state investigation.

## Table of Contents

- *United States ex rel. Jack Chin v. Walgreen Company, et al.* (U.S. District Court for the Central District of California). In March 2010, the Company received a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General (“OIG”) requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to the Company’s pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. In October 2016, the U.S. District Court for the Central District of California unsealed a *qui tam* complaint, filed in April 2009 against CVS Pharmacy and other retail pharmacies, alleging that the Company violated the federal False Claims Act, and the False Claims Acts of several states, by offering such programs. The complaint was served on the Company in January 2017. The federal government has declined intervention in the case. The Company is defending this lawsuit.
- *United States ex rel. Anthony R. Spay v. CVS Caremark Corporation, et al.* (U.S. District Court for the Eastern District of Pennsylvania). In January 2012, the court unsealed a first amended *qui tam* complaint filed in August 2011 by an individual relator, Anthony Spay, who is described in the complaint as having once been employed by a firm providing pharmacy prescription benefit audit and recovery services. The complaint seeks monetary damages and alleges that CVS Caremark’s processing of Medicare claims on behalf of one of its clients violated the federal False Claims Act. The United States declined to intervene in the lawsuit. In September 2015, the Court granted CVS Caremark’s motion for summary judgment in its entirety, and entered judgment in favor of CVS Caremark and against Spay. In October 2015, Spay filed a notice of appeal in the United States Court of Appeals for the Third Circuit; that court heard oral arguments on the appeal in November 2016.
- *State of Texas ex rel. Myron Winkelman and Stephani Martinson, et al. v. CVS Health Corporation.* (Travis County Texas District Court). In February 2012, the Attorney General of the State of Texas issued Civil Investigative Demands and has issued a series of subsequent requests for documents and information in connection with its investigation concerning the CVS Health Savings Pass program and other pricing practices with respect to claims for reimbursement from the Texas Medicaid program. In January 2017, the court unsealed a first amended petition. The amended petition alleges the Company violated the Texas Medicaid Fraud Prevention Act by submitting false claims for reimbursement to Texas Medicaid by, among other things, failing to use the price available to members of the CVS Health Savings Pass program as the usual and customary price. The amended petition was unsealed following the Company’s filing of *CVS Pharmacy, Inc. v. Charles Smith, et al.* (Travis County District Court), a declaratory judgment action against the State of Texas in December 2016 seeking a declaration that the prices charged to members of the CVS Health Savings Pass program do not constitute usual and customary prices under the Medicaid regulation. The State of Texas is also pursuing temporary injunctive relief.
- *Subpoena Concerning PBM Administrative Fees.* In March 2014, the Company received a subpoena from the United States Attorney’s Office for the District of Rhode Island, requesting documents and information concerning bona fide service fees and rebates received from pharmaceutical manufacturers in connection with certain drugs utilized under Medicare Part D, as well as the reporting of those fees and rebates to Part D plan sponsors. The Company has been cooperating with the government and providing documents and information in response to the subpoena.
- *Corcoran et al. v. CVS Health Corporation* (U.S. District Court for the Northern District of California) and *Podgorny et al. v. CVS Health Corporation* (U.S. District Court for the Northern District of Illinois). These putative class actions were filed against the Company in July and September 2015. The cases were consolidated in United States District Court in the Northern District of California. Plaintiffs seek damages and injunctive relief on behalf of a class of consumers who purchased certain prescription drugs under the consumer protection statutes and common laws of certain states. Several third-party payors filed similar putative class actions on behalf of payors captioned *Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp.* and *Plumbers Welfare Fund, Local 130 v. CVS Health Corporation* (both pending in the U.S. District Court for the District of Rhode Island) in February and August 2016. In all of these cases the plaintiffs allege the Company overcharged for certain prescription drugs by not submitting the price available to members of the CVS Health Savings Pass program as the pharmacy’s usual and customary price. In the consumer case (Corcoran), the Court granted summary judgment to CVS on plaintiffs’ claims in their entirety and certified certain subclasses in September 2017. The plaintiffs have filed a notice of appeal to the Ninth Circuit. The Company continues to defend these actions.

## Table of Contents

- *Omnicare DEA Subpoena.* In September 2015, Omnicare was served with an administrative subpoena by the U.S. Drug Enforcement Administration (“DEA”). The subpoena seeks documents related to controlled substance policies, procedures, and practices at eight pharmacy locations from May 2012 to the present. In September 2017, the DEA expanded the investigation to include an additional pharmacy. The Company has been cooperating and providing documents in response to this administrative subpoena.
- *Omnicare Cycle Fill Civil Investigative Demand.* In October 2015, Omnicare received a Civil Investigative Demand from the United States Attorney’s Office for the Southern District of New York requesting information and documents concerning Omnicare’s cycle fill process for assisted living facilities. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand. In July 2017, Omnicare also received a subpoena from the California Department of Insurance requesting documents on similar subject matter.
- *PBM Pricing Civil Investigative Demand.* In October 2015, the Company received from the DOJ a Civil Investigative Demand requesting documents and information in connection with a federal False Claims Act investigation concerning allegations that the Company submitted, or caused to be submitted, to the Medicare Part D program prescription drug event data that misrepresented true prices paid by the Company’s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *United States ex rel. Sally Schimelpfenig and John Segura v. Dr. Reddy’s Laboratories Limited and Dr. Reddy’s Laboratories, Inc.* (U.S. District Court for the Eastern District of Pennsylvania). In November 2015, the court unsealed a second amended *qui tam* complaint filed in September 2015. The DOJ declined to intervene in this action. The relators allege that the Company, Walgreens, Wal-Mart, and Dr. Reddy’s Laboratories violated the federal and various state False Claims Acts by dispensing prescriptions in unit dose packaging supplied by Dr. Reddy’s that was not compliant with the Consumer Product Safety Improvement Act and the Poison Preventive Packaging Act and thereby allegedly rendering the drugs misbranded under the Food, Drug and Cosmetic Act. In March 2017, the Court granted the Company’s motion to dismiss with leave to file an amended complaint. In June 2017, the Company moved to dismiss relators’ third amended complaint.
- *Barchock et al. v. CVS Health Corporation, et al.* (U.S. District Court for the District of Rhode Island). In February 2016, a class action lawsuit was filed against the Company, the Benefit Plans Committee of the Company, and Galliard Capital Management, Inc., by Mary Barchock, Thomas Wasecko, and Stacy Weller, purportedly on behalf of the 401(k) Plan and the Employee Stock Ownership Plan of the Company (the “Plan”), and participants in the Plan. The complaint alleged that the defendants breached fiduciary duties owed to the plaintiffs and the Plan by investing too much of the Plan’s Stable Value Fund in short-term money market funds and cash management accounts. The court recently granted the Company’s motion to dismiss the plaintiffs’ amended complaint. In May 2017, plaintiffs appealed that ruling in the United States Court of Appeals for the First Circuit.
- *State of California ex rel. Matthew Omlansky v. CVS Caremark Corporation* (Superior Court of the State of California, County of Sacramento). In April 2016, the court unsealed a first amended *qui tam* complaint filed in July 2013. The government has declined intervention in this case. The relator alleges that the Company submitted false claims for payment to California Medicaid in connection with reimbursement for drugs available through the CVS Health Savings Pass program as well as certain other generic drugs. The case has been stayed pending the relator’s appeal of the judgment against him in a similar case against another retailer.
- *Retail DEA Matters.* The Company has been also undergoing several audits by the DEA Administrator and is in discussions with the DEA and the U.S. Attorney’s Offices in several locations concerning allegations that the Company has violated certain requirements of the CSA.
- *West Virginia Opioid Litigation.* In March 2017, the Company was named as a defendant in four separate lawsuits filed in the U.S. District Court of the Southern District of West Virginia on behalf of counties in the state of West Virginia (Cabell, Fayette, Kanawha and Wayne counties), each of which alleges that CVS Indiana L.L.C., as well as various other distributors of controlled substances, caused a public nuisance related to opioid

## Table of Contents

abuse by failing to detect and/or report purported suspicious orders of opioids distributed for dispensing in the plaintiff counties. Omnicare Distribution Center, LLC also is named as a defendant in the complaint filed by Kanawha County. The Company is defending these lawsuits.

- *Cherokee Nation Opioid Litigation*. In April 2017, the Company was named as a defendant in an action filed on behalf of the Cherokee Nation in the District Court of Cherokee Nation (the “Cherokee Action”). The lawsuit asserts several causes of action arising from allegations that large retail pharmacies and wholesale distributors caused widespread opioid abuse among members of the Cherokee Nation by purportedly failing to comply with the Controlled Substances Act and/or otherwise failing to prevent the diversion of opioids. In June 2017, the Company filed a motion to dismiss the Cherokee Action. The Cherokee Nation has since filed an amended petition in the Cherokee Action. Also in June 2017, the six defendants in the Cherokee Action collectively filed a complaint in the U.S. District Court for the Northern District of Oklahoma, *McKesson, et al. v. Hembree, et al.*, seeking a declaration and preliminary injunction prohibiting the District Court of Cherokee Nation from exercising jurisdiction over the Cherokee Action.
- *State of Mississippi v. CVS Health Corporation, et al.* (Chancery Court of DeSoto County, Mississippi, Third Judicial District). In July 2016, the Company was served with a complaint filed on behalf of the State of Mississippi alleging that CVS retail pharmacies in Mississippi submitted false claims for reimbursement to Mississippi Medicaid by not submitting the price available to members of the CVS Health Savings Pass program as the pharmacy’s usual and customary price. The Company has responded to the complaint, filed a counterclaim, and moved to transfer the case to circuit court. The motion to transfer was granted, which the State has appealed, and the motion to dismiss remains pending.
- *Mayberry v. Walgreens Co., et al.* (U.S. District Court for the Northern District of Illinois). In March 2017, a complaint was filed against the Company (and several other retail pharmacy defendants) alleging that the defendant pharmacies improperly submitted certain insulin claims through Medicare Part D rather than Part B. The Company’s motion to dismiss the complaint was granted. The Company separately received in December 2016 a Civil Investigative Demand from the U.S. Attorney’s Office for the Northern District of New York, requesting documents and information in connection with a False Claims Act investigation concerning whether the Company’s retail pharmacies improperly submitted certain insulin claims to Medicare Part D rather than Part B. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *Cold Chain Logistics Civil Investigative Demand*. In September 2016, the Company received from the DOJ a Civil Investigative Demand in connection with an investigation as to whether the Company’s handling of certain temperature-sensitive pharmaceuticals violates the federal Food, Drug and Cosmetic Act and the False Claims Act. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *Amburgey, et al. v. CaremarkPCS Health, L.L.C.* (U.S. District Court for the Central District of California). In March 2017, the Company was served with a complaint challenging the policies and procedures used by CVS Specialty pharmacies to ship temperature-sensitive medications. The case is similar to a matter already pending against the Company in the Superior Court of California (Los Angeles County), *Bertram v. Immunex Corp., et al.*, which was filed in October 2014. The Company is defending these lawsuits.
- *Barnett, et al. v. Novo Nordisk Inc., et al.* and *Boss, et al. v. CVS Health Corporation, et al.* (both pending in the U.S. District Court for the District of New Jersey). These putative class actions were filed against the Company and other PBMs and manufacturers of insulin in March 2017. Plaintiffs in both cases allege that the PBMs and manufacturers have engaged in a conspiracy whereby the PBMs sell access to their formularies by demanding the highest rebates, which in turn causes increased list prices for insulin. The primary claims are antitrust claims, claims under the Racketeer Influenced and Corrupt Organizations Act (“RICO”), violations of state unfair competition and consumer protection laws and in *Boss*, claims pursuant to the Employee Retirement Income Security Act (“ERISA”). The *Barnett* plaintiffs seek to represent a nationwide class of all persons who paid any portion of the purchase prices for a prescription for certain insulin products at a price calculated by reference to a benchmark. The *Boss* plaintiffs purport to represent multiple nationwide classes including a non-ERISA Employee/Exchange Plan class, an ERISA class, a Medicare class and an uninsured class. The Company continues to defend these lawsuits.

## Table of Contents

- *Insulin Products Investigation.* In April 2017, the Company separately received a Civil Investigative Demand from the Attorney General of Washington, seeking documents and information regarding pricing and rebates for insulin products in connection with a pending investigation into unfair and deceptive acts or practice regarding insulin pricing. We have been notified by the Office of the Attorney General of Washington that information provided in response to the Civil Investigative Demand will be shared with the Attorneys General of California, Florida, Minnesota and New Mexico. In July 2017, the Company received a Civil Investigative Demand from the Attorney General of Minnesota, seeking documents and information regarding pricing and rebates for insulin and epinephrine products in connection with a pending investigation into unfair and deceptive acts or practices regarding insulin and epinephrine pricing.
- *Bewley, et al. v. CVS Health Corporation, et al. and Prescott, et al. v. CVS Health Corporation, et al.* (both pending in the U.S. District Court for the Western District of Washington). These putative class actions were filed in May 2017 against the Company and other pharmacy benefit managers and manufacturers of glucagon kits (Bewley) and diabetes test strips (Prescott). Both cases allege that, by contracting for rebates with the manufacturers of these diabetes products, the Company and other PBMs caused list prices for these products to increase, thereby harming certain consumers. The primary claims are made under federal antitrust laws, RICO, state unfair competition and consumer protection laws, and ERISA. The Company is defending these lawsuits.
- *Klein, et al. v. Prime Therapeutics, et al.* (U.S. District Court for the District of Minnesota). In June 2017, a putative class action complaint was filed against the Company and other pharmacy benefit managers on behalf of ERISA plan members who purchased and paid for EpiPen or EpiPen Jr. Plaintiffs allege that the pharmacy benefit managers are ERISA fiduciaries to plan members and have violated ERISA by allegedly causing higher inflated prices for EpiPen through the process of negotiating increased rebates from EpiPen manufacturer, Mylan. The Company is defending this lawsuit.
- *Medicare Part D Civil Investigative Demand.* In May 2017, the United States Attorney's Office for the Southern District of New York issued a Civil Investigative Demand to the Company concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *Shareholder Matters.* In August and September 2017, four complaints were filed by putative derivative plaintiffs against certain officers and directors of the Company. Three of those actions, *Sherman v. Merlo, et al.*, *Feghali v. Merlo, et al.*, and *Banchalter v. Merlo, et al.*, were filed in the U.S. District Court for the District of Rhode Island. A fourth, *Boron v. Bracken, et al.*, was filed in Rhode Island Superior Court. These matters assert a variety of causes of action, including breach of fiduciary duty, waste of corporate assets, unjust enrichment, civil conspiracy and violation of Section 14(a) of the Exchange Act, and are premised on the allegation that the defendants approved business plans that exposed the Company to various litigations and investigations. The parties in the three federal matters have filed a joint motion to stay the cases pending resolution of certain of the underlying matters.
- *MSP Recovery Claims Series, LLC, et al. v. CVS Health Corporation, et al.* (U.S. District Court for the Western District of Texas). In September 2017, a putative class action complaint was filed against the company, Express Scripts, Inc., and the manufacturers of insulin on behalf of assignees of claims of Medicare Advantage Organizations. Plaintiffs assert that the PBMs and manufacturers have engaged in a conspiracy whereby the PBMs sell access to their formularies by demanding the highest rebates, which in turn causes increased list prices for insulin. The plaintiffs assert claims on behalf of two putative classes: (1) all Medicare C payors and (2) all Medicare D payors. The complaint asserts claims under RICO, and for common law fraud and unjust enrichment.

The Company is also a party to other legal proceedings, government investigations, inquiries and audits, and has received and is cooperating with subpoenas or similar process from various governmental agencies requesting information, all arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that its business, financial condition and results of operations will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing

Table of Contents

laws or regulations as they may relate to the Company's business, the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industries or to the health care industry generally; (iii) pending or future federal or state governmental investigations of the Company's business or the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or of the health care industry generally; (iv) pending or future government enforcement actions against the Company; (v) adverse developments in any pending *qui tam* lawsuit against the Company, whether sealed or unsealed, or in any future *qui tam* lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or the health care industry generally.



**Report of Independent Registered Public Accounting Firm**

The Board of Directors and Shareholders  
CVS Health Corporation:

We have reviewed the condensed consolidated balance sheet of CVS Health Corporation (the Company) as of September 30, 2017, the related condensed consolidated statements of income and comprehensive income for the three-month and nine-month periods ended September 30, 2017 and 2016, and the condensed consolidated statements of cash flows for the nine-month periods ended September 30, 2017 and 2016. These financial statements are the responsibility of the Company's management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of CVS Health Corporation as of December 31, 2016, and the related consolidated statements of income, comprehensive income, shareholders' equity and cash flows for the year then ended (not presented herein), and we expressed an unqualified audit opinion on those consolidated financial statements in our report dated February 9, 2017. In our opinion, the accompanying condensed consolidated balance sheet of CVS Health Corporation as of December 31, 2016, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ Ernst & Young LLP

November 6, 2017  
Boston, Massachusetts

**Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Overview of Our Business**

CVS Health Corporation, together with its subsidiaries (collectively, "CVS Health," the "Company," "we," "our" or "us"), is a pharmacy innovation company helping people on their path to better health. At the forefront of a changing health care landscape, the Company has an unmatched suite of capabilities and the expertise needed to drive innovations that will help shape the future of health care.

We are currently the only integrated pharmacy health care company with the ability to impact consumers, payors, and providers with innovative, channel-agnostic solutions. We have a deep understanding of their diverse needs through our unique integrated model, and we are bringing them innovative solutions that help increase access to quality care, deliver better health outcomes and lower overall health care costs.

Through more than 9,700 retail locations, more than 1,100 walk-in health care clinics, a leading pharmacy benefits manager with nearly 90 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services and a leading stand-alone Medicare Part D prescription drug plan, we enable people, businesses, and communities to manage health in more affordable, effective ways. We are delivering break-through products and services, from advising patients on their medications at our CVS Pharmacy<sup>®</sup> locations, to introducing unique programs to help control costs for our clients at CVS Caremark<sup>®</sup>, to innovating how care is delivered to our patients with complex conditions through CVS Specialty<sup>™</sup>, to improving pharmacy care for the senior community through Omnicare<sup>®</sup>, or by expanding access to high-quality, low-cost care at CVS MinuteClinic<sup>®</sup>.

We have three reportable segments: Pharmacy Services, Retail/LTC and Corporate.

*Pharmacy Services Segment*

Our Pharmacy Services business generates revenue from a full range of pharmacy benefit management ("PBM") solutions, including plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management.

Our clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D plans, Managed Medicaid plans, plans offered on the public and private exchanges, other sponsors of health benefit plans and individuals throughout the United States. A portion of covered lives, primarily within the Managed Medicaid, health plan and employer markets have access to our services through public and private exchanges.

As a pharmacy benefits manager, we manage the dispensing of prescription drugs through our mail order pharmacies, specialty pharmacies, long-term care pharmacies and national network of more than 68,000 retail pharmacies, consisting of approximately 41,000 chain pharmacies (which includes our CVS Pharmacy<sup>®</sup> pharmacies) and 27,000 independent pharmacies, to eligible members in the benefit plans maintained by our clients and utilize our information systems to perform, among other things, safety checks, drug interaction screenings and brand-to-generic substitutions.

Our specialty pharmacies support individuals who require complex and expensive drug therapies. Our specialty pharmacy business includes mail order and retail specialty pharmacies that operate under the CVS Caremark<sup>®</sup>, CarePlus CVS Pharmacy<sup>®</sup>, Navarro<sup>®</sup> Health Services and Advanced Care Scripts or ACS names. The Pharmacy Services Segment also provides health management programs, which include integrated disease management for 18 conditions, through our Accordant<sup>®</sup> rare disease management offering. In addition, through our SilverScript Insurance Company subsidiary, we are a national provider of drug benefits to eligible beneficiaries under the federal government's Medicare Part D program. The Pharmacy Services Segment operates under the CVS Caremark<sup>®</sup> Pharmacy Services, Caremark<sup>®</sup>, CVS Caremark<sup>®</sup>, CarePlus CVS Pharmacy<sup>®</sup>, Accordant<sup>®</sup>, SilverScript<sup>®</sup>, Coram<sup>®</sup>, CVS Specialty<sup>™</sup>, NovoLogix<sup>®</sup>, Navarro<sup>®</sup> Health Services and Advanced Care Scripts or ACS names. As of September 30, 2017, the Pharmacy Services Segment operated 23 retail specialty pharmacy stores, 15 specialty mail order pharmacies, four mail service dispensing pharmacies, and 82 branches for infusion and enteral services, including approximately 73 ambulatory infusion suites and three centers of excellence, located in 41 states, Puerto Rico and the District of Columbia.

## Table of Contents

### *Retail/LTC Segment*

Our Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing, seasonal merchandise and greeting cards through our CVS Pharmacy<sup>®</sup>, CVS<sup>®</sup>, Longs Drugs<sup>®</sup>, Navarro Discount Pharmacy<sup>®</sup> and Drogeria Onofre<sup>™</sup> retail locations and online through CVS.com<sup>®</sup>, Navarro.com<sup>™</sup> and Onofre.com.br<sup>™</sup>. The Retail/LTC Segment also includes providing the distribution of prescription drugs, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services that are provided under the name RxCrossroads<sup>®</sup>. Our Retail/LTC Segment derives the majority of its revenues through the sale of prescription drugs, which are dispensed by our more than 31,000 pharmacists. Our Retail/LTC Segment also provides health care services through our MinuteClinic health care clinics. MinuteClinics are staffed by nurse practitioners and physician assistants who utilize nationally recognized protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. As of September 30, 2017, our Retail/LTC Segment included 9,751 retail locations (of which 8,016 were the Company's stores that operated a pharmacy and 1,687 were the Company's pharmacies located within a Target store) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy<sup>®</sup>, CVS<sup>®</sup>, CVS Pharmacy y más<sup>®</sup>, Longs Drugs<sup>®</sup>, Navarro Discount Pharmacy<sup>®</sup> and Drogeria Onofre<sup>™</sup> names, 38 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy<sup>®</sup>, CarePlus<sup>®</sup> and CVS Pharmacy<sup>®</sup> names, 1,129 retail health care clinics operating under the MinuteClinic<sup>®</sup> name (of which 1,122 were located in CVS Pharmacy and Target stores), and our online retail websites, CVS.com<sup>®</sup>, Navarro.com<sup>™</sup> and Onofre.com.br<sup>™</sup>. LTC operations are comprised of 143 spoke pharmacies that primarily handle new prescription orders, of which 31 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare<sup>®</sup> and NeighborCare<sup>®</sup> names.

### *Corporate Segment*

The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of our executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

### **Results of Operations**

The following discussion explains the material changes in our results of operations for the three and nine months ended September 30, 2017 and 2016, and the significant developments affecting our financial condition since December 31, 2016. We strongly recommend that you read our audited consolidated financial statements and notes thereto and Management's Discussion and Analysis of Financial Condition and Results of Operations included as Exhibit 13 to our 2016 Form 10-K along with this report.

Table of Contents

**Summary of the Condensed Consolidated Financial Results:**

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
<i><u>In millions, except per share amounts</u></i>	<b>2017</b>	<b>2016</b>	<b>2017</b>	<b>2016</b>
Net revenues	\$ 46,181	\$ 44,615	\$ 136,380	\$ 131,555
Cost of revenues	39,055	37,123	115,739	110,304
Gross profit	7,126	7,492	20,641	21,251
Operating expenses	4,627	4,668	14,232	13,885
Operating profit	2,499	2,824	6,409	7,366
Interest expense, net	245	253	744	816
Loss on early extinguishment of debt	—	101	—	643
Other expense	192	7	206	23
Income before income tax provision	2,062	2,463	5,459	5,884
Income tax provision	777	921	2,115	2,271
Income from continuing operations	1,285	1,542	3,344	3,613
Loss from discontinued operations, net of tax	—	(1)	(8)	(1)
Net income	1,285	1,541	3,336	3,612
Net income attributable to noncontrolling interest	—	(1)	(1)	(2)
Net income attributable to CVS Health	<u>\$ 1,285</u>	<u>\$ 1,540</u>	<u>\$ 3,335</u>	<u>\$ 3,610</u>

***Net Revenues***

Net revenues increased approximately \$1.6 billion, or 3.5%, and \$4.8 billion, or 3.7%, in the three and nine months ended September 30, 2017, respectively, as compared to the prior year. The increase is due to increases in the Pharmacy Services Segment partially offset by decreases in the Retail/LTC Segment. The increase in the Pharmacy Services Segment was driven by growth in pharmacy network claim volume attributable to net new business, brand inflation and specialty pharmacy volume, partially offset by increased price compression and generic dispensing. The decrease in the Retail/LTC Segment was primarily due to a decline in same stores sales as a result of the previously-announced marketplace changes, which began to have an impact in the fourth quarter of 2016, that restrict CVS Pharmacy from participating in certain networks. The Retail/LTC Segment decrease was also due to continued reimbursement pressure and an increase in the generic dispensing rate. Generic prescription drugs typically have a lower selling price than brand name prescription drugs.

Please see the section entitled “Segment Analysis” below for additional information regarding net revenues.

***Gross Profit***

Gross profit dollars decreased \$366 million, or 4.9%, and \$610 million, or 2.9%, in the three and nine months ended September 30, 2017, respectively, as compared to the prior year. Gross profit dollars for the three months ended September 30, 2017, were negatively affected by continued reimbursement pressure as well as the loss of prescription volume in the Retail/LTC Segment as a result of previously-announced marketplace changes. Gross profit as a percentage of net revenues decreased approximately 135 basis points in the three months ended September 30, 2017 to 15.4%, as compared to the prior year. Gross profit as a percentage of net revenues decreased approximately 100 basis points in the nine months ended September 30, 2017 to 15.1%, as compared to the prior year. The decrease in gross profit as a percentage of net revenues was driven by the increased weighting toward the Pharmacy Services Segment, which has a lower gross profit than the Retail/LTC Segment.

Please see the section entitled “Segment Analysis” below for additional information regarding gross profit.

## Table of Contents

### ***Operating Expenses***

Operating expenses decreased \$41 million, or 0.9%, in the three months ended September 30, 2017 as compared to the prior year. Operating expenses as a percentage of net revenues decreased approximately 45 basis points to 10.0% in the three months ended September 30, 2017 as compared to the prior year. The decrease in operating expenses in the three months ended September 30, 2017 was primarily due to the following:

- A decrease in acquisition-related integration costs of \$56 million versus the same period in the prior year.
- The realization of partially reserved receivables within the Pharmacy Services Segment.

These items were partially offset by:

- Hurricane related expenses of \$55 million, predominately in the Retail/LTC Segment, as a result of the three major hurricanes that hit the southern United States and Puerto Rico.
- An increase in operating expenses due to incremental store operating costs associated with operating more stores.

Operating expenses increased \$347 million, or 2.5%, in the nine months ended September 30, 2017 as compared to the prior year. Operating expenses as a percentage of net revenues decreased approximately 10 basis points to 10.4% in the nine months ended September 30, 2017 as compared to the prior year. The increase in operating expenses in the nine months ended September 30, 2017 was due to the items mentioned above, which were more than offset by the following:

- A goodwill impairment charge of \$135 million in the second quarter of 2017 in the RxCrossroads reporting unit (see “Note 2 – Goodwill and Intangible Assets” to our condensed consolidated financial statements).
- Charges of \$211 million in the nine months ended September 30, 2017 associated with the closure of 68 retail stores in connection with our enterprise streamlining initiative (see “Note 8 – Store Closures” to our condensed consolidated financial statements).

Please see the section entitled “Segment Analysis” below for additional information regarding operating expenses.

### ***Interest Expense, net***

Interest expense, net, decreased \$8 million and \$72 million in the three and nine months ended September 30, 2017, respectively, as compared to the prior year. The decrease in the three and nine months ended was primarily due to the Company’s debt issuance and debt tender offers that occurred in 2016 which resulted in overall more favorable interest rates on the Company’s long-term debt.

For additional information on our financing activities, please see the “Liquidity and Capital Resources” section below.

### ***Loss on Early Extinguishment of Debt***

During the three months ended September 30, 2016, the Company exercised its option to redeem outstanding senior notes of approximately \$1.1 billion aggregate principal amount. The Company paid a premium of \$97 million in excess of the debt principal in connection with the purchase of the senior notes and wrote off \$4 million of unamortized deferred financing costs, for a total loss on the early extinguishment of debt of \$101 million.

During the nine months ended September 30, 2016, the Company purchased approximately \$4.2 billion aggregate principal amount of certain of its senior notes pursuant to its tender offer for such senior notes and option to redeem the outstanding senior notes. The Company paid a premium of \$583 million in excess of the debt principal, wrote off \$54 million of unamortized deferred financing costs and incurred \$6 million in fees, for a total loss on the early extinguishment of debt of \$643 million.

## Table of Contents

### ***Other Expense***

Other expense increased \$185 million and \$183 million in the three and nine months ended September 30, 2017, respectively, as compared to the prior year. The increase in the three and nine months ended was primarily driven by the losses on the settlements of defined benefit pension plans of \$187 million. See “Note 4 – Pension Settlements” to the Company’s condensed consolidated financial statements.

### ***Income Tax Provision***

Our effective income tax rate was 37.7% and 37.4% for the three months ended September 30, 2017 and 2016, respectively. The effective income tax rate in 2017 was higher than in 2016 primarily due to a discrete tax benefit recorded in 2016 related to the successful resolution with the IRS of certain tax matters, partially offset by the tax benefit recognized in 2017 for employee share-based compensation. Our effective income tax rate was 38.7% and 38.6% for the nine months ended September 30, 2017 and 2016, respectively. The effective income tax rate in 2017 was higher than in 2016 primarily due to the impact of the nondeductible goodwill impairment charge recognized in 2017, partially offset by the excess tax benefit recognized for employee share-based compensation.

### ***Loss from Discontinued Operations***

The loss from discontinued operations of \$8 million for the nine months ended September 30, 2017, was primarily comprised of a \$15 million charge (net of tax of \$6 million) associated with lease guarantees the Company provided on store lease obligations of Bob’s Stores, a former subsidiary of the Company that filed for bankruptcy subsequent to its disposition. See “Note 12 - Commitments and Contingencies” to the Company’s condensed consolidated financial statements.

Table of Contents

**Segment Analysis**

We evaluate the performance of our Pharmacy Services and Retail/LTC segments based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. We evaluate the performance of our Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of our segments to the condensed consolidated financial statements:

<i>In millions</i>	<b>Pharmacy Services Segment<sup>(1)</sup></b>	<b>Retail/LTC Segment</b>	<b>Corporate Segment</b>	<b>Intersegment Eliminations</b>	<b>Consolidated Totals</b>
<b>Three Months Ended</b>					
<b>September 30, 2017:</b>					
Net revenues	\$ 32,896	\$ 19,593	\$ —	\$ (6,308)	\$ 46,181
Gross profit <sup>(3)</sup>	1,645	5,685	—	(204)	7,126
Operating profit (loss) <sup>(4)(5)(6)</sup>	1,353	1,553	(220)	(187)	2,499
<b>September 30, 2016:</b>					
Net revenues	30,429	20,143	—	(5,957)	44,615
Gross profit <sup>(3)</sup>	1,797	5,893	—	(198)	7,492
Operating profit (loss) <sup>(5)(6)(7)</sup>	1,459	1,778	(228)	(185)	2,824
<b>Nine Months Ended</b>					
<b>September 30, 2017:</b>					
Net revenues	96,444	58,488	—	(18,552)	136,380
Gross profit <sup>(3)</sup>	4,210	17,036	—	(605)	20,641
Operating profit (loss) <sup>(4)(5)(6)</sup>	3,272	4,375	(686)	(552)	6,409
<b>September 30, 2016:</b>					
Net revenues	88,704	60,253	—	(17,402)	131,555
Gross profit <sup>(3)</sup>	4,266	17,560	—	(575)	21,251
Operating profit (loss) <sup>(5)(6)(7)</sup>	3,282	5,273	(660)	(529)	7,366

- (1) Net revenues of the Pharmacy Services Segment include approximately \$2.6 billion and \$2.5 billion of retail co-payments for the three months ended September 30, 2017 and 2016, respectively, as well as \$8.4 billion and \$8.1 billion of retail co-payments for the nine months ended September 30, 2017 and 2016, respectively.
- (2) Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients ("members") fill prescriptions at the Company's retail pharmacies to purchase covered products, when members enrolled in programs such as Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company's retail pharmacies instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
- (3) The Retail/LTC Segment gross profit for the three months ended September 30, 2017 and 2016 includes \$2 million and \$5 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment gross profit for the nine months ended September 30, 2017 and 2016 includes \$7 million and \$15 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (4) The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2017 includes \$6 million and \$211 million, respectively, of charges associated with store closures (see "Note 8 – Store Closures" to the condensed consolidated financial statements). The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 also includes a \$135 million goodwill impairment charge related to the segment's RxCrossroads reporting unit (see "Note 2 – Goodwill and Intangible Assets" to the condensed consolidated financial statements).
- (5) The Retail/LTC Segment operating profit for the three months ended September 30, 2017 and 2016 includes \$9 million and \$52 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 and 2016 includes \$34 million and \$194 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (6) The Corporate Segment operating loss for the three and nine months ended September 30, 2017 include a \$3 million reduction in integration costs for a change in estimate related to the acquisition of Omnicare. The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes \$13 million of integration costs related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (7) Amounts revised to reflect the adoption of ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which increased consolidated operating profit by \$7 and \$23 million for the three and nine months ended September 30, 2016, respectively (see "Note 1 - Accounting Policies" to the condensed consolidated financial statements).

**Pharmacy Services Segment**

The following table summarizes our Pharmacy Services Segment's performance for the respective periods:

<i>In millions</i>	Three Months Ended September 30,		Nine Months Ended September 30,	
	2017	2016	2017	2016
Net revenues	\$32,896	\$30,429 <sup>(1)</sup>	\$ 96,444	\$ 88,704
Gross profit	1,645	1,797	4,210	4,266
Gross profit % of net revenues	5.0 %	5.9 %	4.4 %	4.8 %
Operating expenses <sup>(1)</sup>	292	338	938	984
Operating expenses % of net revenues	0.9 %	1.1 %	1.0 %	1.1 %
Operating profit <sup>(1)</sup>	1,353	1,459	3,272	3,282
Operating profit % of net revenues	4.1 %	4.8 %	3.4 %	3.7 %
Net revenues:				
Mail choice <sup>(2)</sup>	\$11,590	\$10,872	\$ 33,950	\$ 31,668
Pharmacy network <sup>(3)</sup>	21,216	19,469	62,258	56,783
Other	90	88	236	253
Pharmacy claims processed (90 Day = 3 prescriptions) <sup>(4)(5)</sup> :				
Total	441.1	408.7	1,323.2	1,213.8
Mail choice <sup>(2)</sup>	66.9	63.0	196.2	186.3
Pharmacy network <sup>(3)</sup>	374.2	345.7	1,127.0	1,027.5
Generic dispensing rate <sup>(4)(5)</sup> :				
Total	87.0 %	86.0 %	87.1 %	85.8 %
Mail choice <sup>(2)</sup>	83.3 %	81.7 %	83.1 %	81.1 %
Pharmacy network <sup>(3)</sup>	87.7 %	86.8 %	87.8 %	86.7 %
Mail choice penetration rate <sup>(4)(5)</sup>	15.2 %	15.4 %	14.8 %	15.3 %

- (1) Amounts revised to reflect the adoption of ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which decreased operating expenses and increased operating profit by \$1 million for the three months ended September 30, 2016. For the nine months ended September 30, 2016, the adoption of ASU 2017-07 decreased operating expenses and increased operating profit by \$4 million.
- (2) Mail choice is defined as claims filled at a Pharmacy Services mail facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at retail, as well as prescriptions filled at our retail pharmacies under the Maintenance Choice® program.
- (3) Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice activity, which is included within the mail choice category. Pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including our retail pharmacies and long-term care pharmacies, but excluding Maintenance Choice activity.
- (4) Includes the adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
- (5) The pharmacy claims processed, the generic dispensing rate and the mail choice penetration rate for the three and nine months ended September 30, 2016 has been revised to reflect 90-day prescriptions to the equivalent of three 30-day prescriptions.

**Net Revenues**

Net revenues in our Pharmacy Services Segment increased \$2.5 billion, or 8.1%, to \$32.9 billion in the three months ended September 30, 2017, as compared to the prior year. Net revenues in our Pharmacy Services Segment increased \$7.7 billion, or 8.7%, to \$96.4 billion in the nine months ended September 30, 2017, as compared to the prior year. The increase is primarily due to growth in pharmacy network claim volume, brand inflation and specialty pharmacy volume, partially offset by increased price compression and generic dispensing. As you review our Pharmacy Services Segment's performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2017:

- In the three months ended September 30, 2017, our mail choice claims processed, on a 30-day equivalent basis, increased 6.1% to 66.9 million claims compared to 63.0 million claims in the prior year. In the nine months ended September 30, 2017, our mail choice claims processed, on a 30-day equivalent basis, increased 5.3% to 196.2 million claims compared to 186.3 million claims in the prior year. The increase in mail choice claims was primarily driven by the continued adoption of our Maintenance Choice offerings and an increase in specialty pharmacy claims.



## Table of Contents

- Our average revenue per mail choice claim, on a 30-day equivalent basis, increased 0.4% and 1.8% in the three and nine months ended September 30, 2017, respectively, compared to the prior year. This increase was primarily due to growth in specialty pharmacy.
- In the three months ended September 30, 2017, our pharmacy network claims processed, on a 30-day equivalent basis, increased 8.3% to 374.2 million claims compared to 345.7 million claims in the prior year. In the nine months ended September 30, 2017, our pharmacy network claims processed, on a 30-day equivalent basis, increased 9.7% to 1,127.0 million claims compared to 1,027.5 million claims in the prior year. The increase in the pharmacy network claim volume was primarily due to net new business.
- Our average revenue per pharmacy network claim processed, on a 30-day equivalent basis, increased 0.6% and decreased 0.1% in the three and nine months ended September 30, 2017, respectively, compared to the prior year.
- In the three months ended September 30, 2017, our total generic dispensing rate increased to 87.0%, compared to 86.0% in the prior year. In the nine months ended September 30, 2017, our total generic dispensing rate increased to 87.1%, compared to 85.8% in the prior year. These continued increases in our generic dispensing rate were primarily due to the impact of new generic drug introductions, and our continuous efforts to encourage plan members to use generic drugs when they are available and clinically appropriate. We believe our generic dispensing rate will continue to increase in future periods, albeit at a slower pace. This increase will be affected by, among other things, the number of new brand and generic drug introductions and our success at encouraging plan members to utilize generic drugs when they are available and clinically appropriate.

### **Gross Profit**

Gross profit in our Pharmacy Services Segment includes net revenues less cost of revenues. Cost of revenues includes (i) the cost of pharmaceuticals dispensed, either directly through our mail service, specialty mail and specialty retail pharmacies or indirectly through our retail pharmacy networks, (ii) shipping and handling costs and (iii) the operating costs of our mail service dispensing pharmacies, customer service operations and related information technology support.

Gross profit decreased \$152 million, or 8.4%, to approximately \$1.6 billion in the three months ended September 30, 2017, as compared to the prior year. Gross profit decreased \$56 million, or 1.3%, to approximately \$4.2 billion in the nine months ended September 30, 2017, as compared to the prior year. The decrease in gross profit dollars was primarily due to price compression and a shift in the timing of the Medicare Part D gross profit dollars between the third and fourth quarter in 2017 due to participants moving through benefits slower relative to the prior year, partially offset by network volume increases. Gross profit as a percentage of net revenues decreased to 5.0% in the three months ended September 30, 2017, compared to 5.9% in the prior year. Gross profit as a percentage of net revenues decreased to 4.4% in the nine months ended September 30, 2017, compared to 4.8% in the prior year. The decrease in gross profit as a percentage of net revenues was primarily due to continued price compression and changes in the mix of our business, partially offset by favorable generic dispensing.

As you review our Pharmacy Services Segment's performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2017:

- Our efforts to (i) retain existing clients, (ii) obtain new business and (iii) maintain or improve the rebates and/or discounts we received from manufacturers, wholesalers and retail pharmacies continue to have an impact on our gross profit dollars and gross profit as a percentage of net revenues. In particular, competitive pressures in the PBM industry have caused us and other PBMs to continue to share with clients a larger portion of rebates and/or discounts received from pharmaceutical manufacturers. In addition, market dynamics and regulatory changes have limited our ability to offer plan sponsors pricing that includes retail network "differential" or "spread," and we expect these trends to continue. The "differential" or "spread" is any difference between the drug price charged to plan sponsors, including Medicare Part D plan sponsors, by a PBM and the price paid for the drug by the PBM to the dispensing provider.
- Our gross profit as a percentage of revenues benefited from the increase in our total generic dispensing rate, as noted previously.

## Table of Contents

### *Operating Expenses*

Operating expenses in our Pharmacy Services Segment include selling, general and administrative expenses; depreciation and amortization related to selling, general and administrative activities; and expenses related to specialty retail pharmacies, which include store and administrative payroll, employee benefits and occupancy costs.

Operating expenses decreased \$46 million to \$292 million, or 0.9% as a percentage of net revenues, in the three months ended September 30, 2017, compared to \$338 million, or 1.1% as a percentage of net revenues, in the prior year. Operating expenses decreased \$46 million to \$938 million, or 1.0% as a percentage of net revenues, in the nine months ended September 30, 2017, compared to \$984 million, or 1.1% as a percentage of net revenues, in the prior year. The decrease in operating expenses in the three and nine months ended September 30, 2017 is primarily due to the realization of partially reserved receivables.

**Retail/LTC Segment**

The following table summarizes our Retail/LTC Segment's performance for the respective periods:

<i>In millions</i>	Three Months Ended September 30,		Nine Months Ended September 30,	
	2017	2016	2017	2016
Net revenues	\$19,593	\$20,143	\$58,488	\$60,253
Gross profit <sup>(1)(2)</sup>	5,685	5,893	17,036	17,560
Gross profit % of net revenues	29.0 %	29.3 %	29.1 %	29.1 %
Operating expenses <sup>(1)(2)(3)(4)</sup>	4,132	4,115	12,661	12,287
Operating expenses % of net revenues	21.1 %	20.4 %	21.6 %	20.4 %
Operating profit <sup>(4)</sup>	1,553	1,778	4,375	5,273
Operating profit % of net revenues	7.9 %	8.8 %	7.5 %	8.8 %
Prescriptions filled (90 Day = 3 prescriptions) <sup>(5)</sup>	304.0	302.9	908.7	908.9
Net revenue increase (decrease):				
Total	(2.7)%	12.5 %	(2.9)%	15.6 %
Pharmacy	(2.9)%	15.3 %	(3.1)%	19.9 %
Front Store	(2.1)%	0.8 %	(2.4)%	0.9 %
Total prescription volume (90 Day = 3 prescriptions) <sup>(5)</sup>	0.4 %	17.1 %	0.0 %	22.1 %
Same store sales increase (decrease) <sup>(6)</sup> :				
Total	(3.2)%	2.3 %	(3.5)%	2.8 %
Pharmacy	(3.4)%	3.4 %	(3.6)%	4.3 %
Front Store	(2.8)%	(1.0)%	(3.3)%	(1.0)%
Prescription volume (90 Day = 3 prescriptions) <sup>(5)</sup>	0.3 %	3.0 %	(0.4)%	4.1 %
Generic dispensing rates	87.2 %	85.8 %	87.4 %	85.8 %
Pharmacy % of net revenues	75.9 %	76.0 %	75.1 %	75.2 %

- (1) Gross profit and operating expenses for the three months ended September 30, 2017 include \$2 million and \$7 million of acquisition-related integration costs. Gross profit and operating expenses for the nine months ended September 30, 2017 include \$7 million and \$27 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisition of Omnicare.
- (2) Gross profit and operating expenses for the three months ended September 30, 2016 include \$5 million and \$47 million, respectively, of acquisition-related integration costs. Gross profit and operating expenses for the nine months ended September 30, 2016 include \$15 million and \$179 million, respectively, of acquisition-related integration costs. The integration costs are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (3) Operating expenses for the three and nine months ended September 30, 2017 includes \$6 million and \$211 million, respectively, of charges associated with store closures (see "Note 8 – Store Closures" to our condensed consolidated financial statements). Operating expenses for the nine months ended September 30, 2017 also include a \$135 million goodwill impairment charge related to the segment's RxCrossroads reporting unit (see "Note 2 – Goodwill and Intangible Assets" to our condensed consolidated financial statements).
- (4) Amounts revised to reflect the adoption of ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which decreased operating expenses and increased operating profit by \$5 million for the three months ended September 30, 2016. For the nine months ended September 30, 2016, the adoption of ASU 2017-07 decreased operating expenses and increased operating profit by \$18 million.
- (5) Includes the adjustment to convert 90-day non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
- (6) Same store sales and prescriptions exclude revenues from MinuteClinic, and revenue and prescriptions from stores in Brazil, LTC operations and from commercialization services.

As of September 30, 2017, we operated 9,751 retail locations (of which 8,016 were our stores that operated a pharmacy and 1,687 were our pharmacies located within Target stores), compared to 9,694 retail locations as of September 30, 2016.

**Net Revenues**

Net revenues in our Retail/LTC Segment decreased \$549 million, or 2.7%, to approximately \$19.6 billion in the three months ended September 30, 2017, as compared to the prior year. Net revenues in our Retail/LTC Segment decreased \$1.8 billion, or 2.9%, to approximately \$58.5 billion in the nine months ended September 30, 2017, as compared to the prior year. As you review our Retail/LTC Segment's performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2017:

- Front store same store sales decreased by 2.8% and 3.3% for the three and nine months ended September 30, 2017, respectively, compared to the prior year as a result of continued softer customer traffic and as promotional

## Table of Contents

strategies continue to be rationalized, partially offset by an increase in basket size. For the nine months ended September 30, 2017, front store same store sales were negatively impacted by approximately 35 basis points due to the absence of leap day in the current year.

- Pharmacy same store sales decreased 3.4% and 3.6% for the three and nine months ended September 30, 2017, respectively, due to the negative impact of approximately 435 and 440 basis points, respectively, of recent generic introductions. Same store prescription volumes increased 0.3% and decreased 0.4%, on a 30-day equivalent basis, in the three and nine months ended September 30, 2017, respectively. The previously-discussed marketplace changes that restrict CVS Pharmacy from participating in certain networks had an approximately 420 and 450 basis point negative impact on same store prescription volumes in the three and nine months ended September 30, 2017, respectively.
- Due to the previously-discussed marketplace changes that restrict CVS Pharmacy from participating in certain networks, we continue to expect prescription growth to be negatively impacted for the remainder of 2017 although to a lesser extent than the first nine months of the year.
- Pharmacy revenues continue to be negatively impacted by the conversion of brand name drugs to equivalent generic drugs, which typically have a lower selling price. The generic dispensing rate grew to 87.2% and 87.4% for the three and nine months ended September 30, 2017, respectively, compared to 85.8% in both periods in the prior year. In addition, our pharmacy revenue growth has also been affected by continued reimbursement pressure, the mix of drugs sold and the lack of significant new brand name drug introductions.
- Pharmacy revenue growth may be impacted by industry changes in the LTC business, such as lower occupancy rates at skilled nursing facilities.
- Pharmacy revenue continued to benefit from our ability to attract and retain managed care customers, and the increased use of pharmaceuticals by an aging population as the first line of defense for health care.

### ***Gross Profit***

Gross profit in our Retail/LTC Segment includes net revenues less the cost of merchandise sold in the period and the related purchasing costs, warehousing costs, delivery costs and actual and estimated inventory losses.

Gross profit decreased \$209 million, or 3.5%, to \$5.7 billion in the three months ended September 30, 2017, as compared to the prior year. Gross profit decreased \$524 million, or 3.0%, to \$17.0 billion in the nine months ended September 30, 2017, as compared to the prior year. Gross profit as a percentage of net revenues decreased to 29.0% in the three months ended September 30, 2017, compared to 29.3% in the prior year. Gross profit as a percentage of net revenues remained flat at 29.1% in the nine months ended September 30, 2017, compared to the prior year.

The decrease in gross profit dollars in both Retail Pharmacy and LTC, was primarily driven by the continued reimbursement pressure as well as loss of prescriptions in Retail Pharmacy due to previously discussed network restrictions. The decrease in gross profit as a percentage of net revenues in the three months ended September 30, 2017 was primarily due to continued reimbursement pressure. Gross profit as a percentage of net revenues in the nine months ended September 30, 2017 was flat primarily driven by increased front store margins which offset the continued reimbursement pressure on pharmacy. Front store margins increased due to changes in the mix of products sold and efforts to rationalize promotional strategies.

As you review our Retail/LTC Segment's performance in this area, we believe you should consider the following important information about the business for the three and nine months ended September 30, 2017:

- Front store revenues as a percentage of total net revenues for the three and nine months ended September 30, 2017 was 22.8% and 23.6% for the three and nine months ended September 30, 2017, respectively, compared to 22.7% and 23.5%, respectively, in the prior year. On average, our gross profit on front store revenues is higher than our gross profit on pharmacy revenues.
- Our pharmacy gross profit rates have been adversely affected by the efforts of managed care organizations, PBMs and governmental and other third-party payors to reduce their prescription drug costs, including the use

## Table of Contents

of restrictive networks, as well as changes in the mix of our business within the pharmacy portion of the Retail/LTC Segment. In the event the reimbursement pressure accelerates, we may not be able to sustain our current rate of revenue growth and gross profit dollars could be adversely impacted. The increased use of generic drugs has positively impacted our gross profit but has resulted in third-party payors augmenting their efforts to reduce reimbursement payments to retail pharmacies for prescriptions. This trend, which we expect to continue, reduces the benefit we realize from brand to generic product conversions.

### ***Operating Expenses***

Operating expenses in our Retail/LTC Segment include payroll and employee benefits, occupancy costs, selling expenses, advertising expenses, depreciation and amortization expense and certain administrative expenses.

Operating expenses increased \$16 million to \$4.1 billion, or 21.1% as a percentage of net revenues, in the three months ended September 30, 2017, as compared to \$4.1 billion, or 20.4% as a percentage of net revenues, in the prior year. Operating expenses increased \$373 million to \$12.7 billion, or 21.6% as a percentage of net revenues, in the nine months ended September 30, 2017, as compared to \$12.3 billion, or 20.4% as a percentage of net revenues, in the prior year. The increase in operating expenses in the three and nine months ended September 30, 2017 was primarily due to the following:

- Hurricane related expenses of \$53 million in the three and nine months ended September 30, 2017 as a result of the three major hurricanes that hit the southern United States and Puerto Rico.
- Charges of \$6 million and \$211 million in the three and nine months ended September 30, 2017, respectively, associated with the closure of five and 68 retail stores, respectively, in connection with our enterprise streamlining initiative (see "Note 8 - Store Closures" to our condensed consolidated financial statements).
- An increase in operating expenses due to incremental store operating costs associated with operating more stores.
- These items were partially offset by a decrease in acquisition-related integration costs of \$40 million and \$152 million in the three and nine months ended September 30, 2017, respectively, versus the same periods in the prior year.

The increase in the nine months ended September 30, 2017 was also due to a goodwill impairment charge of \$135 million in the second quarter of 2017 in the RxCrossroads reporting unit (see "Note 2 - Goodwill and Intangible Assets" to our condensed consolidated financial statements).

## Table of Contents

### **Corporate Segment**

#### ***Operating Expenses***

Operating expenses in our Corporate Segment include expenses from the Company's executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

Operating expenses decreased \$8 million, or 3.1%, to \$220 million and increased \$26 million, or 4.3%, to \$686 million in the three and nine months ended September 30, 2017, respectively, as compared to the prior year. The change in operating expenses was partially driven by ongoing investments in strategic initiatives and increased employee benefit costs, offset by a decrease in acquisition-related integration costs of \$16 million for the three and nine months ended September 30, 2017 versus the same periods in prior year.

#### **Liquidity and Capital Resources**

We maintain a level of liquidity sufficient to allow us to cover our cash needs in the short-term. Over the long-term, we manage our cash and capital structure to maximize shareholder return, maintain our financial position and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, capital expenditure requirements, dividend payouts, potential share repurchases and future investments or acquisitions. We believe our operating cash flows, commercial paper program, sale-leaseback program, as well as any potential future borrowings, will be sufficient to fund these future payments and long-term initiatives.

The change in cash and cash equivalents is as follows:

<u><i>In millions</i></u>	<u>Nine Months Ended September 30,</u>	
	<u>2017</u>	<u>2016</u>
Net cash provided by operating activities	\$ 8,143	\$ 8,020
Net cash used in investing activities	(1,608)	(1,652)
Net cash used in financing activities	(7,421)	(6,640)
Effect of exchange rate changes on cash and cash equivalents	—	2
Net decrease in cash and cash equivalents	<u>\$ (886)</u>	<u>\$ (270)</u>

*Net cash provided by operating activities* was approximately \$8.1 billion in the nine months ended September 30, 2017, compared to \$8.0 billion in the nine months ended September 30, 2016.

*Net cash used in investing activities* was approximately \$1.6 billion in the nine months ended September 30, 2017, compared to \$1.7 billion in the nine months ended September 30, 2016. During the nine months ended September 30, 2017 cash used for acquisitions and other investments increased approximately \$0.2 billion from the prior year, which was offset by a decrease in capital expenditures of approximately \$0.2 billion in the current year.

*Net cash used in financing activities* was \$7.4 billion in the nine months ended September 30, 2017, compared to net cash used in financing activities of \$6.6 billion in the nine months ended September 30, 2016. The cash used in financing activities increased \$0.8 billion primarily due to an increase of \$0.4 billion in net debt repayments and an increase of \$0.4 billion in share repurchases in the current year.

During the nine months ended September 30, 2017, the Company had the following outstanding share repurchase programs, both of which had previously been authorized by the Company's Board of Directors:

#### *In billions*

<u>Authorization Date</u>	<u>Authorized</u>	<u>Remaining</u>
November 2, 2016 ("2016 Repurchase Program")	\$ 15.0	\$ 13.9
December 15, 2014 ("2014 Repurchase Program")	10.0	—

Each of the 2014 and 2016 Repurchase Programs, which were effective immediately, permitted the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. Each of the repurchase programs could be

## Table of Contents

modified or terminated by the Board of Directors at any time. The 2014 Repurchase Program was completed during the second quarter of 2017.

During the nine months ended September 30, 2017, the Company repurchased an aggregate of approximately 55.4 million shares of common stock for approximately \$4.4 billion pursuant to the 2014 and 2016 Repurchase Programs. This activity includes the accelerated share repurchase agreements (“ASRs”) described below.

Pursuant to the authorization under the 2014 Repurchase Program, effective August 29, 2016, the Company entered into two fixed dollar ASRs with Barclays Bank PLC (“Barclays”) for a total of \$3.6 billion. Upon payment of the \$3.6 billion purchase price on January 6, 2017, the Company received a number of shares of its common stock equal to 80% of the \$3.6 billion notional amount of the ASRs or approximately 36.1 million shares, which were placed into treasury stock in January 2017. The ASRs were accounted for as an initial treasury stock transaction for \$2.9 billion and a forward contract for \$0.7 billion. In April 2017, the Company received 9.9 million shares of common stock, representing the remaining 20% of the \$3.6 billion notional amount of the ASRs, thereby concluding the ASRs. The remaining 9.9 million shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in April 2017.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted net income per share.

The Company had \$110 million of commercial paper outstanding at a weighted average interest rate of 1.26% as of September 30, 2017. In connection with its commercial paper program, the Company maintains a \$1.0 billion, 364-day unsecured back-up credit facility, which expires on May 17, 2018, a \$1.25 billion, five-year unsecured back-up credit facility, which expires on July 24, 2019, a \$1.25 billion, five-year unsecured back-up credit facility, which expires on July 1, 2020, and a \$1.0 billion, five-year unsecured back-up credit facility, which expires on May 18, 2022. The credit facilities allow for borrowings at various rates that are dependent, in part, on the Company’s public debt ratings and require the Company to pay a weighted average quarterly facility fee of approximately 0.02%, regardless of usage. As of September 30, 2017, there were no borrowings outstanding under the back-up credit facilities.

On January 3, 2017, the Company entered into a \$2.5 billion revolving credit facility. The credit facility allowed for borrowings at various rates that are dependent, in part, on the Company’s debt ratings and required the Company to pay a weighted average quarterly facility fee of approximately 0.03%, regardless of usage. The maximum available under this credit facility decreased by \$750 million to \$1.75 billion on March 31, 2017. The Company terminated this facility effective May 17, 2017.

Our back-up credit facilities and unsecured senior notes contain customary restrictive financial and operating covenants. These covenants do not include a requirement for the acceleration of our debt maturities in the event of a downgrade in our credit rating. We do not believe the restrictions contained in these covenants materially affect our financial or operating flexibility. As of September 30, 2017, the Company is in compliance with all debt covenants.

As of September 30, 2017, our long-term debt was rated by Moody’s as “Baa1” with a stable outlook and by Standard & Poor’s as “BBB+” with a stable outlook, and our commercial paper program was rated “P-2” by Moody’s and “A-2” by Standard & Poor’s. In assessing our credit strength, we believe that both Moody’s and Standard & Poor’s considered, among other things, our capital structure and financial policies as well as our consolidated balance sheet, our historical acquisition activity and other financial information. Although we currently believe our long-term debt ratings will remain investment grade, we cannot guarantee the future actions of Moody’s and/or Standard & Poor’s. Our debt ratings have a direct impact on our future borrowing costs, access to capital markets and new store operating lease costs.

### **Off-Balance Sheet Arrangements**

In connection with executing operating leases, we provide a guarantee of the lease payments. We also finance a portion of our new store development through sale-leaseback transactions, which involve selling stores to unrelated parties and then leasing the stores back under leases that generally qualify and are accounted for as operating leases. We do not have any retained or contingent interests in the stores, and we do not provide any guarantees, other than a guarantee of the lease payments, in connection with the transactions. In accordance with GAAP, such operating leases are not reflected in

## Table of Contents

our condensed consolidated balance sheet. See “Note 12 – Commitments and Contingencies” to our condensed consolidated financial statements for a detailed discussion of these guarantees.

### **Critical Accounting Policies**

We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgment. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the condensed consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

As discussed in “Note 2 – Goodwill and Intangible Assets” to our condensed consolidated financial statements, during the three months ended September 30, 2017, we performed our required annual impairment tests of goodwill. The results of the impairment tests indicated that there was no impairment of goodwill. The goodwill impairment tests resulted in the fair values of our Pharmacy Services and Retail Pharmacy reporting units exceeding their carrying values by significant margins. The fair values of our LTC and RxC reporting units exceeded their carrying values by approximately 1% and 6%, respectively. The balance of goodwill for our LTC and RxC reporting units at September 30, 2017 was approximately \$6.4 billion and \$0.4 billion, respectively.

The fair value of our reporting units is estimated using a combination of a discounted cash flow method and a market multiple method. The determination of the fair value of our reporting units requires the Company to make significant assumptions and estimates. These assumptions and estimates primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums and valuation multiples appropriate for acquisitions in the industries in which the Company competes; discount rates, terminal growth rates; and forecasts of revenue, operating profit, depreciation and amortization, capital expenditures and future working capital requirements. When determining these assumptions and preparing these estimates, we consider each reporting unit’s historical results and current operating trends and our consolidated revenues, profitability and cash flow results, forecasts and industry trends. Our estimates can be affected by a number of factors including, but not limited to, general economic and regulatory conditions, our market capitalization, efforts of customers and payers to reduce costs including their prescription drug costs and/or increase member co-payments, the continued efforts of competitors to gain market share and consumer spending patterns.

As previously discussed, the results of our annual goodwill impairment test resulted in the fair value of our LTC reporting unit exceeding its carrying value by approximately 1%. Our multi-year cash flow projections for our LTC reporting unit have declined from the prior year due to customer reimbursement pressures, industry trends such as lower occupancy rates in skilled nursing facilities, and client retention rates. Our projected discounted cash flow model assumes future script growth from our senior living initiative and the impact of acquisitions. Such projections also include expected cost savings from labor productivity and other initiatives. Our market multiple method is heavily dependent on earnings multiples of market participants in the pharmacy industry, including certain competitors and suppliers. If we do not achieve our forecasts, given the small excess of fair value over the related carrying value, as well as current market conditions in the healthcare industry, it is reasonably possible that the operational performance of the LTC reporting unit could be below our current expectations in the near term and the LTC reporting unit could be deemed to be impaired by a material amount.

For a full description of our other critical accounting policies, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2016 Form 10-K.



### Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 (the “Reform Act”) provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. The Company and its representatives may, from time to time, make written or verbal forward-looking statements, including statements contained in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and in its reports to stockholders, press releases, webcasts, conference calls, meetings and other communications. Generally, the inclusion of the words “believe,” “expect,” “intend,” “estimate,” “project,” “anticipate,” “will,” “should” and similar expressions identify statements that constitute forward-looking statements. All statements addressing operating performance of CVS Health Corporation or any subsidiary, events or developments that the Company expects or anticipates will occur in the future, including statements relating to corporate strategy; revenue growth; earnings or earnings per common share growth; adjusted earnings or adjusted earnings per common share growth; free cash flow; debt ratings; inventory levels; inventory turn and loss rates; store development; relocations and new market entries; retail pharmacy business, sales trends and operations; PBM business, sales trends and operations; specialty pharmacy business, sales trends and operations; LTC pharmacy business, sales trends and operations; the Company’s ability to attract or retain customers and clients; Medicare Part D competitive bidding, enrollment and operations; new product development; and the impact of industry and regulatory developments, as well as statements expressing optimism or pessimism about future operating results or events, are forward-looking statements within the meaning of the Reform Act.

The forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section within the 2016 Form 10-K, and including, but not limited to:

- *Risks relating to the health of the economy in general and in the markets we serve, which could impact consumer purchasing power, preferences and/or spending patterns, drug utilization trends, the financial health of our PBM and LTC clients, retail and specialty pharmacy payors or other payors doing business with the Company and our ability to secure necessary financing, suitable store locations and sale-leaseback transactions on acceptable terms.*
- *Efforts to reduce reimbursement levels and alter health care financing practices, including pressure to reduce reimbursement levels for generic drugs.*
- *The possibility of PBM and LTC client loss and/or the failure to win new PBM and LTC business, including as a result of failure to win renewal of expiring contracts, contract termination rights that may permit clients to terminate a contract prior to expiration and early or periodic renegotiation of pricing by clients prior to expiration of a contract.*
- *The possibility of loss of Medicare Part D business and/or failure to obtain new Medicare Part D business, whether as a result of the annual Medicare Part D competitive bidding process or otherwise.*
- *Risks related to the frequency and rate of the introduction of generic drugs and brand name prescription products.*
- *Risks of declining gross margins attributable to increased competitive pressures, increased client demand for lower prices, enhanced service offerings and/or higher service levels and market dynamics and, with respect to the PBM industry, regulatory changes that impact our ability to offer plan sponsors pricing that includes the use of retail “differential” or “spread” or the use of maximum allowable cost pricing.*
- *Regulatory changes, business changes and compliance requirements and restrictions that may be imposed by Centers for Medicare and Medicaid Services (“CMS”), Office of Inspector General or other government agencies relating to the Company’s participation in Medicare, Medicaid and other federal and state government-funded programs, including sanctions and remedial actions that may be imposed by CMS on our Medicare Part D business.*

## Table of Contents

- *Risks and uncertainties related to the timing and scope of reimbursement from Medicare, Medicaid and other government-funded programs, including the possible impact of sequestration, the impact of other federal budget, debt and deficit negotiations and legislation that could delay or reduce reimbursement from such programs and the impact of any closure, suspension or other changes affecting federal or state government funding or operations.*
- *Possible changes in industry pricing benchmarks used to establish pricing in many of our PBM and LTC client contracts, pharmaceutical purchasing arrangements, retail network contracts, specialty payor agreements and other third party payor contracts.*
- *Efforts to increase reimbursement rates in PBM pharmacy networks and to inhibit the ability of PBMs to audit network pharmacies for fraud, waste and abuse.*
- *Risks related to increasing oversight of PBM activities by state departments of insurance and boards of pharmacy.*
- *A highly competitive business environment, including the uncertain impact of increased consolidation in the PBM industry, the possibility of combinations, joint ventures or other collaboration between PBMs and retailers, uncertainty concerning the ability of our retail pharmacy business to secure and maintain contractual relationships with PBMs and other payors on acceptable terms, uncertainty concerning the ability of our PBM business to secure and maintain competitive access, pricing and other contract terms from retail network pharmacies in an environment where some PBM clients are willing to consider adopting narrow or more restricted retail pharmacy networks, and the possibility of our retail stores or specialty pharmacies being excluded from narrow or restricted networks.*
- *The Company's ability to timely identify or effectively respond to changing consumer preferences and spending patterns, an inability to expand the products being purchased by our customers, or the failure or inability to obtain or offer particular categories of products.*
- *Risks relating to our ability to secure timely and sufficient access to the products we sell from our domestic and/or international suppliers, including limited distribution drugs.*
- *Reform of the U.S. health care system, including ongoing implementation of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, "ACA") and the possible repeal and replacement of all or parts of ACA, continuing legislative efforts, regulatory changes and judicial interpretations impacting our health care system and the possibility of shifting political and legislative priorities related to reform of the health care system in the future.*
- *Risks related to changes in legislation, regulation and government policy (including through the use of Executive Orders) that could significantly impact our business and the health care and retail industries, including, but not limited to, the possibility of major developments in tax policy or trade relations, such as the imposition of unilateral tariffs on imported product, changes with respect to the approval process for biosimilars, or changes or developments with respect to the regulation of drug pricing, including federal and state drug pricing programs.*
- *Risks relating to any failure to properly maintain our information technology systems, our information security systems and our infrastructure to support our business and to protect the privacy and security of sensitive customer and business information.*
- *Risks related to compliance with a broad and complex regulatory framework, including compliance with new and existing federal, state and local laws and regulations relating to health care, network pharmacy reimbursement and auditing, accounting standards, corporate securities, tax, environmental and other laws and regulations affecting our business.*
- *Risks related to litigation, government investigations and other legal proceedings as they relate to our business, the pharmacy services, retail pharmacy, LTC pharmacy or retail clinic industries, or to the health care industry generally.*

## Table of Contents

- *The risk that any condition related to the closing of any proposed acquisition may not be satisfied on a timely basis or at all, including the inability to obtain required regulatory approvals of any proposed acquisition, or on the terms desired or anticipated; the risk that such approvals may result in the imposition of conditions that could adversely affect the resulting combined company or the expected benefits of any proposed transaction; and the risk that the proposed transactions fail to close for any other reason.*
- *The possibility that the anticipated synergies and other benefits from any acquisition by us will not be realized, or will not be realized within the expected time periods.*
- *The risks and uncertainties related to our ability to integrate the operations, products, services and employees of any entities acquired by us and the effect of the potential disruption of management's attention from ongoing business operations due to any pending acquisitions.*
- *The accessibility or availability of adequate financing on a timely basis and on reasonable terms.*
- *Risks related to the outcome of any legal proceedings related to, or involving any entity that is a part of, any proposed acquisition contemplated by us.*
- *The possibility of lower than expected valuations at the Company's reporting units could result in goodwill impairment charges at those reporting units.*
- *Other risks and uncertainties detailed from time to time in our filings with the SEC.*

The foregoing list is not exhaustive. There can be no assurance that the Company has correctly identified and appropriately assessed all factors affecting its business. Additional risks and uncertainties not presently known to the Company or that it currently believes to be immaterial also may adversely impact the Company. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the Company's business, financial condition and results of operations. For these reasons, you are cautioned not to place undue reliance on the Company's forward-looking statements.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As of September 30, 2017, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes that as of September 30, 2017 its exposure to interest rate risk (inherent in the Company's debt portfolio), foreign currency exchange rate risk and commodity price risk is not material.

### **Item 4. Controls and Procedures**

**Evaluation of disclosure controls and procedures:** The Company's Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) as of September 30, 2017, have concluded that as of such date the Company's disclosure controls and procedures were adequate and effective and designed to provide reasonable assurance that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Part II**

**Item 1. Legal Proceedings**

**I. Legal Proceedings**

We refer you to “Note 12 - Commitments and Contingencies” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2017 for a description of our legal proceedings.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended September 30, 2017, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2016 Repurchase Program. See “Note 3 - Share Repurchase Programs” contained in the “Notes to the Condensed Consolidated Financial Statements” of our Quarterly Report on Form 10-Q for the three months ended September 30, 2017.

<u>Fiscal Period</u>	<u>Total Number of Shares Purchased</u>	<u>Average Price Paid per Share</u>	<u>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</u>	<u>Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs</u>
July 1, 2017 through July 31, 2017	—	\$ —	—	\$ 14,269,392,432
August 1, 2017 through August 31, 2017	1,713,436	\$ 76.72	1,713,436	\$ 14,137,945,704
September 1, 2017 through September 30, 2017	<u>3,364,345</u>	\$ 79.82	<u>3,364,345</u>	\$ 13,869,392,446
	<u>5,077,781</u>		<u>5,077,781</u>	

## Table of Contents

### **Item 6. Exhibits**

#### Exhibits:

Exhibits marked with an asterisk (\*) are hereby incorporated by reference to exhibits or appendices previously filed by the Registrant as indicated in brackets following the description of the exhibit.

- 3.1\* Amended and Restated Certificate of Incorporation of the Registrant [incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 1996 (Commission File No. 001-01011)].
- 3.1A\* Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective May 13, 1998 [incorporated by reference to Exhibit 4.1A to the Registrant's Registration Statement No. 333-52055 on Form S-3/A dated May 18, 1998 (Commission File No. 001-01001)].
- 3.1B\* Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K dated March 22, 2007 (Commission File No. 001-01011)].
- 3.1C\* Certificate of Merger dated May 9, 2007 [incorporated by reference to Exhibit 3.1C to the Registrant's Quarterly Report on Form 10-Q dated November 1, 2007 (Commission File No. 001-01011)].
- 3.1D\* Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K dated May 13, 2010 (Commission File No. 001-01011)].
- 3.1E\* Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K dated May 10, 2012 (Commission File No. 001-01011)].
- 3.1F\* Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K dated May 13, 2013 (Commission File No. 001-01011)].
- 3.1G\* Certificate of Amendment to the Amended and Restated Certificate of Incorporation [incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K dated September 3, 2014 (Commission File No. 001-01011)].
- 3.2\* By-laws of Registrant, as amended and restated [incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K dated January 26, 2016 (Commission File No. 001-01011)].
- 15.1 Letter re: Unaudited Interim Financial Information.
- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101 The following materials from the CVS Health Corporation Quarterly Report on Form 10-Q for the three months ended September 30, 2017 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Statements of Income, (ii) the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows and (v) related Footnotes to the Condensed Consolidated Financial Statements.

Table of Contents

Signatures:

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

CVS Health Corporation  
*(Registrant)*

/s/ David M. Denton  
David M. Denton  
Executive Vice President and Chief Financial Officer  
November 6, 2017

**Letter re: Unaudited Interim Financial Information**

November 6, 2017

The Board of Directors and Shareholders:  
CVS Health Corporation

We are aware of the incorporation by reference in the Registration Statements (Nos. 333-49407, 333-34927, 333-28043, 333-91253, 333-63664, 333-139470, 333-141481, 333-167746, 333- 208805, and 333-217853 on Form S-8, Nos. 333-187440, 333-200217, and 333-217596 on Form S-3ASR, Nos. 333-205156 and 333-210872 on Form S-3 and No. 333-210873 on Form S-4) of CVS Health Corporation of our report dated November 6, 2017, relating to the unaudited condensed consolidated interim financial statements of CVS Health Corporation that are included in its Form 10-Q for the quarter ended September 30, 2017.

/s/ Ernst & Young LLP

Boston, Massachusetts

---

**Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Larry J. Merlo, President and Chief Executive Officer of CVS Health Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CVS Health Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2017

By: /s/ Larry J. Merlo

Larry J. Merlo  
President and Chief Executive Officer

---



**Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, David M. Denton, Executive Vice President and Chief Financial Officer of CVS Health Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CVS Health Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2017

By: /s/ David M. Denton  
David M. Denton  
Executive Vice President and Chief Financial Officer

---

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The certification set forth below is being submitted in connection with the Quarterly Report of CVS Health Corporation (the "Company") on Form 10-Q for the period ended September 30, 2017 (the "Report"), for the purpose of complying with Rule 13(a)-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code.

I, Larry J. Merlo, President and Chief Executive Officer of the Company, certify that, to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 6, 2017

/s/ Larry J. Merlo  
\_\_\_\_\_  
Larry J. Merlo  
President and Chief Executive Officer

---

---

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The certification set forth below is being submitted in connection with the Quarterly Report of CVS Health Corporation (the "Company") on Form 10-Q for the period ended September 30, 2017 (the "Report"), for the purpose of complying with Rule 13(a)-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code.

I, David M. Denton, Executive Vice President and Chief Financial Officer of the Company, certify that, to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 6, 2017

/s/ David M. Denton

David M. Denton  
Executive Vice President and Chief Financial Officer

---

**Document and Entity  
Information - shares**

**9 Months Ended  
Sep. 30, 2017    Oct. 31, 2017**

**Document and Entity Information**

<u>Entity Registrant Name</u>	CVS HEALTH Corp	
<u>Entity Central Index Key</u>	0000064803	
<u>Document Type</u>	10-Q	
<u>Document Period End Date</u>	Sep. 30, 2017	
<u>Amendment Flag</u>	false	
<u>Current Fiscal Year End Date</u>	--12-31	
<u>Entity Current Reporting Status</u>	Yes	
<u>Entity Filer Category</u>	Large Accelerated Filer	
<u>Entity Common Stock, Shares Outstanding</u>		1,012,992,425
<u>Document Fiscal Year Focus</u>	2017	
<u>Document Fiscal Period Focus</u>	Q3	

**Condensed Consolidated  
Statements of Income - USD**  
(**\$**)  
**shares in Millions, \$ in  
Millions**

**3 Months Ended**

**9 Months Ended**

**Sep. 30,  
2017**

**Sep. 30,  
2016**

**Sep. 30,  
2017**

**Sep. 30,  
2016**

**Condensed Consolidated Statements of Income**

<u>Net revenues</u>	\$ 46,181	\$ 44,615	\$ 136,380	\$ 131,555
<u>Cost of revenues</u>	39,055	37,123	115,739	110,304
<u>Gross profit</u>	7,126	7,492	20,641	21,251
<u>Operating expenses</u>	4,627	4,668	14,232	13,885
<u>Operating profit</u>	2,499	2,824	6,409	7,366
<u>Interest expense, net</u>	245	253	744	816
<u>Loss on early extinguishment of debt</u>		101		643
<u>Other expense</u>	192	7	206	23
<u>Income before income tax provision</u>	2,062	2,463	5,459	5,884
<u>Income tax provision</u>	777	921	2,115	2,271
<u>Income from continuing operations</u>	1,285	1,542	3,344	3,613
<u>Loss from discontinued operations, net of tax</u>		(1)	(8)	(1)
<u>Net income</u>	1,285	1,541	3,336	3,612
<u>Net income attributable to noncontrolling interest</u>		(1)	(1)	(2)
<u>Net income attributable to CVS Health</u>	\$ 1,285	\$ 1,540	\$ 3,335	\$ 3,610
<b><u>Basic earnings per share:</u></b>				
<u>Income from continuing operations attributable to CVS Health (in dollars per share)</u>	\$ 1.26	\$ 1.44	\$ 3.26	\$ 3.34
<u>Loss from discontinued operations attributable to CVS Health (in dollars per share)</u>			(0.01)	
<u>Net income attributable to CVS Health (in dollars per share)</u>	\$ 1.26	\$ 1.44	\$ 3.25	\$ 3.34
<u>Weighted average shares outstanding (in shares)</u>	1,016	1,068	1,022	1,076
<b><u>Diluted earnings per share:</u></b>				
<u>Income from continuing operations attributable to CVS Health (in dollars per share)</u>	\$ 1.26	\$ 1.43	\$ 3.25	\$ 3.32
<u>Loss from discontinued operations attributable to CVS Health (in dollars per share)</u>			(0.01)	
<u>Net income attributable to CVS Health (in dollars per share)</u>	\$ 1.26	\$ 1.43	\$ 3.24	\$ 3.32
<u>Weighted average shares outstanding (in shares)</u>	1,020	1,073	1,026	1,082
<u>Dividends declared per share (in dollars per share)</u>	\$ 0.50	\$ 0.425	\$ 1.50	\$ 1.275

Condensed Consolidated Statements of Comprehensive Income - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
<b><u>Condensed Consolidated Statements of Comprehensive Income</u></b>				
<u>Net income</u>	\$ 1,285	\$ 1,541	\$ 3,336	\$ 3,612
<b><u>Other comprehensive income:</u></b>				
<u>Foreign currency translation adjustments, net of tax</u>	8	(3)	6	37
<u>Net cash flow hedges, net of tax</u>		1	1	2
<u>Pension and other postretirement benefits, net of tax</u>	151		151	
<u>Total other comprehensive income (loss)</u>	159	(2)	158	39
<u>Comprehensive income</u>	1,444	1,539	3,494	3,651
<u>Comprehensive income attributable to noncontrolling interest</u>		(1)	(1)	(2)
<u>Comprehensive income attributable to CVS Health</u>	\$ 1,444	\$ 1,538	\$ 3,493	\$ 3,649

**Condensed Consolidated  
Balance Sheets - USD (\$)  
\$ in Millions**

	<b>Sep. 30, 2017</b>	<b>Dec. 31, 2016</b>
<b>Assets:</b>		
<u>Cash and cash equivalents</u>	\$ 2,485	\$ 3,371
<u>Short-term investments</u>	75	87
<u>Accounts receivable, net</u>	12,440	12,164
<u>Inventories</u>	14,147	14,760
<u>Other current assets</u>	776	660
<u>Total current assets</u>	29,923	31,042
<u>Property and equipment, net</u>	9,914	10,175
<u>Goodwill</u>	38,169	38,249
<u>Intangible assets, net</u>	13,303	13,511
<u>Other assets</u>	1,544	1,485
<u>Total assets</u>	92,853	94,462
<b>Liabilities:</b>		
<u>Accounts payable</u>	7,899	7,946
<u>Claims and discounts payable</u>	9,807	9,451
<u>Accrued expenses</u>	8,404	6,937
<u>Short-term debt</u>	110	1,874
<u>Current portion of long-term debt</u>	2,293	42
<u>Total current liabilities</u>	28,513	26,250
<u>Long-term debt</u>	23,386	25,615
<u>Deferred income taxes</u>	4,442	4,214
<u>Other long-term liabilities</u>	1,644	1,549
<b>Shareholders' equity:</b>		
<u>Preferred stock, par value \$0.01: 0.1 shares authorized; none issued or outstanding</u>		
<u>Common stock, par value \$0.01: 3,200 shares authorized; 1,712 shares issued and 1,013 shares outstanding at September 30, 2017 and 1,705 shares issued and 1,061 shares outstanding at December 31, 2016</u>	17	17
<u>Treasury stock, at cost: 698 shares at September 30, 2017 and 643 shares at December 31, 2016</u>	(37,764)	(33,452)
<u>Shares held in trust: 1 share at September 30, 2017 and December 31, 2016</u>	(31)	(31)
<u>Capital surplus</u>	32,009	31,618
<u>Retained earnings</u>	40,779	38,983
<u>Accumulated other comprehensive income (loss)</u>	(147)	(305)
<u>Total CVS Health shareholders' equity</u>	34,863	36,830
<u>Noncontrolling interest</u>	5	4
<u>Total shareholders' equity</u>	34,868	36,834
<u>Total liabilities and shareholders' equity</u>	\$ 92,853	\$ 94,462

**Condensed Consolidated  
Balance Sheets  
(Parenthetical) - \$ / shares**

**Sep. 30, 2017 Dec. 31, 2016**

**Condensed Consolidated Balance Sheets**

<u>Preferred Stock, par value (in dollars per share)</u>	\$ 0.01	\$ 0.01
<u>Preferred Stock, shares authorized (in shares)</u>	100,000	100,000
<u>Preferred Stock, shares issued (in shares)</u>	0	0
<u>Preferred Stock, shares outstanding (in shares)</u>	0	0
<u>Common Stock, par value (in dollars per share)</u>	\$ 0.01	\$ 0.01
<u>Common Stock, shares authorized (in shares)</u>	3,200,000,000	3,200,000,000
<u>Common Stock, shares issued (in shares)</u>	1,712,000,000	1,705,000,000
<u>Common Stock, shares outstanding (in shares)</u>	1,013,000,000	1,061,000,000
<u>Treasury Stock, shares (in shares)</u>	698,000,000	643,000,000
<u>Shares held in trust: 1 share at September 30, 2017 and December 31, 2016 (in shares)</u>	1,000,000	1,000,000



**Condensed Consolidated  
Statements of Cash Flows -  
USD (\$)  
\$ in Millions**

**9 Months Ended**  
**Sep. 30,**      **Sep. 30,**  
**2017**           **2016**

**Cash flows from operating activities:**

<u>Cash receipts from customers</u>	\$ 133,055	\$ 128,545
<u>Cash paid for inventory and prescriptions dispensed by retail network pharmacies</u>	(110,788)	(106,371)
<u>Cash paid to other suppliers and employees</u>	(11,230)	(11,020)
<u>Interest received</u>	15	14
<u>Interest paid</u>	(869)	(954)
<u>Income taxes paid</u>	(2,040)	(2,194)
<u>Net cash provided by operating activities</u>	8,143	8,020

**Cash flows from investing activities:**

<u>Purchases of property and equipment</u>	(1,412)	(1,607)
<u>Proceeds from sale -leaseback transactions</u>	265	230
<u>Proceeds from sale of property and equipment and other assets</u>	20	22
<u>Acquisitions (net of cash acquired) and other investments</u>	(502)	(333)
<u>Purchase of available -for-sale investments</u>		(40)
<u>Maturity of available -for-sale investments</u>	21	76
<u>Net cash used in investing activities</u>	(1,608)	(1,652)

**Cash flows from financing activities:**

<u>Increase (decrease) in short -term debt</u>	(1,764)	340
<u>Proceeds from issuance of long -term debt</u>		3,455
<u>Repayments of long-term debt</u>		(5,185)
<u>Purchase of noncontrolling interest in subsidiary</u>		(39)
<u>Payment of contingent consideration</u>		(26)
<u>Dividends paid</u>	(1,539)	(1,384)
<u>Proceeds from exercise of stock options</u>	314	277
<u>Payments for taxes related to net share settlement of equity awards</u>	(70)	(72)
<u>Repurchase of common stock</u>	(4,361)	(4,000)
<u>Other</u>	(1)	(6)
<u>Net cash used in financing activities</u>	(7,421)	(6,640)
<u>Effect of exchange rate changes on cash and cash equivalents</u>		2
<u>Net decrease in cash and cash equivalents</u>	(886)	(270)
<u>Cash and cash equivalents at the beginning of the period</u>	3,371	2,459
<u>Cash and cash equivalents at the end of the period</u>	2,485	2,189

**Reconciliation of net income to net cash provided by operating activities:**

<u>Net income</u>	3,336	3,612
-------------------	-------	-------

**Adjustments required to reconcile net income to net cash provided by operating activities:**

<u>Depreciation and amortization</u>	1,857	1,847
<u>Goodwill impairment</u>	135	
<u>Loss on settlement of defined benefit pension plans</u>	187	
<u>Stock-based compensation</u>	173	166
<u>Loss on early extinguishment of debt</u>		643

<u>Deferred income taxes and other noncash items</u>	271	119
<b><u>Change in operating assets and liabilities, net of effects from acquisitions:</u></b>		
<u>Accounts receivable, net</u>	(280)	(1,714)
<u>Inventories</u>	620	(337)
<u>Other current assets</u>	(212)	2
<u>Other assets</u>	(15)	(86)
<u>Accounts payable and claims and discounts payable</u>	330	1,570
<u>Accrued expenses</u>	1,670	2,149
<u>Other long-term liabilities</u>	71	49
<u>Net cash provided by operating activities</u>	\$ 8,143	\$ 8,020

Accounting PoliciesAccounting Policies

CVS Health Corporation  
Notes to Condensed Consolidated Financial Statements  
(Unaudited)

**Note1– Accounting Policies*****Basis of Presentation***

The accompanying unaudited condensed consolidated financial statements of CVS Health Corporation and its subsidiaries (collectively, “CVS Health” or the “Company”) have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in Exhibit 13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (“2016 Form 10-K”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.

***Principles of Consolidation***

The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary. Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.

***Fair Value of Financial Instruments***

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

- Level 1– Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
- Level 2– Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.
- Level 3– Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

As of September 30, 2017, the carrying value of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and the contingent consideration liability included in accrued expenses approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company’s short-term investments of \$75 million at September 30, 2017 consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at September 30, 2017. The carrying amount and estimated fair value of the Company’s total long-term debt was \$25.7 billion and \$27.0 billion, respectively, as of September 30, 2017. The fair value of the Company’s long-term debt was estimated based on quoted prices currently offered in active markets for the Company’s debt, which is considered Level 1 of the fair value hierarchy.

***Related Party Transactions***

The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Pharmacy Services and Retail/LTC segments utilize this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of approximately \$5 million and \$7 million in the three months ended September 30, 2017 and 2016, respectively, and expensed fees for the use of this network of approximately \$29 million in the nine months ended September 30, 2017 and 2016. The Company’s investment in and equity in earnings of SureScripts for all periods presented is immaterial.

The Company has an equity method investment in Heartland Healthcare Services (“Heartland”). Heartland operates several long-term care pharmacies in four states. Heartland paid the Company approximately \$36 million and \$46 million for pharmaceutical inventory purchases during the three months ended September 30, 2017 and 2016, respectively, and approximately \$106 million and \$116 million for pharmaceutical inventory purchases during the nine months ended September 30, 2017 and 2016. Additionally, the Company performs certain collection functions for Heartland and then passes those

customer cash collections back to Heartland. The Company's investment and equity in earnings of Heartland for all periods presented is immaterial.

#### **Discontinued Operations**

In connection with certain business dispositions completed between 1991 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Bob's Stores and Linens 'n Things, both of which subsequently filed for bankruptcy. See "Note 12 – Commitments and Contingencies" to the condensed consolidated financial statements. The Company's discontinued operations include lease-related costs which the Company believes it will likely be required to satisfy pursuant to its lease guarantees.

#### **New Accounting Pronouncements Recently Adopted**

In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-11, *Inventory*, which amends Accounting Standard Codification ("ASC") Topic 330. This ASU simplifies current accounting treatments by requiring entities to measure most inventories at "the lower of cost and net realizable value" rather than using lower of cost or market. This guidance does not apply to inventories measured using the last-in, first-out method or the retail inventory method. The Company adopted this standard effective January 1, 2017. The adoption of this new guidance did not have any impact on the Company's condensed consolidated results of operations, financial position or cash flows.

In March 2016, the FASB issued ASU No. 2016-09, *Improvements to Employee Share-Based Payment Accounting*, which amends the accounting for certain aspects of shared-based payments to employees in ASC Topic 718, *Compensation - Stock Compensation*. The new guidance eliminates the accounting for any excess tax benefits and deficiencies through equity, and requires all excess tax benefits and deficiencies related to employee share-based compensation arrangements to be recorded in the income statement. This aspect of the guidance is required to be applied prospectively. The guidance also requires the presentation of excess tax benefits on the statement of cash flows as an operating activity rather than a financing activity, a change which may be applied prospectively or retrospectively. The guidance further provides an accounting policy election to account for forfeitures as they occur rather than utilizing the estimated amount of forfeitures at the time of issuance. The Company adopted this guidance effective January 1, 2017. The primary impact of adopting this guidance was the recognition of excess tax benefits in the income statement instead of recognizing them in equity. This income statement guidance was adopted on a prospective basis. As a result, a discrete tax benefit of \$18 million and \$51 million was recognized in the income tax provision in the three and nine months ended September 30, 2017, respectively.

The Company elected to retrospectively adopt the guidance on the presentation of excess tax benefits in the statement of cash flows. The following is a reconciliation of the effect of the resulting reclassification of the excess tax benefits on the Company's condensed consolidated statement of cash flows for the nine months ended September 30, 2016:

<u>In millions</u>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
Cash paid to other suppliers and employees	\$ (11,092)	\$ 72	\$ (11,020)
Net cash provided by operating activities	7,948	(72)	8,020
Excess tax benefits from stock-based compensation	72	(72)	—
Net cash used in financing activities	(6,568)	(72)	(6,640)
Reconciliation of net income to net cash provided by operating activities:			
Accrued expenses	2,077	72	2,149

The Company elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. None of the other provisions in this guidance had a material impact on the Company's condensed consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which amends ASC Topic 715, *Compensation – Retirement Benefits*. ASU 2017-17 requires entities to disaggregate the current service cost component from the other components of net benefit cost and present it with other current compensation costs for related employees in the income statement and present the other components of net benefit cost elsewhere in the income statement and outside of operating income. Only the service cost component of net benefit cost is eligible for capitalization. The guidance is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of any annual periods for which an entity's financial statements have not been issued. Entities are required to retrospectively apply the requirement for a separate presentation in the income statement of service costs and other components of net benefit cost and prospectively adopt the requirement to limit the capitalization of benefit costs to the service component. The Company adopted the income statement presentation aspects of this new guidance on a retrospective basis effective January 1, 2017. Nearly all of the Company's net benefit costs for the Company's defined benefit pension and postretirement plans do not contain a service cost component as most of these defined benefit plans have been frozen for an extended period of time. The following is a reconciliation of the effect of the reclassification of the net benefit cost from operating expenses to other expense in the Company's condensed consolidated statements of income for the three and nine months ended September 30, 2016:

<u>In millions</u>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
<b>Three Months Ended September 30, 2016</b>			
Operating expenses	\$ 4,675	\$ (7)	\$ 4,668
Operating profit	2,817	7	2,824
Other expense	—	7	7
<b>Nine Months Ended September 30, 2016</b>			
Operating expenses	13,908	(23)	13,885
Operating profit	7,343	23	7,366
Other expense	—	23	23

In January 2017, the FASB issued ASU 2017-04, *Simplifying the Test for Goodwill Impairment*, which amends ASC Topic 350, *Intangibles – Goodwill and Other*. This ASU requires the Company to perform its annual, or applicable interim, goodwill impairment test by comparing the fair value of each reporting unit with its carrying amount. An impairment charge must be recognized at the amount by which the carrying amount exceeds the fair value of the reporting unit; however, the charge recognized should not exceed the

total amount of goodwill allocated to that reporting unit. Income tax effects resulting from any tax deductible goodwill should be considered when measuring a goodwill impairment charge, if applicable. The guidance in ASU 2017-04 is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company elected to early adopt this standard as of January 1, 2017. At the date of adoption of this new guidance, the guidance did not have any impact on the Company's condensed consolidated results of operations, financial position or cash flows.

***New Accounting Pronouncements Not Yet Adopted***

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers* (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, "*Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)*," which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, "*Identifying Performance Obligations and Licensing*," which amends the guidance in those areas in the new revenue recognition standard. Both ASUs were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. The new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018. The Company chose not to early adopt the new standard. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the standard. The Company intends to adopt the new standard on a modified retrospective basis. The Company formed a project team to assess and implement the new revenue standard and is substantially complete in documenting its accounting policies applying the new revenue guidance. The Company does not expect that the implementation of the new standard will have a material effect on the Company's consolidated results of operations, cash flows or financial position. The new standard will however require more extensive revenue-related disclosures. The Company has identified one difference in its Retail/LTC Segment related to the accounting for its ExtraBucks Rewards customer loyalty program, which is currently accounted for under a cost deferral method. Under the new standard, this program will be accounted for under a revenue deferral method; however, the difference is not expected to be material.

In February 2016, the FASB issued ASU 2016-02, *Leases* (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet. The Company is currently evaluating the effect that implementation of this standard will have on the Company's consolidated results of operations, cash flows, financial position and related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, *Classification of Certain Cash Receipts and Cash Payments*. ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this accounting guidance.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows*, which amends ASC Topic 230. This ASU requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer be required to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. Entities will also have to disclose the nature of their restricted cash and restricted cash equivalent balances. The guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted. Entities are required to apply the guidance retrospectively. The Company is currently evaluating the effect of adopting this accounting guidance.

**Goodwill and Intangible  
Assets**

**9 Months Ended  
Sep. 30, 2017**

**Goodwill and Intangible**

**Assets**

**Goodwill and Intangible Assets**

**Note 2 – Goodwill and Intangible Assets**

Goodwill is not amortized, but is subject to annual impairment reviews, or more frequent reviews if events or circumstances indicate there may be impairment.

Below is a summary of the changes in the carrying value of goodwill by segment for the nine months ended September 30, 2017:

<i>Inmillions</i>	Pharmacy		Total
	Services	Retail/I,TC	
Balance, December31,2016	\$ 21,637	\$ 16,612	\$38,249
Acquisitions	—	52	52
Foreign currency translation adjustments	—	3	3
Impairment	—	(135)	(135)
Balance, September30,2017	\$ 21,637	\$ 16,532	\$38,169

During 2017, the Company began pursuing various strategic alternatives for its RxCrossroads (“RxC”) reporting unit. In connection with this ongoing effort, the Company performed an interim goodwill impairment test in the second quarter of 2017. In conjunction with the impairment test, the fair value of the RxC reporting unit was estimated to be lower than the carrying value, resulting in a \$135 million goodwill impairment charge within operating expenses during the second quarter of 2017. The fair value of the RxC reporting unit was determined using a combination of a discounted cash flow method and a market multiple method. During the second quarter of 2017, the Company also performed an impairment test of the intangible assets of the RxC reporting unit and none were impaired. During the third quarter of 2017, the Company performed its required annual impairment tests and concluded there was no impairment of goodwill or trade names.

On November 6, 2017, the Company entered into a definitive agreement to sell RxC to McKesson Corporation for \$735 million. The transaction is subject to a working capital adjustment and is expected to close in the first quarter of 2018, subject to customary regulatory approvals.

The following is a summary of the Company’s intangible assets as of September 30, 2017 and December 31, 2016:

<i>Inmillions</i>	September30,2017		December31,2016		Net Carrying Amount	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization		
Trademark (indefinitely-lived)	\$ 6,398	\$ —	\$ 6,398	\$ 6,398	\$ 6,398	
Customer contracts and relationships and covenants not to compete	11,848	(5,345)	6,503	11,485	(4,802)	6,683
Favorable leases and other	1,151	(749)	402	1,123	(693)	430
	\$ 19,397	\$ (6,094)	\$ 13,303	\$ 19,006	\$ (5,495)	\$ 13,511

## Share Repurchase Programs

9 Months Ended

Sep. 30, 2017

### Share Repurchase Programs

#### Share Repurchase Programs

#### **Note3– Share Repurchase Programs**

During the nine months ended September 30, 2017, the Company had the following outstanding share repurchase programs, both of which had previously been authorized by the Company's Board of Directors:

#### In billions

<u>Authorization Date</u>	<u>Authorized</u>	<u>Remaining</u>
November 2, 2016 ("2016 Repurchase Program")	\$ 15.0	\$ 13.9
December 15, 2014 ("2014 Repurchase Program")	10.0	—

Each of the 2014 and 2016 Repurchase Programs, which were effective immediately, permitted the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. Each of the repurchase programs could be modified or terminated by the Board of Directors at any time. The 2014 Repurchase Program was completed during the second quarter of 2017.

During the three months ended September 30, 2017, the Company repurchased an aggregate of approximately 5.0 million shares of common stock for approximately \$0.4 billion pursuant to the 2016 Repurchase Program. During the nine months ended September 30, 2017, the Company repurchased an aggregate of approximately 55.4 million shares of common stock for approximately \$4.4 billion pursuant to the 2014 and 2016 Repurchase Programs. This activity includes the accelerated share repurchase agreements ("ASRs") described below.

Pursuant to the authorization under the 2014 Repurchase Program, effective August 29, 2016, the Company entered into two fixed dollar ASRs with Barclays Bank PLC ("Barclays") for a total of \$3.6 billion. Upon payment of the \$3.6 billion purchase price on January 6, 2017, the Company received a number of shares of its common stock equal to 80% of the \$3.6 billion notional amount of the ASRs or approximately 36.1 million shares, which were placed into treasury stock in January 2017. The ASRs were accounted for as an initial treasury stock transaction for \$2.9 billion and a forward contract for \$0.7 billion. In April 2017, the Company received 9.9 million shares of common stock, representing the remaining 20% of the \$3.6 billion notional amount of the ASRs, thereby concluding the ASRs. The remaining 9.9 million shares of common stock delivered to the Company by Barclays were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in April 2017.

At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share.

## Pension Settlements

9 Months Ended

Sep. 30, 2017

### Pension Settlements

#### Pension Settlements

#### **Note 4 – Pension Settlements**

As of December 31, 2016, the Company sponsored seven defined benefit pension plans. Two of the plans are tax-qualified plans that are funded based on actuarial calculations and applicable federal laws and regulations. The other five plans are unfunded nonqualified supplemental retirement plans. All seven of these plans are closed to new participants. During the three months ended September 30, 2017, the Company settled the pension obligations of its two tax-qualified plans by irrevocably transferring pension liabilities to an insurance company through the purchase of group annuity contracts and through lump sum distributions. These purchases, funded with pension plan assets, resulted in pre-tax settlement losses of \$187 million in the three months ended September 30, 2017, related to the recognition of accumulated deferred actuarial losses. The settlement losses are included in other expense in the condensed consolidated statement of income.



Accumulated Other  
Comprehensive Income

9 Months Ended  
Sep. 30, 2017

Accumulated Other  
Comprehensive Income

Accumulated Other  
Comprehensive Income

**Note 5— Accumulated Other Comprehensive Income**

Accumulated other comprehensive income consists of foreign currency translation adjustments, unrealized losses on cash flow hedges executed in previous years associated with the issuance of long-term debt, and changes in the net actuarial gains and losses associated with pension and other postretirement benefit plans. The following table summarizes the activity within the components of accumulated other comprehensive income.

Changes in accumulated other comprehensive income (loss) by component is shown on the following tables:

	Three Months Ended September 30, 2017			
	Foreign Currency	Losses on Cash Flow Hedges	Pension and Other Postretirement Benefits	Total
<i>In millions</i>				
Balance, June 30, 2017	\$ (129)	\$ (4)	(173)	\$ (306)
Other comprehensive income before reclassifications	8	—	—	8
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	—	151	151
Net other comprehensive income	8	—	151	159
Balance, September 30, 2017	\$ (121)	\$ (4)	(22)	\$ (147)
	Three Months Ended September 30, 2016			
	Foreign Currency	Losses on Cash Flow Hedges	Pension and Other Postretirement Benefits	Total
Balance, June 30, 2016	\$ (125)	\$ (6)	(186)	\$ (317)
Other comprehensive income (loss) before reclassifications	(3)	—	—	(3)
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	1	—	1
Net other comprehensive income (loss)	(3)	1	—	(2)
Balance, September 30, 2016	\$ (128)	\$ (5)	(186)	\$ (319)
	Nine Months Ended September 30, 2017 <sup>(1)</sup>			
	Foreign Currency	Losses on Cash Flow Hedges	Pension and Other Postretirement Benefits	Total
Balance, December 31, 2016	\$ (127)	\$ (5)	(173)	\$ (305)
Other comprehensive income before reclassifications	6	—	—	6
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	1	151	152
Net other comprehensive income	6	1	151	158
Balance, September 30, 2017	\$ (121)	\$ (4)	(22)	\$ (147)
	Nine Months Ended September 30, 2016 <sup>(1)</sup>			
	Foreign Currency	Losses on Cash Flow Hedges	Pension and Other Postretirement Benefits	Total
Balance, December 31, 2015	\$ (165)	\$ (7)	(186)	\$ (358)
Other comprehensive income before reclassifications	37	—	—	37
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	2	—	2
Net other comprehensive income	37	2	—	39
Balance, September 30, 2016	\$ (128)	\$ (5)	(186)	\$ (319)

(1) All amounts are net of tax.

(2) The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statements of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in other expense on the condensed consolidated statements of income.

## Stock-Based Compensation

9 Months Ended

Sep. 30, 2017

### Stock-Based Compensation

#### Stock-Based Compensation

#### Note 6 – Stock-Based Compensation

A summary of stock-based compensation for each of the respective periods is as follows:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2017	2016	2017	2016
<i>In millions</i>				
Stock-based compensation:				
Stock options	\$ 15	\$ 20	\$ 49	\$ 60
Restricted stock units	50	38	124	106
Total stock-based compensation	<u>\$ 65</u>	<u>\$ 58</u>	<u>\$ 173</u>	<u>\$ 166</u>

During the nine months ended September 30, 2017, the Company granted approximately 4 million stock options with a weighted average fair value of \$9.43 and a weighted average fair value exercise price of \$78.05. The Company had approximately 21 million stock options outstanding as of September 30, 2017 with a weighted average exercise price of \$75.09 and a weighted average contractual term of 3.87 years. During the nine months ended September 30, 2017, the Company granted approximately 3 million restricted stock units with a weighted average fair value of \$78.35. The Company had approximately 6 million restricted stock units unvested as of September 30, 2017 with a weighted average fair value of \$87.20.

## Sale-Leaseback Transactions

9 Months Ended

Sep. 30, 2017

### Sale-Leaseback Transactions

#### Sale-Leaseback Transactions

##### **Note 7 – Sale-Leaseback Transactions**

The Company finances a portion of its store development program through sale-leaseback transactions. The properties are generally sold at net book value, which approximates fair value, and the resulting leases typically qualify and are accounted for as operating leases. The Company does not have any retained or contingent interests in the stores and does not provide any guarantees, other than a guarantee of lease payments, in connection with the sale-leaseback transactions. Proceeds from sale-leaseback transactions totaled \$265 million and \$230 million for the nine months ended September 30, 2017 and 2016, respectively.

## Store Closures

9 Months Ended

Sep. 30, 2017

### Store Closures

#### Store Closures

##### **Note 8 – Store Closures**

In December 2016, the Company announced an enterprise streamlining initiative designed to reduce costs and enhance operating efficiencies to allow the Company to be more competitive in the current health care environment. In connection with the enterprise streamlining initiative, the Company announced its intention to rationalize the number of retail stores by closing approximately 70 underperforming stores during the year ending December 31, 2017. During the three and nine months ended September 30, 2017, the Company closed five and 68 retail stores, respectively, and recorded charges of \$6 million and \$211 million, respectively, within operating expenses in the Retail/LTC Segment. The charges are primarily comprised of provisions for the present value of noncancelable lease obligations.

The noncancelable lease obligations associated with stores closed during the nine months ended September 30, 2017 extend through the year 2039. In connection with the enterprise streamlining initiative, the Company expects to record additional charges of approximately \$9 million during the fourth quarter of 2017 as it continues to rationalize the number of retail stores.

Interest Expense, Net

9 Months Ended  
Sep. 30, 2017

Interest Expense, Net

Interest Expense, Net

**Note 9 – Interest Expense, Net**

The following are the components of interest expense, net:

	Three Months Ended		Nine Months Ended	
	September 30, 2017	September 30, 2016	September 30, 2017	September 30, 2016
<i>In millions</i>				
Interest expense	\$ 250	\$ 258	\$ 759	\$ 830
Interest income	(5)	(5)	(15)	(14)
Interest expense, net	<u>\$ 245</u>	<u>\$ 253</u>	<u>\$ 744</u>	<u>\$ 816</u>

## Earnings Per Share

9 Months Ended

Sep. 30, 2017

### Earnings Per Share

#### Earnings Per Share

#### **Note 10— Earnings Per Share**

Earnings per share is computed using the two-class method. Options to purchase 10.9 million and 9.9 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share, for the three and nine months ended September 30, 2017, respectively, because the exercise prices of the options were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, options to purchase approximately 7.7 million and 6.4 million shares of common stock were outstanding, but were not included in the calculation of diluted earnings per share for the three and nine months ended September 30, 2016, respectively.

The following is a reconciliation of basic and diluted earnings per share from continuing operations for the respective periods:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2017	2016	2017	2016
<i>In millions, except per share amounts</i>				
Numerator for earnings per share calculation:				
Income from continuing operations	\$ 1,285	\$ 1,542	\$ 3,344	\$ 3,613
Income allocated to participating securities	(3)	(7)	(12)	(18)
Net income attributable to noncontrolling interest	—	(1)	(1)	(2)
Income from continuing operations attributable to CVS Health	<u>\$ 1,282</u>	<u>\$ 1,534</u>	<u>\$ 3,331</u>	<u>\$ 3,593</u>
Denominator for earnings per share calculation:				
Weighted average shares, basic	1,016	1,068	1,022	1,076
Effect of dilutive securities	4	5	4	6
Weighted average shares, diluted	<u>1,020</u>	<u>1,073</u>	<u>1,026</u>	<u>1,082</u>
Earnings per share from continuing operations:				
Basic	\$ 1.26	\$ 1.44	\$ 3.26	\$ 3.34
Diluted	\$ 1.26	\$ 1.43	\$ 3.25	\$ 3.32

## Segment Reporting

9 Months Ended

Sep. 30, 2017

### Segment Reporting

#### Segment Reporting

#### Note 11 – Segment Reporting

The Company has three reportable segments: Pharmacy Services, Retail/LTC and Corporate. The Retail/LTC Segment includes the operating results of the Company's Retail Pharmacy and LTC/RxCrossroads operating segments as the operations and economic characteristics are similar. The Company's three reportable segments maintain separate financial information by which operating results are evaluated on a regular basis by the Company's chief operating decision maker in deciding how to allocate resources and in assessing performance.

The Company evaluates its Pharmacy Services and Retail/LTC segments' performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.

The Pharmacy Services Segment provides a full range of pharmacy benefit management ("PBM") solutions including plan design offerings and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management services and medical spend management. The Company's clients are primarily employers, insurance companies, unions, government employee groups, health plans, Medicare Part D, Managed Medicaid plans, plans offered on the public and private exchanges, and other sponsors of health benefit plans and individuals throughout the United States. Through the Company's SilverScript Insurance Company subsidiary, the Pharmacy Services Segment is a national provider of drug benefits to eligible beneficiaries under the federal government's Medicare Part D program. The Pharmacy Services Segment operates under the CVS Caremark® Pharmacy Services, Caremark®, CVS Caremark™, CarePlus CVS Pharmacy™, Accordant®, SilverScript®, Coram®, CVS Specialty™, NovoLogix®, Navarro® Health Services, Advanced Care Scripts and ACS Pharmacy names. As of September 30, 2017, the Pharmacy Services Segment operated 23 retail specialty pharmacy stores, 15 specialty mail order pharmacies, four mail service dispensing pharmacies, and 82 branches for infusion and enteral services, including approximately 73 ambulatory infusion suites and three centers of excellence, located in 41 states, Puerto Rico and the District of Columbia.

The Retail/LTC Segment sells prescription drugs and a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, photo finishing services, seasonal merchandise and greeting cards. The Retail/LTC Segment also includes providing the distribution of prescription drugs, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings, as well as commercialization services that are provided under the name RxCrossroads®. The Retail/LTC Segment also provides health care services through its MinuteClinic® health care clinics. MinuteClinics are staffed by nurse practitioners and physician assistants who utilize nationally recognized protocols to diagnose and treat minor health conditions, perform health screenings, monitor chronic conditions and deliver vaccinations. As of September 30, 2017, our Retail/LTC Segment included 9,751 retail locations (of which 8,016 were the Company's stores that operated a pharmacy and 1,687 were the Company's pharmacies located within Target stores) located in 49 states, the District of Columbia, Puerto Rico and Brazil operating primarily under the CVS Pharmacy®, CVS®, CVS Pharmacy y más®, Longs Drugs®, Navarro Discount Pharmacy® and Drogeria Onofre™ names. 38 onsite pharmacies primarily operating under the CarePlus CVS Pharmacy™, CarePlus® and CVS Pharmacy® names. 1,129 retail health care clinics operating under the MinuteClinic® name (of which 1,122 were located in CVS Pharmacy and Target stores), and our online retail websites, CVS.com®, Navarro.com™ and Onofre.com.br™. LTC operations are comprised of 143 spoke pharmacies that primarily handle new prescription orders, of which 31 are also hub pharmacies that use proprietary automation to support spoke pharmacies with refill prescriptions. LTC operates primarily under the Omnicare® and NeighborCare® names. The Corporate Segment provides management and administrative services to support the Company. The Corporate Segment consists of certain aspects of executive management, corporate relations, legal, compliance, human resources, information technology and finance departments.

<u>In millions</u>	<u>Pharmacy Services Segment</u>	<u>Retail/LTC Segment</u>	<u>Corporate Segment</u>	<u>Intersegment Eliminations</u>	<u>Consolidated Totals</u>
<b>Three Months Ended</b>					
September 30, 2017:					
Net revenues	\$ 32,896	\$ 19,593	\$ —	\$ (6,308)	\$ 46,181
Gross profit <sup>(3)</sup>	1,645	5,685	—	(204)	7,126
Operating profit (loss) <sup>(4)(5)(6)</sup>	1,353	1,553	(220)	(187)	2,499
September 30, 2016:					
Net revenues	30,429	20,143	—	(5,957)	44,615
Gross profit <sup>(3)</sup>	1,797	5,893	—	(198)	7,492
Operating profit (loss) <sup>(5)(6)(7)</sup>	1,459	1,778	(228)	(185)	2,824
<b>Nine Months Ended</b>					
September 30, 2017:					
Net revenues	96,444	58,488	—	(18,552)	136,380
Gross profit <sup>(3)</sup>	4,210	17,036	—	(605)	20,641
Operating profit (loss) <sup>(4)(5)(6)</sup>	3,272	4,375	(686)	(552)	6,409
September 30, 2016:					
Net revenues	88,704	60,253	—	(17,402)	131,555
Gross profit <sup>(3)</sup>	4,266	17,560	—	(575)	21,251
Operating profit (loss) <sup>(5)(6)(7)</sup>	3,282	5,273	(660)	(529)	7,366

- (1) Net revenues of the Pharmacy Services Segment include approximately \$2.6 billion and \$2.5 billion of retail co-payments for the three months ended September 30, 2017 and 2016, respectively, as well as \$8.4 billion and \$8.1 billion of retail co-payments for the nine months ended September 30, 2017 and 2016, respectively.
- (2) Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients ("members") fill prescriptions at the Company's retail pharmacies to purchase covered products, when members enrolled in programs such as Maintenance Choice<sup>®</sup> elect to pick up maintenance prescriptions at one of the Company's retail pharmacies instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
- (3) The Retail/LTC Segment gross profit for the three months ended September 30, 2017 and 2016 includes \$2 million and \$5 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment gross profit for the nine months ended September 30, 2017 and 2016 includes \$7 million and \$15 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (4) The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2017 includes \$6 million and \$211 million, respectively, of charges associated with store closures (see "Note 8 – Store Closures" to the condensed consolidated financial statements). The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 also includes a \$135 million goodwill impairment charge related to the segment's RxCrossroads reporting unit (see "Note 2 – Goodwill and Intangible Assets" to the condensed consolidated financial statements).
- (5) The Retail/LTC Segment operating profit for the three months ended September 30, 2017 and 2016 includes \$9 million and \$52 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 and 2016 includes \$34 million and \$194 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (6) The Corporate Segment operating loss for the three and nine months ended September 30, 2017 include a \$3 million reduction in integration costs for a change in estimate related to the acquisition of Omnicare. The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes \$13 million of integration costs related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- (7) Amounts revised to reflect the adoption of ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which increased consolidated operating profit by \$7 and \$23 million for the three and nine months ended September 30, 2016, respectively (see "Note 1 – Accounting Policies" to the condensed consolidated financial statements).



## Commitments and Contingencies

9 Months Ended  
Sep. 30, 2017

### Commitments and Contingencies.

#### Commitments and Contingencies

##### **Note 12– Commitments and Contingencies** **Lease Guarantees**

Between 1991 and 1997, the Company sold or spun off a number of subsidiaries, including Bob's Stores, Linens 'n Things, Marshalls, Kay-Bee Toys, Wilsons, This End Up and Footstar. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the store's lease obligations. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company's guarantees remained in place, although each initial purchaser has agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries were to become insolvent and failed to make the required payments under a store lease, the Company could be required to satisfy these obligations. As of September 30, 2017, the Company guaranteed approximately 86 such store leases (excluding the lease guarantees related to Linens 'n Things, which have been recorded as a liability on the condensed consolidated balance sheet), with the maximum remaining lease term extending through 2047.

In April 2016 and again in February 2017, Bob's Stores and its related and successor entities filed for Chapter 11 bankruptcy protection. As described above, the Company, through one or more of its affiliates, is alleged to have guaranteed certain of the Bob's Stores' leases (the "Bob's Leases"). Following these bankruptcy filings, in May 2017 the Company and SDI Stores, LLC ("SDI Stores"), entered into an agreement regarding the Bob's Leases, which was amended in August 2017 (the "CVS/SDI Stores Agreement"). Pursuant to the CVS/SDI Stores Agreement, SDI Stores has accepted the assignment of the Bob's Leases and has agreed to be bound by certain restrictions regarding renewals, extensions and modifications to the Bob's Leases, in exchange for a series of payments that are immaterial to the Company.

##### **Legal Matters**

The Company is a party to legal proceedings, investigations and claims in the ordinary course of its business, including the matters described below. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company's accruals for outstanding legal matters are material individually or in the aggregate to the Company's financial position.

Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters.

- *Indiana State District Council of Laborers and HOD Carriers Pension and Welfare Fund v. Omnicare, Inc.*, et al. (U.S. District Court for the Eastern District of Kentucky). In February 2006, two substantially similar putative class action lawsuits were filed and subsequently consolidated. The consolidated complaint was filed against Omnicare, three of its officers and two of its directors and purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, as well as all purchasers who bought shares of Omnicare common stock in Omnicare's public offering in December 2005. The complaint alleged violations of the Securities Exchange Act of 1934 and Section 11 of the Securities Act of 1933 and sought, among other things, compensatory damages and injunctive relief. After dismissals and appeals to the United States Court of Appeals for the Sixth Circuit, the United States Supreme Court remanded the case to the district court. In October 2016, Omnicare filed an answer to plaintiffs' third amended complaint, and discovery commenced.
- *FTC and Multi-State Investigation*. In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies were conducting a multi-state investigation of certain of the Company's business practices similar to those being investigated at that time by the U.S. Federal Trade Commission ("FTC"). Twenty-eight states, the District of Columbia and the County of Los Angeles are known to be participating in this investigation. The prior FTC investigation, which commenced in August 2009, was officially concluded in May 2012 when the consent order entered into between the FTC and the Company became final. The Company has cooperated with the multi-state investigation.
- *United States ex rel. Jack Chin v. Walgreen Company*, et al. (U.S. District Court for the Central District of California). In March 2010, the Company received a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General ("OIG") requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to the Company's pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. In October 2016, the U.S. District Court for the Central District of California unsealed a *qui tam* complaint, filed in April 2009 against CVS Pharmacy and other retail pharmacies, alleging that the Company violated the federal False Claims Act, and the False Claims Acts of several states, by offering such programs. The complaint was served on the Company in January 2017. The federal government has declined intervention in the case. The Company is defending this lawsuit.
- *United States ex rel. Anthony R. Spay v. CVS Caremark Corporation*, et al. (U.S. District Court for the Eastern District of Pennsylvania). In January 2012, the court unsealed a first amended *qui tam* complaint filed in August 2011 by an individual relator, Anthony Spay, who is described in the complaint as having once been employed by a firm providing pharmacy prescription benefit audit and recovery services. The complaint seeks monetary damages and alleges that CVS Caremark's processing of Medicare claims on behalf of one of its clients violated the federal False Claims Act.

The United States declined to intervene in the lawsuit. In September 2015, the Court granted CVS Caremark's motion for summary judgment in its entirety, and entered judgment in favor of CVS Caremark and against Spay. In October 2015, Spay filed a notice of appeal in the United States Court of Appeals for the Third Circuit; that court heard oral arguments on the appeal in November 2016.

- *State of Texas ex rel. Myron Winkelman and Stephani Martinson, et al. v. CVS Health Corporation.* (Travis County Texas District Court). In February 2012, the Attorney General of the State of Texas issued Civil Investigative Demands and has issued a series of subsequent requests for documents and information in connection with its investigation concerning the CVS Health Savings Pass program and other pricing practices with respect to claims for reimbursement from the Texas Medicaid program. In January 2017, the court unsealed a first amended petition. The amended petition alleges the Company violated the Texas Medicaid Fraud Prevention Act by submitting false claims for reimbursement to Texas Medicaid by, among other things, failing to use the price available to members of the CVS Health Savings Pass program as the usual and customary price. The amended petition was unsealed following the Company's filing of *CVS Pharmacy, Inc. v. Charles Smith, et al.* (Travis County District Court), a declaratory judgment action against the State of Texas in December 2016 seeking a declaration that the prices charged to members of the CVS Health Savings Pass program do not constitute usual and customary prices under the Medicaid regulation. The State of Texas is also pursuing temporary injunctive relief.
- *Subpoena Concerning PBM Administrative Fees.* In March 2014, the Company received a subpoena from the United States Attorney's Office for the District of Rhode Island, requesting documents and information concerning bona fide service fees and rebates received from pharmaceutical manufacturers in connection with certain drugs utilized under Medicare Part D, as well as the reporting of those fees and rebates to Part D plan sponsors. The Company has been cooperating with the government and providing documents and information in response to the subpoena.
- *Corcoran et al. v. CVS Health Corporation* (U.S. District Court for the Northern District of California) and *Podgorny et al. v. CVS Health Corporation* (U.S. District Court for the Northern District of Illinois). These putative class actions were filed against the Company in July and September 2015. The cases were consolidated in United States District Court in the Northern District of California. Plaintiffs seek damages and injunctive relief on behalf of a class of consumers who purchased certain prescription drugs under the consumer protection statutes and common laws of certain states. Several third-party payors filed similar putative class actions on behalf of payors captioned *Sheet Metal Workers Local No. 20 Welfare and Benefit Fund v. CVS Health Corp.* and *Plumbers Welfare Fund, Local 130 v. CVS Health Corporation* (both pending in the U.S. District Court for the District of Rhode Island) in February and August 2016. In all of these cases the plaintiffs allege the Company overcharged for certain prescription drugs by not submitting the price available to members of the CVS Health Savings Pass program as the pharmacy's usual and customary price. In the consumer case (*Corcoran*), the Court granted summary judgment to CVS on plaintiffs' claims in their entirety and certified certain subclasses in September 2017. The plaintiffs have filed a notice of appeal to the Ninth Circuit. The Company continues to defend these actions.
- *Omnicare DEA Subpoena.* In September 2015, Omnicare was served with an administrative subpoena by the U.S. Drug Enforcement Administration ("DEA"). The subpoena seeks documents related to controlled substance policies, procedures, and practices at eight pharmacy locations from May 2012 to the present. In September 2017, the DEA expanded the investigation to include an additional pharmacy. The Company has been cooperating and providing documents in response to this administrative subpoena.
- *Omnicare Cycle Fill Civil Investigative Demand.* In October 2015, Omnicare received a Civil Investigative Demand from the United States Attorney's Office for the Southern District of New York requesting information and documents concerning Omnicare's cycle fill process for assisted living facilities. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand. In July 2017, Omnicare also received a subpoena from the California Department of Insurance requesting documents on similar subject matter.
- *PBM Pricing Civil Investigative Demand.* In October 2015, the Company received from the DOJ a Civil Investigative Demand requesting documents and information in connection with a federal False Claims Act investigation concerning allegations that the Company submitted, or caused to be submitted, to the Medicare Part D program prescription drug event data that misrepresented true prices paid by the Company's PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company's PBM. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *United States ex rel. Sally Schimelpfenig and John Segura v. Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories, Inc.* (U.S. District Court for the Eastern District of Pennsylvania). In November 2015, the court unsealed a second amended *qui tam* complaint filed in September 2015. The DOJ declined to intervene in this action. The relators allege that the Company, Walgreens, Wal-Mart, and Dr. Reddy's Laboratories violated the federal and various state False Claims Acts by dispensing prescriptions in unit dose packaging supplied by Dr. Reddy's that was not compliant with the Consumer Product Safety Improvement Act and the Poison Preventive Packaging Act and thereby allegedly rendering the drugs misbranded under the Food, Drug and Cosmetic Act. In March 2017, the Court granted the Company's motion to dismiss with leave to file an amended complaint. In June 2017, the Company moved to dismiss relators' third amended complaint.
- *Barchock et al. v. CVS Health Corporation, et al.* (U.S. District Court for the District of Rhode Island). In February 2016, a class action lawsuit was filed against the Company, the Benefit Plans Committee of the Company, and Galliard Capital Management, Inc., by Mary Barchock, Thomas Wasecko, and Stacy Weller, purportedly on behalf of the 401(k) Plan and the Employee Stock Ownership Plan of the Company (the "Plan"), and participants in the Plan. The complaint alleged that the defendants breached fiduciary duties owed to the plaintiffs and the Plan by investing too

much of the Plan's Stable Value Fund in short-term money market funds and cash management accounts. The court recently granted the Company's motion to dismiss the plaintiffs' amended complaint. In May 2017, plaintiffs appealed that ruling in the United States Court of Appeals for the First Circuit.

- *State of California ex rel. Matthew Omlansky v. CVS Caremark Corporation* (Superior Court of the State of California, County of Sacramento). In April 2016, the court unsealed a first amended *qui tam* complaint filed in July 2013. The government has declined intervention in this case. The relator alleges that the Company submitted false claims for payment to California Medicaid in connection with reimbursement for drugs available through the CVS Health Savings Pass program as well as certain other generic drugs. The case has been stayed pending the relator's appeal of the judgment against him in a similar case against another retailer.
- *Retail DEA Matters*. The Company has been also undergoing several audits by the DEA Administrator and is in discussions with the DEA and the U.S. Attorney's Offices in several locations concerning allegations that the Company has violated certain requirements of the CSA.
- *West Virginia Opioid Litigation*. In March 2017, the Company was named as a defendant in four separate lawsuits filed in the U.S. District Court of the Southern District of West Virginia on behalf of counties in the state of West Virginia (Cabell, Fayette, Kanawha and Wayne counties), each of which alleges that CVS Indiana L.L.C., as well as various other distributors of controlled substances, caused a public nuisance related to opioid abuse by failing to detect and/or report purported suspicious orders of opioids distributed for dispensing in the plaintiff counties. Omnicare Distribution Center, LLC also is named as a defendant in the complaint filed by Kanawha County. The Company is defending these lawsuits.
- *Cherokee Nation Opioid Litigation*. In April 2017, the Company was named as a defendant in an action filed on behalf of the Cherokee Nation in the District Court of Cherokee Nation (the "Cherokee Action"). The lawsuit asserts several causes of action arising from allegations that large retail pharmacies and wholesale distributors caused widespread opioid abuse among members of the Cherokee Nation by purportedly failing to comply with the Controlled Substances Act and/or otherwise failing to prevent the diversion of opioids. In June 2017, the Company filed a motion to dismiss the Cherokee Action. The Cherokee Nation has since filed an amended petition in the Cherokee Action. Also in June 2017, the six defendants in the Cherokee Action collectively filed a complaint in the U.S. District Court for the Northern District of Oklahoma, *McKesson, et al. v. Hembree, et al.*, seeking a declaration and preliminary injunction prohibiting the District Court of Cherokee Nation from exercising jurisdiction over the Cherokee Action.
- *State of Mississippi v. CVS Health Corporation, et al.* (Chancery Court of DeSoto County, Mississippi, Third Judicial District). In July 2016, the Company was served with a complaint filed on behalf of the State of Mississippi alleging that CVS retail pharmacies in Mississippi submitted false claims for reimbursement to Mississippi Medicaid by not submitting the price available to members of the CVS Health Savings Pass program as the pharmacy's usual and customary price. The Company has responded to the complaint, filed a counterclaim, and moved to transfer the case to circuit court. The motion to transfer was granted, which the State has appealed, and the motion to dismiss remains pending.
- *Mayberry v. Walgreens Co., et al.* (U.S. District Court for the Northern District of Illinois). In March 2017, a complaint was filed against the Company (and several other retail pharmacy defendants) alleging that the defendant pharmacies improperly submitted certain insulin claims through Medicare Part D rather than Part B. The Company's motion to dismiss the complaint was granted. The Company separately received in December 2016 a Civil Investigative Demand from the U.S. Attorney's Office for the Northern District of New York, requesting documents and information in connection with a False Claims Act investigation concerning whether the Company's retail pharmacies improperly submitted certain insulin claims to Medicare Part D rather than Part B. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *Cold Chain Logistics Civil Investigative Demand*. In September 2016, the Company received from the DOJ a Civil Investigative Demand in connection with an investigation as to whether the Company's handling of certain temperature-sensitive pharmaceuticals violates the federal Food, Drug and Cosmetic Act and the False Claims Act. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *Amburgey, et al. v. CaremarkPCS Health, L.L.C.* (U.S. District Court for the Central District of California). In March 2017, the Company was served with a complaint challenging the policies and procedures used by CVS Specialty pharmacies to ship temperature-sensitive medications. The case is similar to a matter already pending against the Company in the Superior Court of California (Los Angeles County), *Bertram v. Immunex Corp., et al.*, which was filed in October 2014. The Company is defending these lawsuits.
- *Barnett, et al. v. Novo Nordisk Inc., et al. and Boss, et al. v. CVS Health Corporation, et al.* (both pending in the U.S. District Court for the District of New Jersey). These putative class actions were filed against the Company and other PBMs and manufacturers of insulin in March 2017. Plaintiffs in both cases allege that the PBMs and manufacturers have engaged in a conspiracy whereby the PBMs sell access to their formularies by demanding the highest rebates, which in turn causes increased list prices for insulin. The primary claims are antitrust claims, claims under the Racketeer Influenced and Corrupt Organizations Act ("RICO"), violations of state unfair competition and consumer protection laws and in *Boss*, claims pursuant to the Employee Retirement Income Security Act ("ERISA"). The *Barnett* plaintiffs seek to represent a nationwide class of all persons who paid any portion of the purchase prices for a prescription for certain insulin products at a price calculated by reference to a benchmark. The *Boss* plaintiffs purport to represent multiple nationwide classes including a non-ERISA Employee/Exchange Plan class, an ERISA class, a Medicare class and an uninsured class. The Company continues to defend these lawsuits.
- *Insulin Products Investigation*. In April 2017, the Company separately received a Civil Investigative Demand from the Attorney General of Washington, seeking documents and information regarding pricing and rebates for insulin products in connection with a pending investigation into unfair and deceptive acts or practice regarding insulin pricing. We have been

notified by the Office of the Attorney General of Washington that information provided in response to the Civil Investigative Demand will be shared with the Attorneys General of California, Florida, Minnesota and New Mexico. In July 2017, the Company received a Civil Investigative Demand from the Attorney General of Minnesota, seeking documents and information regarding pricing and rebates for insulin and epinephrine products in connection with a pending investigation into unfair and deceptive acts or practices regarding insulin and epinephrine pricing.

- *Bewley, et al. v. CVS Health Corporation, et al. and Prescott, et al. v. CVS Health Corporation, et al.* (both pending in the U.S. District Court for the Western District of Washington). These putative class actions were filed in May 2017 against the Company and other pharmacy benefit managers and manufacturers of glucagon kits (Bewley) and diabetes test strips (Prescott). *Both cases allege that, by contracting for rebates with the manufacturers of these diabetes products, the Company and other PBMs caused list prices for these products to increase, thereby harming certain consumers. The primary claims are made under federal antitrust laws, RICO, state unfair competition and consumer protection laws, and ERISA. The Company is defending these lawsuits.*
- *Klein, et al. v. Prime Therapeutics, et al.* (U.S. District Court for the District of Minnesota). In June 2017, a putative class action complaint was filed against the Company and other pharmacy benefit managers on behalf of ERISA plan members who purchased and paid for EpiPen or EpiPen Jr. Plaintiffs allege that the pharmacy benefit managers are ERISA fiduciaries to plan members and have violated ERISA by allegedly causing higher inflated prices for EpiPen through the process of negotiating increased rebates from EpiPen manufacturer, Mylan. The Company is defending this lawsuit.
- *Medicare Part D Civil Investigative Demand.* In May 2017, the United States Attorney's Office for the Southern District of New York issued a Civil Investigative Demand to the Company concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to the Civil Investigative Demand.
- *Shareholder Matters.* In August and September 2017, four complaints were filed by putative derivative plaintiffs against certain officers and directors of the Company. Three of those actions, *Sherman v. Merlo, et al., Feghali v. Merlo, et al., and Banchalter v. Merlo, et al.*, were filed in the U.S. District Court for the District of Rhode Island. A fourth, *Boron v. Bracken, et al.*, was filed in Rhode Island Superior Court. These matters assert a variety of causes of action, including breach of fiduciary duty, waste of corporate assets, unjust enrichment, civil conspiracy and violation of Section 14(a) of the Exchange Act, and are premised on the allegation that the defendants approved business plans that exposed the Company to various litigations and investigations. The parties in the three federal matters have filed a joint motion to stay the cases pending resolution of certain of the underlying matters.
- *MSP Recovery Claims Series, LLC, et al. v. CVS Health Corporation, et al.* (U.S. District Court for the Western District of Texas). In September 2017, a putative class action complaint was filed against the company, Express Scripts, Inc., and the manufacturers of insulin on behalf of assignees of claims of Medicare Advantage Organizations. Plaintiffs assert that the PBMs and manufacturers have engaged in a conspiracy whereby the PBMs sell access to their formularies by demanding the highest rebates, which in turn causes increased list prices for insulin. The plaintiffs assert claims on behalf of two putative classes: (1) all Medicare C payors and (2) all Medicare D payors. The complaint asserts claims under RICO, and for common law fraud and unjust enrichment.

The Company is also a party to other legal proceedings, government investigations, inquiries and audits, and has received and is cooperating with subpoenas or similar process from various governmental agencies requesting information, all arising in the normal course of its business, none of which is expected to be material to the Company. The Company can give no assurance, however, that its business, financial condition and results of operations will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations as they may relate to the Company's business, the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industries or to the health care industry generally; (iii) pending or future federal or state governmental investigations of the Company's business or the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or of the health care industry generally; (iv) pending or future government enforcement actions against the Company; (v) adverse developments in any pending *qui tam* lawsuit against the Company, whether sealed or unsealed, or in any future *qui tam* lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting the pharmacy services, specialty pharmacy, retail pharmacy, long-term care pharmacy or retail clinic industry or the health care industry generally.

**9 Months Ended  
Sep. 30, 2017**

**Accounting Policies (Policies)**

**Accounting Policies**

**Principles of Consolidation**

***Principles of Consolidation***

The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities ("VIEs") for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated.

The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity's economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary.

Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company's condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.

***Fair Value of Financial Instruments***

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

- Level1– Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
- Level2– Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.
- Level3– Inputs to the valuation methodology are unobservable inputs based upon management's best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

As of September 30, 2017, the carrying value of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and the contingent consideration liability included in accrued expenses approximated their fair value due to the nature of these financial instruments. The Company invests in money market funds, commercial paper and time deposits that are classified as cash and cash equivalents within the accompanying condensed consolidated balance sheets, as these funds are highly liquid and readily convertible to known amounts of cash. These investments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company's short-term investments of \$75million at September 30, 2017 consist of certificates of deposit with initial maturities of greater than three months when purchased that mature within one year from the balance sheet date. These investments, which are classified within Level 1 of the fair value hierarchy, are carried at fair value, which approximated historical cost at September 30, 2017. The carrying amount and estimated fair value of the Company's total long-term debt was \$25.7billion and \$27.0billion, respectively, as of September 30, 2017. The fair value of the Company's long-term debt was estimated based on quoted prices currently offered in active markets for the Company's debt, which is considered Level 1 of the fair value hierarchy.

**Fair Value of Financial Instruments**

**Related Party Transactions**

***Related Party Transactions***

The Company has an equity method investment in SureScripts, LLC ("SureScripts"), which operates a clinical health information network. The Pharmacy Services and Retail/LTC segments utilize this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of approximately \$5million and \$7million in the three months ended September 30, 2017 and 2016, respectively, and expensed fees for the use of this network of approximately \$29 million in the nine months ended September 30, 2017 and 2016. The Company's investment in and equity in earnings of SureScripts for all periods presented is immaterial.

The Company has an equity method investment in Heartland Healthcare Services ("Heartland"). Heartland operates several long-term care pharmacies in four states. Heartland paid the Company approximately \$36million and \$46 million for pharmaceutical inventory purchases during the three months ended September 30, 2017 and 2016, respectively, and approximately \$106 million and \$116 million for pharmaceutical inventory purchases during the nine months ended September 30, 2017 and 2016. Additionally, the Company performs certain collection functions for Heartland and then passes those customer cash collections back to Heartland. The Company's investment and equity in earnings of Heartland for all periods presented is immaterial.

**Discontinued Operations**

***Discontinued Operations***

In connection with certain business dispositions completed between 1991 and 1997, the Company retained guarantees on store lease obligations for a number of former subsidiaries, including Bob's Stores and Linens 'n Things, both of which subsequently filed for bankruptcy. See "Note 12 – Commitments and Contingencies" to the condensed consolidated financial statements. The Company's discontinued operations include lease-related costs which the Company believes it will likely be required to satisfy pursuant to its lease guarantees.

**New Accounting Pronouncements**

***New Accounting Pronouncements Recently Adopted***

In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-11, *Inventory*, which amends Accounting Standard Codification ("ASC") Topic 330. This ASU simplifies current accounting treatments by requiring entities to measure most inventories at "the lower of cost and net realizable value" rather than using lower of cost or market. This guidance does not apply to inventories measured using the last-in, first-out method or the retail inventory method. The Company adopted this standard effective January 1, 2017. The adoption of this new guidance did not have any impact on the Company's condensed consolidated results of operations, financial position or cash flows.

In March 2016, the FASB issued ASU No. 2016-09, *Improvements to Employee Share-Based Payment Accounting*, which amends the accounting for certain aspects of shared-based payments to employees in

ASC Topic 718, *Compensation - Stock Compensation*. The new guidance eliminates the accounting for any excess tax benefits and deficiencies through equity, and requires all excess tax benefits and deficiencies related to employee share-based compensation arrangements to be recorded in the income statement. This aspect of the guidance is required to be applied prospectively. The guidance also requires the presentation of excess tax benefits on the statement of cash flows as an operating activity rather than a financing activity, a change which may be applied prospectively or retrospectively. The guidance further provides an accounting policy election to account for forfeitures as they occur rather than utilizing the estimated amount of forfeitures at the time of issuance. The Company adopted this guidance effective January 1, 2017. The primary impact of adopting this guidance was the recognition of excess tax benefits in the income statement instead of recognizing them in equity. This income statement guidance was adopted on a prospective basis. As a result, a discrete tax benefit of \$18 million and \$51 million was recognized in the income tax provision in the three and nine months ended September 30, 2017, respectively. The Company elected to retrospectively adopt the guidance on the presentation of excess tax benefits in the statement of cash flows. The following is a reconciliation of the effect of the resulting reclassification of the excess tax benefits on the Company's condensed consolidated statement of cash flows for the nine months ended September 30, 2016:

<u>In millions</u>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
Cash paid to other suppliers and employees	\$ (11,092)	\$ 72	\$ (11,020)
Net cash provided by operating activities	7,948	72	8,020
Excess tax benefits from stock-based compensation	72	(72)	—
Net cash used in financing activities	(6,568)	(72)	(6,640)
Reconciliation of net income to net cash provided by operating activities:			
Accrued expenses	2,077	72	2,149

The Company elected to continue to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized in each period. None of the other provisions in this guidance had a material impact on the Company's condensed consolidated financial statements.

In March 2017, the FASB issued ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which amends ASC Topic 715, *Compensation - Retirement Benefits*. ASU 2017-17 requires entities to disaggregate the current service cost component from the other components of net benefit cost and present it with other current compensation costs for related employees in the income statement and present the other components of net benefit cost elsewhere in the income statement and outside of operating income. Only the service cost component of net benefit cost is eligible for capitalization. The guidance is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted as of the beginning of any annual periods for which an entity's financial statements have not been issued. Entities are required to retrospectively apply the requirement for a separate presentation in the income statement of service costs and other components of net benefit cost and prospectively adopt the requirement to limit the capitalization of benefit costs to the service component. The Company adopted the income statement presentation aspects of this new guidance on a retrospective basis effective January 1, 2017. Nearly all of the Company's net benefit costs for the Company's defined benefit pension and postretirement plans do not contain a service cost component as most of these defined benefit plans have been frozen for an extended period of time. The following is a reconciliation of the effect of the reclassification of the net benefit cost from operating expenses to other expense in the Company's condensed consolidated statements of income for the three and nine months ended September 30, 2016:

<u>In millions</u>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
<b>Three Months Ended September 30, 2016</b>			
Operating expenses	\$ 4,675	\$ (7)	\$ 4,668
Operating profit	2,817	7	2,824
Other expense	—	7	7
<b>Nine Months Ended September 30, 2016</b>			
Operating expenses	13,908	(23)	13,885
Operating profit	7,343	23	7,366
Other expense	—	23	23

In January 2017, the FASB issued ASU 2017-04, *Simplifying the Test for Goodwill Impairment*, which amends ASC Topic 350, *Intangibles - Goodwill and Other*. This ASU requires the Company to perform its annual, or applicable interim, goodwill impairment test by comparing the fair value of each reporting unit with its carrying amount. An impairment charge must be recognized at the amount by which the carrying amount exceeds the fair value of the reporting unit; however, the charge recognized should not exceed the total amount of goodwill allocated to that reporting unit. Income tax effects resulting from any tax deductible goodwill should be considered when measuring a goodwill impairment charge, if applicable. The guidance in ASU 2017-04 is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company elected to early adopt this standard as of January 1, 2017. At the date of adoption of this new guidance, the guidance did not have any impact on the Company's condensed consolidated results of operations, financial position or cash flows.

#### ***New Accounting Pronouncements Not Yet Adopted***

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers* (Topic 606). ASU 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU 2016-08, *Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net)*, which amends the principal-versus-agent implementation guidance and in April 2016 the FASB issued ASU 2016-10, *Identifying Performance Obligations and Licensing*, which amends the guidance in those areas in the new revenue recognition standard. Both ASUs were issued in response to feedback received from the FASB-International Accounting Standards Board joint revenue recognition transition resource group. The new revenue standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018. The Company chose not to early adopt the new standard. Companies have the option of using either a full retrospective or a modified retrospective approach to adopt the standard. The Company intends to adopt the new standard on a modified retrospective basis. The Company formed a project team to assess

and implement the new revenue standard and is substantially complete in documenting its accounting policies applying the new revenue guidance. The Company does not expect that the implementation of the new standard will have a material effect on the Company's consolidated results of operations, cash flows or financial position. The new standard will however require more extensive revenue-related disclosures. The Company has identified one difference in its Retail/LTC Segment related to the accounting for its ExtraBucks Rewards customer loyalty program, which is currently accounted for under a cost deferral method. Under the new standard, this program will be accounted for under a revenue deferral method; however, the difference is not expected to be material.

In February 2016, the FASB issued ASU 2016-02, *Leases* (Topic 842). Lessees will be required to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance leases. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Lessor accounting is similar to the current model, but updated to align with certain changes to the lessee model (e.g., certain definitions, such as initial direct costs, have been updated) and the new revenue recognition standard. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company believes that the new standard will have a material impact on its consolidated balance sheet. The Company is currently evaluating the effect that implementation of this standard will have on the Company's consolidated results of operations, cash flows, financial position and related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, *Classification of Certain Cash Receipts and Cash Payments*. ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The guidance in ASU 2016-15 is required for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect on its consolidated statement of cash flows of adopting this accounting guidance.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows*, which amends ASC Topic 230. This ASU requires entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer be required to present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. Entities will also have to disclose the nature of their restricted cash and restricted cash equivalent balances. The guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted. Entities are required to apply the guidance retrospectively. The Company is currently evaluating the effect of adopting this accounting guidance.

Accounting Policies (Tables)

9 Months Ended  
Sep. 30, 2017

Accounting Policies

Reconciliation of condensed consolidated statement of cash flows

<i>In millions</i>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
Cash paid to other suppliers and employees	\$ (11,092)	\$ 72	\$ (11,020)
Net cash provided by operating activities	7,948	72	8,020
Excess tax benefits from stock-based compensation	72	(72)	—
Net cash used in financing activities	(6,568)	(72)	(6,640)
Reconciliation of net income to net cash provided by operating activities:			
Accrued expenses	2,077	72	2,149

Reconciliation of condensed consolidated statement of income

<i>In millions</i>	<u>As Previously Reported</u>	<u>Adjustments</u>	<u>As Revised</u>
<b>Three Months Ended September 30, 2016</b>			
Operating expenses	\$ 4,675	\$ (7)	\$ 4,668
Operating profit	2,817	7	2,824
Other expense	—	7	7
<b>Nine Months Ended September 30, 2016</b>			
Operating expenses	13,908	(23)	13,885
Operating profit	7,343	23	7,366
Other expense	—	23	23



**Goodwill and Intangible  
Assets (Tables)**

**9 Months Ended  
Sep. 30, 2017**

**Goodwill and Intangible Assets**

**Goodwill by Segment**

<i>Inmillions</i>	Pharmacy		
	Services	Retail/LTC	Total
Balance, December31,2016	\$ 21,637	\$ 16,612	\$38,249
Acquisitions	—	52	52
Foreign currency translation adjustments	—	3	3
Impairment	—	(135)	(135)
Balance, September30,2017	\$ 21,637	\$ 16,532	\$38,169

**Summary of the Company's intangible  
assets**

<i>Inmillions</i>	September30,2017		December31,2016		Net Carrying Amount	Net Carrying Amount
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization		
Trademark (indefinitely-lived)	\$ 6,398	\$ —	\$ 6,398	\$ 6,398	\$ —	\$ 6,398
Customer contracts and relationships and covenants not to compete	11,848	(5,345)	6,503	11,485	(4,802)	6,683
Favorable leases and other	1,151	(749)	402	1,123	(693)	430
	\$ 19,397	\$ (6,094)	\$ 13,303	\$ 19,006	\$ (5,495)	\$ 13,511

**Share Repurchase Programs  
(Tables)**

**9 Months Ended  
Sep. 30, 2017**

**Share Repurchase Programs**

<u>Share Repurchase Programs</u>	<u>In billions</u>	<u>Authorized</u>	<u>Remaining</u>
Authorization Date			
November 2, 2016 ("2016 Repurchase Program")	\$	15.0	\$ 13.9
December 15, 2014 ("2014 Repurchase Program")		10.0	—

**Accumulated Other  
Comprehensive Income  
(Tables)**

**9 Months Ended  
Sep. 30, 2017**

**Accumulated Other Comprehensive  
Income**

**Schedule of Accumulated Other  
Comprehensive Income (Loss) by  
Component**

<u>In millions</u>	<b>Three Months Ended September 30, 2017</b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, June 30, 2017	\$ (129)	\$ (4)	\$ (173)	\$ (306)
Other comprehensive income before reclassifications	8	—	—	8
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	—	151	151
Net other comprehensive income	8	—	151	159
Balance, September 30, 2017	\$ (121)	\$ (4)	\$ (22)	\$ (147)
	<b>Three Months Ended September 30, 2016</b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, June 30, 2016	\$ (125)	\$ (6)	\$ (186)	\$ (317)
Other comprehensive income (loss) before reclassifications	(3)	—	—	(3)
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	1	—	1
Net other comprehensive income (loss)	(3)	1	—	(2)
Balance, September 30, 2016	\$ (128)	\$ (5)	\$ (186)	\$ (319)
	<b>Nine Months Ended September 30, 2017 <sup>(1)</sup></b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, December 31, 2016	\$ (127)	\$ (5)	\$ (173)	\$ (305)
Other comprehensive income before reclassifications	6	—	—	6
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	1	151	152
Net other comprehensive income	6	1	151	158
Balance, September 30, 2017	\$ (121)	\$ (4)	\$ (22)	\$ (147)
	<b>Nine Months Ended September 30, 2016 <sup>(1)</sup></b>			
	<b>Foreign Currency</b>	<b>Losses on Cash Flow Hedges</b>	<b>Pension and Other Postretirement Benefits</b>	<b>Total</b>
Balance, December 31, 2015	\$ (165)	\$ (7)	\$ (186)	\$ (358)
Other comprehensive income before reclassifications	37	—	—	37
Amounts reclassified from accumulated other comprehensive income <sup>(2)</sup>	—	2	—	2
Net other comprehensive income	37	2	—	39
Balance, September 30, 2016	\$ (128)	\$ (5)	\$ (186)	\$ (319)

(1) All amounts are net of tax.

The amounts reclassified from accumulated other comprehensive income for losses on cash flow hedges are recorded within interest expense, net on the condensed consolidated statements of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in other expense on the condensed consolidated statements of income.

**Stock-Based Compensation  
(Tables)**

**9 Months Ended  
Sep. 30, 2017**

**Stock-Based Compensation**

Schedule of Compensation Cost for Share-based Payment Arrangements.

Allocation of Share-based Compensation Costs by Plan

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2017	2016	2017	2016
<i>In millions</i>				
Stock-based compensation:				
Stock options	\$ 15	\$ 20	\$ 49	\$ 60
Restricted stock units	50	38	124	106
Total stock-based compensation	<u>\$ 65</u>	<u>\$ 58</u>	<u>\$ 173</u>	<u>\$ 166</u>

Interest Expense, Net  
(Tables)

9 Months Ended  
Sep. 30, 2017

Interest Expense, Net

Components of net interest expense

	Three Months Ended		Nine Months Ended	
	September 30, 2017	September 30, 2016	September 30, 2017	September 30, 2016
<i>In millions</i>				
Interest expense	\$ 250	\$ 258	\$ 759	\$ 830
Interest income	(5)	(5)	(15)	(14)
Interest expense, net	<u>\$ 245</u>	<u>\$ 253</u>	<u>\$ 744</u>	<u>\$ 816</u>

Earnings Per Share (Tables)

9 Months Ended  
Sep. 30, 2017

Earnings Per Share

Reconciliation of basic and diluted earnings per common share

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2017	2016	2017	2016
<i>In millions, except per share amounts</i>				
Numerator for earnings per share calculation:				
Income from continuing operations	\$1,285	\$1,542	\$3,344	\$3,613
Income allocated to participating securities	(3)	(7)	(12)	(18)
Net income attributable to noncontrolling interest	—	(1)	(1)	(2)
Income from continuing operations attributable to CVS Health	<u>\$1,282</u>	<u>\$1,534</u>	<u>\$3,331</u>	<u>\$3,593</u>
Denominator for earnings per share calculation:				
Weighted average shares, basic	1,016	1,068	1,022	1,076
Effect of dilutive securities	4	5	4	6
Weighted average shares, diluted	<u>1,020</u>	<u>1,073</u>	<u>1,026</u>	<u>1,082</u>
Earnings per share from continuing operations:				
Basic	\$ 1.26	\$ 1.44	\$ 3.26	\$ 3.34
Diluted	\$ 1.26	\$ 1.43	\$ 3.25	\$ 3.32

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting

Reconciliation of the Company's business segments to the consolidated financial statements

<u>In millions</u>	<u>Pharmacy Services Segment</u>	<u>Retail/LTC Segment</u>	<u>Corporate Segment</u>	<u>Intersegment Eliminations</u>	<u>Consolidated Totals</u>
<b>Three Months Ended</b>					
September 30, 2017:					
Net revenues	\$ 32,896	\$ 19,593	\$ —	\$ (6,308)	\$ 46,181
Gross profit <sup>(1)</sup>	1,645	5,685	—	(204)	7,126
Operating profit (loss) <sup>(4)(5)(6)</sup>	1,353	1,553	(220)	(187)	2,499
September 30, 2016:					
Net revenues	30,429	20,143	—	(5,957)	44,615
Gross profit <sup>(1)</sup>	1,797	5,893	—	(198)	7,492
Operating profit (loss) <sup>(5)(6)(7)</sup>	1,459	1,778	(228)	(185)	2,824
<b>Nine Months Ended</b>					
September 30, 2017:					
Net revenues	96,444	58,488	—	(18,552)	136,380
Gross profit <sup>(1)</sup>	4,210	17,036	—	(605)	20,641
Operating profit (loss) <sup>(4)(5)(6)</sup>	3,272	4,375	(686)	(552)	6,409
September 30, 2016:					
Net revenues	88,704	60,253	—	(17,402)	131,555
Gross profit <sup>(1)</sup>	4,266	17,560	—	(575)	21,251
Operating profit (loss) <sup>(5)(6)(7)</sup>	3,282	5,273	(660)	(529)	7,366

- (1) Net revenues of the Pharmacy Services Segment include approximately \$2.6 billion and \$2.5 billion of retail co-payments for the three months ended September 30, 2017 and 2016, respectively, as well as \$8.4 billion and \$8.1 billion of retail co-payments for the nine months ended September 30, 2017 and 2016, respectively.
  - (2) Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services Segment and the Retail/LTC Segment. These occur in the following ways: when members of Pharmacy Services Segment clients ("members") fill prescriptions at the Company's retail pharmacies to purchase covered products, when members enrolled in programs such as Maintenance Choice\* elect to pick up maintenance prescriptions at one of the Company's retail pharmacies instead of receiving them through the mail, or when members have prescriptions filled at the Company's long-term care pharmacies. When these occur, both the Pharmacy Services and Retail/LTC segments record the revenues, gross profit and operating profit on a standalone basis.
  - (3) The Retail/LTC Segment gross profit for the three months ended September 30, 2017 and 2016 includes \$2 million and \$5 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment gross profit for the nine months ended September 30, 2017 and 2016 includes \$7 million and \$15 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
  - (4) The Retail/LTC Segment operating profit for the three and nine months ended September 30, 2017 includes \$6 million and \$211 million, respectively, of charges associated with store closures (see "Note 8 – Store Closures" to the condensed consolidated financial statements). The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 also includes a \$135 million goodwill impairment charge related to the segment's RxCrossroads reporting unit (see "Note 2 – Goodwill and Intangible Assets" to the condensed consolidated financial statements).
  - (5) The Retail/LTC Segment operating profit for the three months ended September 30, 2017 and 2016 includes \$9 million and \$52 million, respectively, of acquisition-related integration costs. The Retail/LTC Segment operating profit for the nine months ended September 30, 2017 and 2016 includes \$34 million and \$194 million, respectively, of acquisition-related integration costs. The integration costs in 2017 are related to the acquisition of Omnicare and the integration costs in 2016 are related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
  - (6) The Corporate Segment operating loss for the three and nine months ended September 30, 2017 include a \$3 million reduction in integration costs for a change in estimate related to the acquisition of Omnicare. The Corporate Segment operating loss for the three and nine months ended September 30, 2016 includes \$13 million of integration costs related to the acquisitions of Omnicare and the pharmacies and clinics of Target.
- Amounts revised to reflect the adoption of ASU 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which increased consolidated operating profit by \$7 and \$23 million for the three and nine months ended September 30, 2016, respectively (see "Note 1 – Accounting Policies" to the condensed consolidated financial statements).

**Accounting Policies - Fair  
Value of Financial  
Instruments (Details) - USD    Sep. 30, 2017 Dec. 31, 2016  
( $\$$ )  
 $\$$  in Millions**

**Accounting Policies**

<u>Short-term investments</u>	\$ 75	\$ 87
<u>Carrying amount of long-term debt</u>	25,700	
<u>Estimated fair value of long-term debt</u>	\$ 27,000	



Accounting Policies - Related Party Transactions (Details) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017 USD (\$) state	Sep. 30, 2016 USD (\$)	Sep. 30, 2017 USD (\$) state	Sep. 30, 2016 USD (\$)
<b><u>Related Party Transaction [Line Items]</u></b>				
<u>Expenses from transactions with related party</u> <u>Equity Method Investee</u>	\$ 5	\$ 7	\$ 29	\$ 29
<b><u>Related Party Transaction [Line Items]</u></b>				
<u>Other revenues from transactions with related party</u> <u>Heartland Healthcare Services</u>	\$ 36	\$ 46	\$ 106	\$ 116
<b><u>Related Party Transaction [Line Items]</u></b>				
<u>Number of states in which entity operates   state</u>	4		4	

Accounting Policies - New Accounting Pronouncements (Details) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017 USD (\$)	Sep. 30, 2016 USD (\$)	Sep. 30, 2017 USD (\$) item	Sep. 30, 2016 USD (\$)
<b><u>New Accounting Pronouncements or Change in Accounting Principle</u></b>				
Income tax provision	\$ 777	\$ 921	\$ 2,115	\$ 2,271
<b><u>Condensed Consolidated Statements of Cash Flows</u></b>				
Cash paid to other suppliers and employees			(11,230)	(11,020)
Net cash provided by operating activities			8,143	8,020
Net cash used in financing activities			(7,421)	(6,640)
<b><u>Reconciliation of net income to net cash provided by operating activities:</u></b>				
Accrued expenses			1,670	2,149
<b><u>Condensed Consolidated Statements of Income</u></b>				
Operating expenses	4,627	4,668	14,232	13,885
Operating profit	2,499	2,824	6,409	7,366
Other expense	192	7	206	23
<b><u>Previously Reported</u></b>				
<b><u>Condensed Consolidated Statements of Cash Flows</u></b>				
Cash paid to other suppliers and employees				(11,092)
Net cash provided by operating activities				7,948
Excess tax benefits from stock -based compensation				72
Net cash used in financing activities				(6,568)
<b><u>Reconciliation of net income to net cash provided by operating activities:</u></b>				
Accrued expenses				2,077
<b><u>Condensed Consolidated Statements of Income</u></b>				
Operating expenses		4,675		13,908
Operating profit		2,817		7,343
<b><u>Adjustment</u></b>				
<b><u>Condensed Consolidated Statements of Cash Flows</u></b>				
Cash paid to other suppliers and employees				72
Net cash provided by operating activities				72
Excess tax benefits from stock -based compensation				(72)
Net cash used in financing activities				(72)
<b><u>Reconciliation of net income to net cash provided by operating activities:</u></b>				
Accrued expenses				72
<b><u>Condensed Consolidated Statements of Income</u></b>				
Operating expenses		(7)		(23)
Operating profit		7		23
Other expense		\$ 7		\$ 23
<b><u>ASU 2016-09   Previously Reported</u></b>				
<b><u>New Accounting Pronouncements or Change in Accounting Principle</u></b>				
Income tax provision	\$ (18)		\$ (51)	

ASU 2014-09 | Retail/LTC Segment

**Condensed Consolidated Statements of Income**

Number of differences related to revenue accounting for ExtraBucks Rewards  
customer loyalty program | item

Goodwill and Intangible Assets - Goodwill and Disposal (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2017	Nov. 06, 2017
<b><u>Goodwill [Line Items]</u></b>				
<u>Goodwill, impairment loss</u>	\$ 0		\$ 135	
<b><u>Goodwill [Roll Forward]</u></b>				
<u>Goodwill, beginning balance</u>			38,249	
<u>Acquisitions</u>			52	
<u>Foreign currency translation adjustments</u>			3	
<u>Impairment</u>	0		(135)	
<u>Goodwill, ending balance</u>	38,169		38,169	
<b><u>Pharmacy Services Segment</u></b>				
<b><u>Goodwill [Roll Forward]</u></b>				
<u>Goodwill, beginning balance</u>			21,637	
<u>Goodwill, ending balance</u>	21,637		21,637	
<b><u>Retail/LTC Segment</u></b>				
<b><u>Goodwill [Line Items]</u></b>				
<u>Goodwill, impairment loss</u>			135	
<b><u>Goodwill [Roll Forward]</u></b>				
<u>Goodwill, beginning balance</u>			16,612	
<u>Acquisitions</u>			52	
<u>Foreign currency translation adjustments</u>			3	
<u>Impairment</u>			(135)	
<u>Goodwill, ending balance</u>	\$ 16,532		\$ 16,532	
<b><u>Rx Crossroads Member</u></b>				
<b><u>Goodwill [Line Items]</u></b>				
<u>Goodwill, impairment loss</u>		\$ 135		
<b><u>Goodwill [Roll Forward]</u></b>				
<u>Impairment</u>		\$ (135)		
<u>Forecast   Rx Crossroads Member   Disposal Group by sale</u>				
<b><u>Disposal group</u></b>				
<u>Consideration</u>				\$ 735

**Goodwill and Intangible  
Assets - Intangible Assets  
(Details) - USD (\$)  
\$ in Millions**

**3 Months Ended**

**Sep. 30, 2017    Dec. 31, 2016**

**Finite-Lived Intangible Assets, Net [Abstract]**

<u>Intangible assets, accumulated amortization</u>	\$ (6,094)	\$ (5,495)
<u>Intangible assets, gross carrying amount</u>	19,397	19,006
<u>Intangible assets, net carrying amount</u>	13,303	13,511
<u>Customer contracts and relationships and covenants not to compete</u>		

**Finite-Lived Intangible Assets, Net [Abstract]**

<u>Gross Carrying Amount</u>	11,848	11,485
<u>Intangible assets, accumulated amortization</u>	(5,345)	(4,802)
<u>Net Carrying Amount</u>	6,503	6,683
<u>Favorable leases and other</u>		

**Finite-Lived Intangible Assets, Net [Abstract]**

<u>Gross Carrying Amount</u>	1,151	1,123
<u>Intangible assets, accumulated amortization</u>	(749)	(693)
<u>Net Carrying Amount</u>	402	430
<u>Trademarks (indefinitely-lived)</u>		

**Intangible assets**

<u>Impairment of intangible assets, indefinite-lived</u>	0	
--	---	--

**Finite-Lived Intangible Assets, Net [Abstract]**

<u>Indefinite-lived intangible assets</u>	\$ 6,398	\$ 6,398
---	----------	----------

<b>Share Repurchase Programs (Details) shares in Millions, \$ in Billions</b>	<b>Aug. 29, 2016 USD (\$) agreement</b>	<b>1 Months Ended Apr. 30, 2017 shares</b>	<b>3 Months Ended Sep. 30, 2017 USD (\$) shares</b>	<b>9 Months Ended Sep. 30, 2017 USD (\$) shares</b>	<b>Jan. 31, 2017 shares</b>	<b>Jan. 06, 2017</b>
<u>2016 Repurchase Program</u>						
<b><u>Share repurchases</u></b>						
<u>Share repurchase program, authorized amount</u>			\$ 15.0	\$ 15.0		
<u>Amount available for repurchases</u>			13.9	13.9		
<u>2014 Repurchase Program</u>						
<b><u>Share repurchases</u></b>						
<u>Share repurchase program, authorized amount</u>			\$ 10.0	\$ 10.0		
<u>2014 Repurchase Program   August 29, 2016</u>						
<b><u>Share repurchases</u></b>						
<u>Number of agreements   agreement</u>	2					
<u>Amount under ASR agreement</u>	\$ 3.6					
<u>ASR, shares received as a percent of notional amount</u>						80.00%
<u>Shares repurchased under ASR agreement (in shares)   shares</u>					36.1	
<u>ASR, shares to be received at end of program as a percent of notional amount</u>		20.00%				
<u>ASR, maximum number of shares (in shares)   shares</u>		9.9				
<u>Transfer of shares to treasury stock value</u>	2.9					
<u>2014 Repurchase Program   Forward contract   August 29, 2016</u>						
<b><u>Share repurchases</u></b>						
<u>Derivative, Notional Amount</u>	\$ 0.7					
<u>Share Repurchase Program 2016 and 2014</u>						
<b><u>Share repurchases</u></b>						
<u>Repurchase of common stock (in shares)   shares</u>			5.0	55.4		
<u>Repurchase of common stock</u>			\$ 0.4	\$ 4.4		

Pension Settlements (Details) \$ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017 USD (\$)	Sep. 30, 2017 USD (\$)	Dec. 31, 2016 plan
<b><u>Defined Benefit Plan Disclosure [Line Items]</u></b>			
<u>Number of defined benefit plans</u>			7
<u>Settlement loss   \$</u>		\$ 187	
<u>Tax Qualified Pension Plans, Defined Benefit</u>			
<b><u>Defined Benefit Plan Disclosure [Line Items]</u></b>			
<u>Number of defined benefit plans</u>			2
<u>Settlement loss   \$</u>	\$ 187		
<u>Unfunded Nonqualified Supplemental Retirement Plans</u>			
<b><u>Defined Benefit Plan Disclosure [Line Items]</u></b>			
<u>Number of defined benefit plans</u>			5

Accumulated Other Comprehensive Income (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
<b><u>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</u></b>				
<u>Beginning of year</u>			\$ 36,834	
<u>Total other comprehensive income (loss)</u>	\$ 159	\$ (2)	158	\$ 39
<u>End of year</u>	34,868		34,868	
<u>Foreign Currency</u>				
<b><u>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</u></b>				
<u>Beginning of year</u>	(129)	(125)	(127)	(165)
<u>Other comprehensive income (loss) before reclassifications</u>	8	(3)	6	37
<u>Total other comprehensive income (loss)</u>	8	(3)	6	37
<u>End of year</u>	(121)	(128)	(121)	(128)
<u>Losses on Cash Flow Hedges</u>				
<b><u>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</u></b>				
<u>Beginning of year</u>	(4)	(6)	(5)	(7)
<u>Amounts reclassified from accumulated other comprehensive income</u>		1	1	2
<u>Total other comprehensive income (loss)</u>		1	1	2
<u>End of year</u>	(4)	(5)	(4)	(5)
<u>Pension and Other Postretirement Benefits</u>				
<b><u>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</u></b>				
<u>Beginning of year</u>	(173)	(186)	(173)	(186)
<u>Amounts reclassified from accumulated other comprehensive income</u>	151		151	
<u>Total other comprehensive income (loss)</u>	151		151	
<u>End of year</u>	(22)	(186)	(22)	(186)
<u>Accumulated Other Comprehensive Loss</u>				
<b><u>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</u></b>				
<u>Beginning of year</u>	(306)	(317)	(305)	(358)
<u>Other comprehensive income (loss) before reclassifications</u>	8	(3)	6	37
<u>Amounts reclassified from accumulated other comprehensive income</u>	151	1	152	2
<u>Total other comprehensive income (loss)</u>	159	(2)	158	39
<u>End of year</u>	\$ (147)	\$ (319)	\$ (147)	\$ (319)



<b>Stock-Based Compensation (Details) - USD (\$)</b> <b>\$ / shares in Units, shares in Millions, \$ in Millions</b>	<b>Sep. 30, 2017</b>	<b>3 Months Ended</b>		<b>9 Months Ended</b>	
		<b>Sep. 30, 2017</b>	<b>Sep. 30, 2016</b>	<b>Sep. 30, 2017</b>	<b>Sep. 30, 2016</b>
<b><u>Compensation</u></b>					
<u>Stock-based compensation expense</u>		\$ 65	\$ 58	\$ 173	\$ 166
<u>Options, grants in period (in shares)</u>				4	
<u>Options, grants in period, weighted average grant date fair value (in dollars per share)</u>				\$ 9.43	
<u>Options, grants in period, weighted average exercise price (in dollars per share)</u>				\$ 78.05	
<u>Options, outstanding (in shares)</u>	21	21		21	
<u>Options, outstanding, weighted average exercise price (in dollars per share)</u>	\$ 75.09	\$ 75.09		\$ 75.09	
<u>Options, outstanding, weighted average remaining contractual term (in years)</u>	3 years 10 months 13 days				
<u>Employee Stock Option</u>					
<b><u>Compensation</u></b>					
<u>Stock-based compensation expense</u>		\$ 15	20	\$ 49	60
<u>Restricted Stock Units (RSUs)</u>					
<b><u>Compensation</u></b>					
<u>Stock-based compensation expense</u>		\$ 50	\$ 38	\$ 124	\$ 106
<u>Equity instruments other than options, grants in period (in shares)</u>				3	
<u>Equity instruments other than options, grants in period, weighted average grant date fair value (in dollars per share)</u>				\$ 78.35	
<u>Equity instruments other than options, nonvested (in shares)</u>	6	6		6	
<u>Equity instruments other than options, nonvested, weighted average grant date fair value (in dollars per share)</u>	\$ 87.20	\$ 87.20		\$ 87.20	

**Sale-Leaseback Transactions**  
**(Details) - USD (\$)**  
**\$ in Millions**

**9 Months Ended**  
**Sep. 30, 2017 Sep. 30, 2016**

**Sale-Leaseback Transactions**

Proceeds from sale -leaseback transactions \$ 265      \$ 230

Store Closures (Details) \$ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2017 USD (\$) store	Sep. 30, 2017 USD (\$) store	Dec. 31, 2017 USD (\$) store
<b><u>Restructuring and Related Cost, Expected Cost</u></b>			
<u>Number of underperforming store closures   store</u>	5	68	
<u>Restructuring charges incurred   \$</u>	\$ 6	\$ 211	
<u>Forecast</u>			
<b><u>Restructuring and Related Cost, Expected Cost</u></b>			
<u>Number of underperforming store closures   store</u>			70
<u>Additional Restructuring charges expected to be incurred   \$</u>			\$ 9

Interest Expense, Net (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
<b><u>Interest Expense</u></b>				
<u>Interest expense</u>	\$ 250	\$ 258	\$ 759	\$ 830
<u>Interest income</u>	(5)	(5)	(15)	(14)
<u>Interest expense), net</u>	\$ 245	\$ 253	\$ 744	\$ 816

Earnings Per Share (Details) - USD (\$) \$ / shares in Units, shares in Millions, \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
<b><u>Reconciliation of basic and diluted earnings per common share</u></b>				
<u>Antidilutive securities excluded from computation of earnings per share (in shares)</u>	10.9	7.7	9.9	6.4
<b><u>Numerator for earnings per share calculation:</u></b>				
<u>Income from continuing operations</u>	\$ 1,285	\$ 1,542	\$ 3,344	\$ 3,613
<u>Income allocated to participating securities</u>	(3)	(7)	(12)	(18)
<u>Net income attributable to noncontrolling interest</u>		(1)	(1)	(2)
<u>Income from continuing operations attributable to CVS Health</u>	\$ 1,282	\$ 1,534	\$ 3,331	\$ 3,593
<b><u>Denominator for earnings per share calculation:</u></b>				
<u>Weighted average shares, basic (in shares)</u>	1,016.0	1,068.0	1,022.0	1,076.0
<u>Effect of dilutive securities (in shares)</u>	4.0	5.0	4.0	6.0
<u>Weighted average shares, diluted (in shares)</u>	1,020.0	1,073.0	1,026.0	1,082.0
<b><u>Earnings per share from continuing operations:</u></b>				
<u>Earnings per share, basic (in dollars per share)</u>	\$ 1.26	\$ 1.44	\$ 3.26	\$ 3.34
<u>Earnings per share, diluted (in dollars per share)</u>	\$ 1.26	\$ 1.43	\$ 3.25	\$ 3.32

Segment Reporting (Details) \$ in Millions	3 Months Ended		9 Months Ended	
	Sep. 30, 2017 USD (\$) state pharmacy item store Center	Sep. 30, 2016 USD (\$)	Sep. 30, 2017 USD (\$) state segment pharmacy item store Center	Sep. 30, 2016 USD (\$)
<b><u>Segment reporting information</u></b>				
<u>Number of reportable segments   segment</u>			3	
<u>Net revenues</u>	\$ 46,181	\$ 44,615	\$ 136,380	\$ 131,555
<u>Gross profit</u>	7,126	7,492	20,641	21,251
<u>Operating profit (loss)</u>	2,499	2,824	6,409	7,366
<u>Restructuring Charges</u>	6		211	
<u>Goodwill, impairment loss</u>	\$ 0		\$ 135	
<u>ASU 2017-17</u>				
<b><u>Segment reporting information</u></b>				
<u>Operating profit (loss)</u>		7		23
<u>Pharmacy Services Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Centers of excellence for infusion and enteral services   Center</u>	3		3	
<u>Number of states pharmacies operated   state</u>	41		41	
<u>Net revenues, retail co-payments</u>	\$ 2,600	2,500	\$ 8,400	8,100
<u>Retail/LTC Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of states pharmacies operated   state</u>	49		49	
<u>Number of retail drugstores   item</u>	9,751		9,751	
<u>Number of retail drugstores operating a pharmacy   item</u>	8,016		8,016	
<u>Number of LTC spoke pharmacies   item</u>	143		143	
<u>Number of LTC hub pharmacies   item</u>	31		31	
<u>Goodwill, impairment loss</u>			\$ 135	
<u>Retail/LTC Segment   Gross Profit</u>				
<b><u>Segment reporting information</u></b>				
<u>Integration related costs</u>	\$ 2	5	7	15
<u>Retail/LTC Segment   Operating profit</u>				
<b><u>Segment reporting information</u></b>				
<u>Restructuring Charges</u>	6		211	
<u>Acquisition related costs</u>	9	52	34	194
<u>Corporate Segment   Operating profit</u>				
<b><u>Segment reporting information</u></b>				
<u>Integration related costs</u>	3	13	3	13
<u>Operating Segments   Pharmacy Services Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Net revenues</u>	32,896	30,429	96,444	88,704
<u>Gross profit</u>	1,645	1,797	4,210	4,266

<u>Operating profit (loss)</u>	1,353	1,459	3,272	3,282
<u>Operating Segments   Retail/LTC Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Net revenues</u>	19,593	20,143	58,488	60,253
<u>Gross profit</u>	5,685	5,893	17,036	17,560
<u>Operating profit (loss)</u>	1,553	1,778	4,375	5,273
<u>Operating Segments   Corporate Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Operating profit (loss)</u>	(220)	(228)	(686)	(660)
<u>Intersegment Eliminations</u>				
<b><u>Segment reporting information</u></b>				
<u>Net revenues</u>	(6,308)	(5,957)	(18,552)	(17,402)
<u>Gross profit</u>	(204)	(198)	(605)	(575)
<u>Operating profit (loss)</u>	\$ (187)	\$ (185)	\$ (552)	\$ (529)
<u>Minute Clinic Within C V S Pharmacy Stores   Retail/LTC Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of clinics in retail drugstores   item</u>	1,122		1,122	
<u>CarePlus and CVS Pharmacy   Retail/LTC Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of pharmacies (more than 68,000)   pharmacy</u>	38		38	
<u>MinuteClinic   Retail/LTC Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of clinics   item</u>	1,129		1,129	
<u>Target Pharmacy Acquisition   Retail/LTC Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of retail drugstores operating a pharmacy   store</u>	1,687		1,687	
<u>Specialty stores   Pharmacy Services Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of pharmacies (more than 68,000)   pharmacy</u>	23		23	
<u>Specialty mail order   Pharmacy Services Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of pharmacies (more than 68,000)   pharmacy</u>	15		15	
<u>Mail service   Pharmacy Services Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of pharmacies (more than 68,000)   pharmacy</u>	4		4	
<u>Infusion and Enteral Branches   Pharmacy Services Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of infusion and enteral branches   pharmacy</u>	82		82	
<u>Ambulatory Infusion Suites   Pharmacy Services Segment</u>				
<b><u>Segment reporting information</u></b>				
<u>Number of infusion and enteral branches   pharmacy</u>	73		73	

Commitments and Contingencies (Details)	1 Months Ended			Feb. 28, 2006 item lawsuit director	2 Months	9 Months
	Jun. 30, 2017 defendant	Mar. 31, 2017 lawsuit	Sep. 30, 2015 pharmacy		Ended Sep. 30, 2017 complaint store	Ended Sep. 30, 2017 item store
<b><u>Loss contingencies</u></b>						
<u>Number of store leases guaranteed   store</u>					86	86
<u>Number of material accruals for outstanding legal matters</u>						0
<u>Number of pharmacies indicated in subpoena   pharmacy</u>			8			
<u>Number of lawsuits   lawsuit</u>	4					
<u>Number of legal proceedings, government investigations, inquiries and audits expected to be material</u>						0
<u>Omnicare, Inc.</u>						
<b><u>Loss contingencies</u></b>						
<u>New claims filed, number   lawsuit</u>				2		
<u>Number of officers named in lawsuit</u>				3		
<u>Number of directors named in lawsuit   director</u>				2		
<u>Cherokee Nation Opioid Litigation</u>						
<b><u>Loss contingencies</u></b>						
<u>Number of defendants   defendant</u>	6					
<u>Shareholder Matters</u>						
<b><u>Loss contingencies</u></b>						
<u>Number of complaints   complaint</u>					4	
<u>Number of complaints filed in Rhode Island   complaint</u>					3	